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Abstract 
 
Obstructive lung diseases are major causes of morbidity and mortality globally. The most 
common, chronic obstructive pulmonary disorder (COPD), is caused by smoke inhalation, 
whilst bronchiectasis (BR) is often caused by lung infection, and cystic fibrosis (CF) is due 
to the defective passage of fluids through lung epithelial cells. Whilst it is now recognised 
that the healthy lung harbours a microbial flora, obstructive lung diseases are characterised 
by periodic or persistent heavy bacterial colonization that can be determined using 
microbiological cultures of patient sputum as well as by novel genomic analysis, the most 
common species identified being Pseudomonas aeruginosa and Haemophilus influenzae. 
Adaptive immune responses generated against such organisms, in the form of antigen-
specific antibodies and T cells, may be protective against infection but may also contribute 
to the inflammatory disease mechanism such as through IL-17-mediated neutrophil 
recruitment. This thesis asks whether such immune responses can serve as biomarkers of 
microbial colonization and of disease; whether levels of antibodies and T cells indicate lung 
infection and exacerbations frequency. However, high levels may simply indicate exposure 
to microbes. Thus, the aim of this study was to measure antibody and T cell responses against 
a range of lung-colonizing microbes in patients with BR (n=119), COPD (n=58), CF (n=30), 
asthma (n=14), and in healthy controls (n=28). Patients were clinically characterised in terms 
of exacerbations, lung function, sputum microbiology and underlying disease. Enzyme 
linked immunosorbent assays (ELISAs) were set up to measure specific antibodies in serum, 
whilst T cell responses in peripheral blood mononuclear cells (PBMCs) were measured by 
specific Enzyme-linked ImmunoSpot assay (ELIspot), flow cytometry and multiplex 
cytokine ELISA. Typical microbial colonization for the given disease was seen in the 
sputum-producing patients. The results showed that in BR, specific IgG responses against 
 
IV 
 
P. aeruginosa increased according to episodes of colonization, whilst T cell responses in the 
form of antigen-specific IFN showed the opposite effect, suggesting T cell dysregulation. 
As well as IFN, T cells were shown to secrete IL-17 and IL-22 in response to microbial 
antigens and to possess activation and homing receptors. Antibody responses were also 
further characterised for cross-reactivity and Ig isotype, confirming specificity and isotype 
switching. In CF patients that harboured P. aeruginosa, high anti-pseudomonas IgG titres 
were detected, and T cell IFN responses were similar to healthy controls and were 
associated with greater disease stability and FEV1.  In conclusion, immune responses were 
successfully characterised in patients with obstructive lung diseases, and specific antibody 
and T cells showed some associations with colonization and clinical disease, respectively, 
depending upon the disease and the microbe.  
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1. Chapter One: General Introduction and Literature Review 
 
The aim of this thesis is to examine the specific anti-microbial immune responses – both T 
cell and antibody – in the blood of patients with obstructive lung diseases compared to 
healthy volunteers (HV). The patient groups include those with bronchiectasis (BR), chronic 
obstructive pulmonary disease (COPD), asthma and cystic fibrosis (CF). The patients were 
characterized clinically to varying degrees and had microbiology carried out on any sputum 
they produced at the time of blood sampling. As adaptive and innate immune responses are 
closely linked, the literature review describes both aspects of the immune response, as well 
as lung structure and physiology, and then describes lung diseases in terms of the roles 
played by microbial infection and immune responses in their pathology.  
1.1 The innate immune response  
 
The immune system is a complex defence mechanism made up of molecules, cells and 
organs, which has effectively evolved to defend the body from invasive microbial diseases. 
Two inducible immune mechanisms are successively activated during infection and work in 
a coordinated manner to ensure rapid and effective microbial elimination (Albiger et al., 
2007). These are the innate and adaptive arms of the immune system.  
Innate defence consists initially of physical defence, including the cough reflex, mucociliary 
clearance and the antimicrobial properties of the mucosal surface. These constitute the first 
barrier in the host’ defence (Strieter et al., 2002). In addition, phagocytic defence is provided 
by macrophages, neutrophils, basophils and eosinophils; which are recruited in response to 
infections, recognize, and respond to microbes by initiating phagocytosis and/or 
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degranulation. The failure of such local host defences may lead to microbial colonization 
and subsequent pathogenic infection (Bals and Hiemstra, 2004). 
1.1.1 Mucus  
 
Mucus is present  on the moist, and internal surfaces of the human body (Knowles and 
Boucher, 2002). It plays an important role as an adequate mechanical protective barrier of 
the primary airway against many of the particles, microbes and allergens found in inhaled 
air (Hollingsworth and Swanson, 2004, Rajavelu et al., 2015). Mucus prevents the bacteria 
from becoming attached to the epithelium, and those bacteria which cannot attach due to the 
mucus can be cleared by mucus-ciliary clearance (Quie, 1986).  
Discussions of the role of the mucus layer in protection, as suggested by various studies 
show alteration in mucins secretion during inflammatory conditions through altered goblet 
cell responses in germ-free animals and by enhanced mucus secretion in response to 
infections  (Kim and Khan, 2013). 
Mucins are the main constituents of lower airway mucus, and several mucins (including 
MUC2, MUC5AC, MUC5B, MUC6 and MUC8) are secreted in the lower airways (Henke 
et al., 2007). Furthermore, mucins can bind and trap inhaled particles and clear them from 
the lung because of the extraordinary diversity of their carbohydrate side chains. Mucin can 
also bind to all particles and pathogens at the cell surface of the airway and can thus 
neutralize pathogens and eradicate them from the lung (Kim and Khan, 2013, Knowles and 
Boucher, 2002).  
Furthermore, polymeric mucins (glycoproteins) represent the major macromolecular 
components of lung mucus and they form viscoelastic gels by interacting with other mucins 
and proteins (Caramori et al., 2009). Moreover, MUC5AC and MUC5B are the main mucins 
in lung secretions in patients with different obstructive lung diseases. MUC5AC mRNA 
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expression is associated with goblet cells in the epithelium of the conducting airway, while 
MUC5B mRNA is present in mucosal cells of the submucosal glands (Caramori et al., 2009) 
1.1.2 Macrophages  
 
Macrophages are vital phagocytic cells that are found in all tissues and are differentiated 
from monocytes within circulating peripheral blood mononuclear cells (PBMCs), which 
migrate into the tissue in response to inflammation (Sunderkotter et al., 2004). Macrophages 
have multiple functions in the innate immune response, including phagocytic defence 
(uptake and killing of microbes), recognition of exogenous and endogenous molecules, 
antigen presentation (AP) and activation of the adaptive immune response (Zhang and 
Mosser, 2008). Macrophages are involved in the clearance of cellular debris generated 
during tissue remodelling and effectively remove cells that have undergone apoptosis (Kono 
and Rock, 2008, Zhang and Mosser, 2008). Macrophages are subdivided into two subclasses: 
M1 macrophages and M2 macrophages. M1 macrophages, known as classically activated 
macrophages, exhibit enhanced microbicidal activity and secrete high levels of pro-
inflammatory cytokines, such as the interleukins IL-1, IL-6, IL-23 and tumor necrosis factor 
alpha (TNFThese cells are critical in protection against intracellular pathogens (Martinez 
et al., 2008). M2 macrophages are known as alternatively activated macrophages, or wound-
healing macrophages, and are important in defence against parasitic and fungal infections 
and for wound healing. The development of M2 macrophages is based on the production of 
IL-4, produced by basophils and mast cells in response to tissue injury, or microbial 
infections such as chitin (a structural biopolymer found in certain fungi) (Kreider et al., 
2007). These M2 cells also produce chitinase and chitinase-like molecules, which contribute 
to the clearance of parasites and fungi as well as wound healing (Mosser and Edwards, 2008).  
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1.1.3 Granulocytes  
 
 
Polymorph nuclear leukocytes (PMNs) comprise granulocytes including neutrophils, 
eosinophils and basophils, which are important in the innate immune response. Neutrophils 
are the most abundant PMNs. They are differentiated in the bone marrow and released in to 
blood circulation through which they are directed by adhesion molecules and cytokines to 
infected tissues (Amulic et al., 2012, Fuchs et al., 2007). In response to microbial infections, 
neutrophils are rapidly recruited to sites of inflammation where they activate different 
antimicrobial properties, such as phagocytosis, the production of microbicidal reactive 
oxygen and nitrogen species (ROS and RNS) and the formation of neutrophil extracellular 
traps (NETs). NETs are formed of chromatin and specific granular proteins that bind and kill 
microorganisms (Sollberger et al., 2016).  
Eosinophils play a role in the allergic airway inflammatory response and are involved in host 
resistance to extracellular microorganisms and parasites, as well as antimicrobial activities 
against bacterial, viral and protozoan pathogens (Acharya and Ackerman, 2014). 
Eosinophils release granule proteins and toxic enzymes including major basic protein 
(MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), eosinophil-derived 
neurotoxin (EDN), matrix metalloproteinases (MMPs) and reactive oxygen species, which 
target microbes, especially parasites, but also damage the host tissues in allergic 
inflammation (Forman et al., 2016). Similarly, basophils are also involved in the allergic 
response to various IgE-dependent or -independent stimuli; they release effector molecules, 
including proteases, histamine, cytokines, pro-inflammatory chemokines and lipid mediators 
(Otsuka and Kabashima, 2015). They also contribute to immunoglobulin (Ig) synthesis and 
class switching and angiogenesis by producing cytokines such as IL-6 and IL-3. It has been 
established that they are involved in antigen presentation to CD4+ or CD8+ T cells via the 
class I or class II major histocompatibility complex (MHC) (Schneider et al., 2010).  
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1.1.4 Toll-like receptors  
 
The challenge for the innate immune system is discrimination between potential pathogens 
and the self. This is achieved by a variety of pattern recognition receptors (PRRs) expressed 
on the surface of innate cells which are mostly membrane-bound (Kumar et al., 2009). PRRs 
recognize conserved microbial molecules known as pathogen-associated molecular patterns 
(PAMPs) generated by a wide range of pathogens. The recognition of PAMPs via PRRs 
leads to the activation of the pro-inflammatory pathway (Abreu and Arditi, 2004). The main 
category of PRRs is toll-like receptors (TLRs), which are type I transmembrane proteins 
characterized by extracellular leucine-rich repeat (LRR) motifs that mediate the recognition 
of PAMPs, transmembrane domains, and COOH-terminal signal domains, homologous to 
IL-1 receptors, required for signal transduction. Eleven human TLRs have been identified. 
These are divided into two groups, depending on their extracellular localization and 
respective PAMPs. For example, TLR1, TLR2, TLR4, TLR5, TLR6 and TLR11 are present 
on cell surfaces and have the ability to recognize microbial cell wall components such as 
lipids, polysaccharides and lipoproteins. The TLRs in the other group, TLR3, TLR7, TLR8 
and TLR9 and IL-10 are found within intracellular vesicles, such as endosomes and 
lysosomes, and recognize microbial nucleic acids (Abreu and Arditi, 2004). TLRs are 
expressed on dendritic cells (DCs) and other antigen-presenting cells (APCs); these cells 
pick up the antigens, process them into small peptides, then migrate to the local lymph tissues 
to present the antigenic peptides on the MHC for recognition by T cells. These events involve 
cytokine and chemokine secretion and accessory signals. Thus, TLRs are a key component 
of the innate immune response and the activation of antigen-specific adaptive immune 
responses (Iwasaki and Medzhitov, 2004). 
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1.1 The adaptive immune response  
 
The adaptive (acquired) immune response differs from the innate immune response as it is 
more advanced and complex, and is the antigen-specific branch of the immune system. Two 
main cellular subsets, T and B lymphocytes, comprise the adaptive immune response, which 
is characterized by antigen specificity, diversity and memory (den Haan et al., 2014). It is 
highly regulated and slower to respond than the innate response. B cells are responsible for 
antibody production, while T cells control the immunological synapse and are important 
effectors in eliminating infection. Both B and T lymphocytes require the collaboration of the 
DCs for their priming (den Haan et al., 2014).  
B cells are named the Bursa, an equivalent organ in birds, in which they were first identified. 
In mammals, B cells mature in the bone marrow (bone marrow–derived). B cells are 
characterized by the expression of surface-bound Ig, which can bind to antigens (LeBien and 
Tedder, 2008). Once B cells encounter and recognize antigens and receive cytokines secreted 
by antigen-presenting cells and costimulatory signals from T helper (Th) cells, they rapidly 
differentiate into plasma cells or memory cells. Plasma cells will secrete soluble antibody 
that binds to the activating antigen, leading to the clearing of the infection associated with 
it. However, memory B cells reside in the body and provide long-term immunity to this 
particular antigen (LeBien and Tedder, 2008, Pieper et al., 2013).  
T cells (thymus-derived) represent the cell-mediated immune response and express surface 
T-cell receptors (TCRs). They can recognize foreign antigens previously digested and 
presented by APCs via MHC class I and class II molecules (Cooper and Alder, 2006). Other 
transmembrane proteins within the TCR complex are involved in triggering T cells. 
Activated T cells, if CD4+, produce cytokine profiles (described later) that regulate other 
immune cells, while CD8+ differentiate into cytotoxic T lymphocytes (Cooper and Alder, 
2006, Flajnik and Du Pasquier, 2004). Broadly, Th1 responses play a major role in killing 
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intracellular pathogens, whereas antibody responses destroy extracellular pathogens. 
Furthermore, T cells operate to alter the balance between eradicating pathogens and avoiding 
immune-mediated tissue injuries. The failure to clear the pathogens and dysregulated 
inflammation in the lung can cause bronchial wall damage (Grimwood, 2011, Strieter et al., 
2002). For the purposes of this thesis, antibody and T cells are discussed next.  
1.2.1 Immunoglobulins (Igs) – structure and function 
 
Immunoglobulins (Igs) were discovered in 1890 by von Behring and Kitasato when they 
observed substances in the blood that can neutralize the diphtheria toxin, and a year later, 
these substances were named antibodies (Schroeder and Cavacini, 2010). Igs are a “long 
range weapon” produced by activated B lymphocytes, and bind to molecular determinants 
(antigens), leading to neutralization and/or the removal of the antigen or associated microbe 
(Kepler, 2013). Each B cell produces a single specific antibody determined by its antigen-
binding site. Once naïve or memory B cells are activated by antigens, and aided by Th cells, 
they differentiate into antibody-secreting effector cells known as plasma cells. Some plasma 
cells continue to secrete antibodies for years and some die after secretion (Alberts et al., 
2002 ). 
Igs are gamma globulin proteins belonging to the Ig super-family (IgSF). The general 
structure of Igs is Y-shaped and the molecules are large, approximately 150–190KDa. The 
core of all Ig molecules is the same and consists of two heavy chains (HCs), each usually 
containing approximately 440 amino acids, and two light chains (LCs) containing 
approximately 220 amino acids. Genetically determined, each B cell only produces one LC 
sequence and one HC sequence. Therefore, the two HCs and two LCs in Ig molecules are 
identical. The two HCs are joined by covalent disulphide bonds and each HC is connected 
to an LC by an extra disulphide bond (Mak and Saunders, 2005, Schroeder and Cavacini, 
2010). Each HC has only one variable (VH) domain at the N-terminus and three or four 
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constant domains, whereas LCs contain one variable (VL) domain and one constant (CL) 
domain at their N-terminus. Both VH and VL determine the specificity of the B cell receptor 
(BCR) in antigen recognition (Anelli and van Anken, 2013). All antibodies have two 
antigen-binding fragments (Fab) and thus are described as bivalent. The V regions contain 
three short amino acid sequences, which are highly variable between Ig molecules, called 
hypervariable (HV) or complementarity determining regions (CDRs) (Figure 1.1) (Mak and 
Saunders, 2005). If an antigen has three or four repeating antigenic determinants, an antibody 
molecule can cross-link into a large lattice. This lattice can be rapidly phagocytosed and 
degraded by macrophages (Alberts et al., 2002 ). The function of antibodies is twofold due 
to the Fab and the constant fragment (Fc) of the HC, which allow the antibody to engage in 
different activities such as complement activation, binding to phagocytic cells and crossing 
the placenta from mother to foetus. Recent studies of antibody-antigen crystal structures 
have shown that while the VH and VL domains of an antibody are involved in forming the 
antigen binding site, not all antibodies use all six CDRs to interact with the antigen; for 
example, when the antibody binds polysaccharide or small peptide antigens (Mak and 
Saunders, 2005).  
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Figure 1.1: Typical structure of antibody. 
An antibody is formed by two identical HCs and two identical LCs joined by covalent disulphide 
bonds. Each HC and LC is joined by an extra disulphide bond. Each HC has three constant (CH) 
domains and one variable (VL) domain. Each LC has one variable (VL) and one constant (CL) 
domain. The Fab is composed of one LC and part of a HC. The other part of the HC chain contains 
the Fc-receptor-binding sites (Martz et al., 2013).  
 
1.2.2 IgG Fc receptors  
 
The constant region of the Fc domain of the Ig HC can bind to Fc receptors (FcRs) that are 
expressed on different immune cell types – particularly phagocytes – and are present as 
stimulatory and inhibitory pairs. The binding of Fc receptors to the antibody provides a wide 
range of responses, ranging from the effector function, including phagocytosis, and 
antibody-dependent cellular cytotoxicity (ADCC), to the secretion of cytokines or other 
inflammatory mediators (Molfetta et al., 2014). FcγR is encoded by an IgSF of eight genes 
clustered on the long arm of chromosome 1. The diversity of the FcγR family allows the Ig 
complex to stimulate various cell functions related to autoimmunity, inflammation and host 
defence versus microbes and cancer (Salmon and Pricop, 2001). FcγR is capable of 
triggering cellular activation because it possesses intracellular activation motifs, termed 
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immunoreceptor tyrosine-based activation motifs (ITAMs), similar to those of BCRs and 
TCRs. Three different classes of human receptor for IgG (FcγR) have been identified (Figure 
1.2): FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16). Stimulatory FcγR is a multichain 
receptor composed of a ligand-binding subunit associated with ITAMs. This receptor has 
two isoforms known as FcγRI (CD64), a high-affinity FcR for IgG1 and IgG3, which binds 
monomeric IgG and comprises three extracellular Ig-like domains in a ligand-binding chain. 
FcγRIIIa is an intermediate-affinity receptor binding only multivalent IgG (Woof and 
Burton, 2004). In addition, there are three single stimulatory FcγRs, termed FcγRIIa, FcγRIIc 
and FcγRIIIb, which have only two extracellular Ig-like domains and ITAMs and bind with 
low affinity for IgG. However, FcγRIIB is an inhibitory isoform containing an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) which transmits signals leading to 
the negative regulation of immune complex-triggered activation. Therefore, the structural 
diversity of FcγR leads to differences in binding capacity, different signal transduction 
pathways and cell type-specific expression patterns (Salmon and Pricop, 2001, Schroeder 
and Cavacini, 2010). 
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Figure 1.2: Schematic diagram of human Fcγ receptors. 
FcγRI and FcγRIIIa are multichain receptors associated with ITAMs.FcγRIIa and FcγRIIc are single-
chain stimulatory receptors also associated with ITAMs. FcγRIIIb is the only Fcγ lacking ITAMs. 
FcγRIIb is an inhibitory receptor comprising ITAMs. A, B, and C; b1, b1’, b2, and b3; and , 
and  are referred to multiple genes in each receptor class, their alternative spliced products, and 
their individual subunits respectively. Adopted from (Gessner et al., 1998).  
 
 
1.2.3 B cell proliferation and immunoglobulin (Ig) gene rearrangement 
 
B cells are generated from pluripotent hematopoietic stem cells and develop in the bone 
marrow through successive steps in an ordered series to produce an Ig repertoire. Pro-B cells 
are the first irreversible committed B cell precursors, distinguished from pre-B cells by the 
expression of CD19 on the surface as well as increased expression of heat-stable antigen 
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(HSA). In these cells, the expression of Igα and Igβ heterodimer is associated with calnexin 
and other chaperone molecules (Wang and Clark, 2003). The developmental steps of the 
rearrangement of the BCR are tightly regulated by positive and negative selection steps and 
culminate in the formation of immature B cells that migrate to peripheral lymphoid tissues 
(Kato et al., 2013).  
Variable (V), diversity (D) and joining (J) gene segments are assembled to generate an Ig 
variable region gene through a site-specific somatic recombination mechanism called the 
V(D)J recombination (Chen et al., 1993). The Ig gene rearrangement occurs primarily in the 
foetal liver and adult bone marrow at the pro-B cell stage, is initiated at the HC gene locus 
(IGH) and precedes the Ig LC gene rearrangement; DH to JH joining leads to VH to DJH 
joining. This procedure is mediated by several enzymes involving different proteins 
operating at the DNA level and is controlled by recombination signal sequences (RSSs) that 
flank the V, D, and J gene segments (LeBien and Tedder, 2008). The assembly of the LC 
gene is generated by the joining of the VL to the JL segment and the expression of the Ig HC 
gene. The arrangement of the LC occurs at the Ig kappa locus (IGK) and, if the functional 
IGK rearrangement fails, the Ig lambda locus (IGL) undergoes recombination (Gonzalez et 
al., 2007). The assembly of the IgH and IgL protein complex on the B cell surface generates 
BCRs and allows B cells to proceed with maturation, thus avoiding apoptosis (Gonzalez et 
al., 2007). Immature B cells that successfully display Ig on the cell surface exit the bone 
marrow and migrate to the germinal centres of lymph nodes where they are then selected by 
antigens for activation, inactivation, or eradication (Tiegs et al., 1993). In particular, the 
interaction between B cells, antigen-presenting cells and T cells helps B cells to carry 
antigen-specific receptors on their surface. Somatic hypermutation (SHM) and class-
switching recombination (CSR) occur at this stage. High-affinity antibodies are produced 
via SHM, which allows the secreted antibodies to recognize and bind foreign antigens (Klein 
et al., 1998). Following an encounter with an antigen, IgM is first produced and then the 
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mechanism of CSR switches an isotype to an IgG-, IgA- or IgE-secreting specific antibody 
that represents the final step in the B cell differentiation cascade (Gonzalez et al., 2007).  
1.2.4  B cell signalling pathways 
 
BCRs are multimeric complexes comprising an antigen-recognition and membrane-bound 
(mIg) proteins, associated non-covalently with the heterodimer of Igα and Igβ. Only IgG has 
a long cytoplasmic tail, whereas the tails of the other five types of mIg are extremely short 
and lack signalling capacity (Wang and Clark, 2003). In mature B cells, following Ag 
interaction at the BCR, the mIg initiates events in the biochemical cascade leading to the 
phosphorylation of tyrosine within the ITAM (a motif found within each cytosolic tail of Igα 
and Igβ) by the Src family member tyrosine kinase (Fremd et al., 2013). The phosphorylation 
of ITAM tyrosine enhances the recruitment and activation of Syk, which is the main kinase 
that drives many signalling pathways, including the activation of phospholipase Cy2 and 
Ras. However, not all signalling requires Syk, as the activation of nuclear factor NF- 
interacts directly with one or more Src family kinases (Irish et al., 2006, Niemann and 
Wiestner, 2013). In addition, other co-receptor molecules, such as CD19, CD21 and CD22, 
are associated with the BCR multimolecular complex and participate in the signalling 
pathway. 
Other signals for B cells are created by cytokine and stimulatory molecules as B cells present 
their antigens on MHC class II to Th cells, to obtain additional activation signals. The CD40 
ligation of CD40 on B cells with CD40L on T cells provides additional signals for 
proliferation and antibody secretion and it is the key molecule in human T-B interaction 
(Kato et al., 2013). CD40–CD40L engagement induces high levels of Ig secretion by the B 
lymphocyte, but only in the presence of cytokines such as IL-4, IL-13 and IL-10. This 
process promotes the differentiation and activation of B cells to undergo class-switching 
(Garraud and Nutman, 1996, Kato et al., 2013).  
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1.2.5 B cell activation through binding to proteins and polysaccharide antigens  
 
Antigens that activate B cells and stimulate the response are classified into two groups:  
 Thymus-dependent (TD or T cell-dependent) antigens  
 Thymus-independent (TI or T cell-independent) antigens  
1.2.5.1 Thymus-dependent (TD) antigens  
  
T cell-dependent antigens or TD antigens are soluble proteins picked up by specialized 
APCs, processed by endocytic compartments and presented as peptides on the MHC class II 
of APCs to antigen-specific CD4+ T cells. The outcome is T cell activation and the up-
regulation of adhesion molecules on T cells and the expression of co-stimulatory molecules 
for CD40 (i.e. CD40L) (MacLennan et al., 2003). T cells then interact with B cells that 
display the same peptide MHC II molecules and trigger them via CD40 and through the 
secretion of certain cytokines, such as IL-2, IL-4, IL-10 and IL-13. These cytokines have 
key functions in the activation of B cell growth and differentiation into plasma cells that 
produce high-affinity antibody of multiple isotypes. TD antigens also induce lasting immune 
responses, as well as forming memory B and T cells (Abbas et al., 1993, Garraud and 
Nutman, 1996, Lesinski and Westerink, 2001).  
1.2.5.2 Thymus-independent (TI) antigens  
 
Unlike T cell-dependent antigens, T cell-independent (TI) antigens are large multivalent 
molecules that produce multiple domains and interact with many mIg, resulting in highly 
cross-linked membranes that lead to a high level of B cell activation. Thus, TI antigens have 
the ability to induce enhanced mIg signalling without T cell help and do not induce memory 
(Lesinski and Westerink, 2001). Relatively low antigen concentration is necessary to achieve 
the threshold level of B cell activation that is required for stimulating B cells. A lower 
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antigen concentration may reduce the level of modulation and disappearance of Ig from the 
surface of antigen-specific B cells, allowing prolonged binding between antigens and mIg, 
therefore regulating B cell signalling. This may explain the ability of TI antigens to induce 
a humoral response without T cell help (Mond et al., 1995). 
TI antigens are further classified into two classes: TI-1 antigens, such as bacterial 
lipopolysaccharide (LPS), are known to be potent B cell mitogens that lead to polyclonal B-
cell activation. These antigens do not produce memory or the isotype switching of antibodies 
(Lesinski and Westerink, 2001). In contrast, TI-2 antigens are represented by highly 
repetitive structures expressed on the surface of pathogens, mainly polysaccharides. 
Although these reactive B cells do not require T cell help, it has been shown that without IL-
2 the T cells are unable to induce Ig secretion when cultured alone with resting B cells (Haas 
et al., 2005). After the addition of T cell-derived factors, Ig secretion is then induced. Recent 
studies have found that a type of natural killer (NK) cell provides help for the Ig secretory 
response and regulates immune responses through the release of various cytokines. These 
cytokines include colony-stimulating factor (CSF), transforming growth factor β (TGF-β), 
interferon gamma  (IFN IL-1, IL-2 and IL-8, which have all been shown to be important 
in the immune response (Mond et al., 1995). Furthermore, the polysaccharide antigen of 
Streptococcus pneumoniae can provoke B cell activation in the absence of T cell help by 
crosslinking BCR in a different way. A recent study found that pneumococcal 
polysaccharides, such as a vaccine preparation containing a TLR agonist that can be 
extracted by phenol, are critical for their capacity to induce antibody production. In addition, 
cytokines released from DCs and other leukocytes in response to such microbial products 
can contribute to TI-2 antibody responses, especially the response to whole pathogens 
(Lanzavecchia and Sallusto, 2007). The activation of B lymphocytes typically involves 
binding mIg to various molecules, such as a bacterial polysaccharide, LPS or proteins. The 
major sources of polysaccharides are the bacterial membrane and cell wall, resulting in 
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capsular polysaccharides and exopolysaccharides respectively (Leung et al., 2006). LPS or 
endotoxin is the main part of the outer membrane of all Gram-negative bacteria and serves 
as an initial elicitor of the inflammatory response, indicating bacterial infection for the 
mammalian host defence system (Triantafilou et al., 2001). The main differences between 
Gram-negative bacteria and Gram-positive bacteria are the lack of an outer membrane and 
the presence of a thicker peptidoglycan wall in Gram-positive bacteria.  
The receptors and binding proteins of polysaccharide are associated with innate immunity, 
including TLRs, scavenger receptors (SRs), complement receptor type 3 (CR3) and β-glucan 
receptors. Indeed, TLRs are expressed on myeloid cells such as macrophages, monocytes 
and DCs. The main TLRs that recognize polysaccharide are TLR-2 and TLR-4. SRs are 
receptors on macrophages, DCs and endothelial cells. CR3 is mainly expressed on 
macrophages, neutrophils and some types of B and T cells. -glucan is expressed on a wide 
range of cells, including eosinophils, B and T cells, monocytes and DCs (Leung et al., 2006). 
Stimulation with LPS requires the interaction of LPS with several proteins, including LPS-
binding protein (LBP), CD14, MD-2 and TLR4. LBP is a soluble shuttle protein that directly 
binds to LPS and helps the association between LPS and CD14. CD14 is a 
glycosylphosphatidylinositol cell surface 55-kD glycoprotein present on cells of the myeloid 
lineage, which also exists in a soluble form, mediating the transfer of LPS to the TLR4/MD-
2 receptor complex and modulating LPS recognition. MD-2 is a soluble protein that non-
covalently associates with TLR4, but it can directly form a complex with LPS in the absence 
of TLR4. Thus, stimulation by LPS involves the participation of various molecules to induce 
critical inflammatory cytokines, important to elicit potent immune responses (Lu et al., 
2008). 
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1.2.6 Somatic hypermutation (SHM) 
  
SHM operates following the assembly of Ig genes on activated B cells through their 
corresponding antigens and costimulatory signals from Th cells. SHM occurs at a rate of 10–
5 to 10−3 changes per base pair per cell generation (Li et al., 2004). These mutations are 
targeted at the V region gene to exert various actions resulting in nucleotide changes that 
alter the amino acid sequence and protein structures clustered in the CDRs of Ig V-region 
genes and allow B cells to gain amino acid differences in the variable domain. However, 
silent mutations that preserve the amino acid sequence and retain the same protein structure 
are scattered through the V region (Murphy, 2011). Therefore, SHM increases antibody 
diversity and affinity maturation in response to recurrent immunization or exposure to 
antigen (Schroeder and Cavacini, 2010).  
1.2.7 Antibody class switching  
 
1.2.7.1 Class switching recombination (CSR) 
 
CSR is a programmed gene rearrangement that occurs after the activation of a mature B cell. 
It takes place in a germinal centre through a DNA-editing enzyme called activation-induced 
cytidine deaminase (AID) (Figure1.3). CSR enables B cells to change the heavy-chain 
constant region (CH) while maintaining the same variable domains, resulting in a change of 
antibody class (Muramatsu et al., 2000, Winter et al., 2003). This change occurs by replacing 
the Ig CH from Cμ with one of the other CH genes (Cγ, Cα, or Cε). It occurs between the 1–
10 kb tandem repetitive unit sequences, called the S regions, located upstream or in the 5′ 
region to each CH gene (Winter et al., 2003). The Ig isotype is changed from the initial IgM 
that utilizes a Cμ constant region to generate IgG, IgA or IgE. Each isotype is capable of 
determining a way of eliminating captured antigens or the location where Ig is delivered 
(Kaminski and Stavnezer, 2004, Muramatsu et al., 2000). The expressed V(D)J domains and 
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light chain do not change; therefore, the antibody specificity is not affected. Different Ig 
classes have been found in most vertebrates and represent the various effector functions of 
the humoral immune response. Mice, rats and humans have five classes, comprising IgM, 
IgD, IgG, IgE and IgA. IgG contains four subclasses (IgG1, IgG2, IgG3 and IgG4 in humans) 
and the IgA class comprises IgA1 and IgA2 (Chaudhuri and Jasin, 2007, Stavnezer, 1996). 
High-affinity antibody production requires the formation of an immunological synapse 
between T and B cells. The synapse is generated by communication between T cell and B 
cell receptors through the MHC, which incorporates small peptides derived from 
macromolecules (particularly bacteria and viruses) processed in specialized Ag-presenting 
cells (APCs). This allows B cells to form a composite ligand called the peptide-MHC 
complex (pMHC), which can be recognized by TCRs in the immunological synapse. Since 
B cells use their mIg receptors to capture the antigens, then the more pMHC generated in 
the immunological synapse, the better the BCR affinity (Dustin, 2014). In humans, the 
secretion of different Ig isotypes is associated with immune responses to various pathogens. 
Indeed, viral infections and protein antigens lead to high production of both IgG1 and IgG3. 
Encapsulated bacteria expressing polysaccharide-rich Ag, such as streptococcus and 
haemophilus, result in the production of an IgG1, IgG2 and IgG4 response (Cavacini et al., 
2003). Pathogens entering the mucosal barrier elicit the response of IgA. Moreover, the IgG 
subclasses can be altered during an immune response. For instance, during an acute phase, 
virus-specific IgG1 is initially elicited, whereas IgG3 is produced later (Avery et al., 2008). 
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Figure 1.3: Diagram of class switch recombination (CSR). 
(a) illustrates Ig HC genes in a B cell that expresses IgM and IgD (through alternative RNA 
processing), CSR occurs when AID remains within S regions that are transcriptionally active, and 
RNA transcripts from the un-rearranged HC genes are called germline transcripts; (b) during CSR 
from IgM to IgE.  The intra-chromosomal deletional recombination between two switch (S) regions 
and the DNA in between S and S is excised from the chromosome as a circle; (c) after CSR, the 
identical VH region originally expressed with the Cgene is now altered, with the C gene in cells 
expressing IgE (Stavnezer, 2011). 
 
1.2.7.2 Antibody classes and isotypes  
 
 IgM 
Monomeric IgM is the first isotype expressed during B cell development within the immune 
response and is produced before B cells undergo the process of SHM. IgM constitutes 
approximately 5–10% of total antibody in the serum. It is a low-affinity molecule capable of 
binding simultaneously to multivalent antigens such as bacterial capsular polysaccharides 
(Winter et al., 2003). IgM is mainly found in the blood, the mucosa and to a small extent in 
the lymph. The low affinity of the monomeric component of IgM molecules, because of its 
immaturity, can be enhanced in the pentameter through multimeric antigen–antibody 
interactions, especially when the antigen contains multiple repeating epitopes. IgM 
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antibodies are also called natural antibodies, produced against a variety of cross-reactive 
repeating antigens (Winter et al., 2003). Furthermore, IgM is effective at activating the 
complement system and thus combatting extra cellular infections (Janeway  et al., 2001).  
 IgA 
IgA is the most abundant immunoglobulin produced in the body, providing the first line 
defence mechanism against many microbial pathogens that encounter mucosal surfaces 
(Agnello et al., 2013, Twigg, 2005). Most plasma cells producing IgA reside in the lamina 
propria (LP) of mucosal organs, and IgA is polymeric (a dimer) with an integrated joining 
(J) chain associated with the polymeric Ig receptor (pIgR) on the epithelial cell layer. When 
transported to the apical side via a process called transcytosis, in which the pIgR is cleaved, 
IgA passes and is circulated into the mucosal lumen (Agnello et al., 2013, Macpherson et 
al., 2008). Secretory IgA is polymeric, whereas serum IgA is mainly monomeric. The 
protective functions mediated by secreted IgA take place via high-affinity interactions, 
inhibiting the binding of antigen to the mucosal surface and neutralizing toxins and 
microbes. Low-affinity interaction helps contain the dense commensal microbiota residing 
in the intestinal lumen (Macpherson et al., 2008). Two IgA isotypes are found in humans – 
IgA1 and IgA2. IgA1 comprises 80–85% of total serum IgA, whereas IgA2 is mainly found 
in the secretions of the mucosal organs (Brandtzaeg and Johansen, 2005, Twigg, 2005). The 
molecular events eliciting an immune response of IgA1 and IgA2 remain unclear, but 
secreted IgA2 generally operates against lipopolysaccharide whereas secreted IgA1 is 
predominantly stimulated by protein antigens (Brandtzaeg and Johansen, 2005).  
 IgG  
IgG is the predominant isotype in the blood and extracellular fluid and is the main 
characteristic of a secondary immune response produced after antibody class switching. It 
accounts for 80% of total Ig in the serum and is efficient in the recognition, neutralization 
 
21 
 
and removal of pathogens and other toxic antigens by virtue of its opsonizing and 
complement-activating properties (Kaneko et al., 2006). Its small molecular size allows the 
IgG to cross from the blood into the tissue, as well as enabling transplacental transfer 
(Goldsby et al., 1939). Four IgG subclasses are found in the human serum; these subclasses 
were discovered in the 1960s following extensive studies using specific rabbit antisera 
against human IgG myeloma proteins (Vidarsson et al., 2014). The subclasses of IgG are 
distinguished by differences in HC sequences, with diverse amino acid sequences encoded 
by different germ-line CH genes (Figure 1.4). These subclasses – IgG1, IgG2, IgG3 and 
IgG4 – are ordered by their decreasing average serum concentrations in the blood of healthy 
individuals (Twigg, 2005). The different amino acid compositions of the subclasses affect 
the biological properties of the Ig (Table 1.1). Different IgG subclasses are responses to 
various types of antigens. The response against soluble protein antigens and membrane 
proteins elicits IgG1, while bacterial capsular polysaccharide antigens induce the response 
of IgG2 (Vidarsson et al., 2014). Furthermore, IgG3 antibodies have the potential to induce 
effector functions that culminate in excessive inflammatory responses. IgG4 are particularly 
induced by exposure to allergens (Twigg, 2005, Vidarsson et al., 2014).  
 IgE 
IgE was discovered in 1967 as an Ig isotype distinct from IgG, IgA, IgM and IgD. IgE plays 
a major role in immediate hypersensitivity reactions and is responsible for the symptoms of 
hay fever, asthma and anaphylactic shock (Hamilton et al., 2010). IgE is synthesized in 
response to an allergen, this process being initiated when the allergen is taken up by APCs, 
processed and presented to Th2 cell receptors, resulting in the activation of T cells and the 
expression of IL-4, IL-13 and CD154 (CD40 ligand). The engagement between CD154 and 
CD40 expressed on the APC leads to activation of the APC (mainly B cells), resulting in 
isotype switching and the secretion of allergen-specific IgE (Prussin and Metcalfe, 2006). 
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IgE responses are a key potent mechanism against nematode (worm) parasites, with the 
engagement of parasite antigen with IgE on mast cells promoting parasite ejection. 
 IgD 
IgD was first discovered in 1965 in human serum as myeloma protein. More recently, it was 
identified on the surface of naïve mature B cells, being important in initiating BCR signal 
transduction (Edholm et al., 2011). IgD is produced at very low levels in the serum with a 
short serum half-life that may be due to the sensitivity of the molecule to enzyme 
degradation. It is also co-expressed with IgM on the surface of mature B cells before 
antigenic stimulation and functions as an Ag-binding receptor (Schroeder and Cavacini, 
2010). Structural differences in the H region of IgD, in length, amino acid arrangement and 
glycosylation provide a flexible T shape rather than the usual Y shape of other antibody 
isotypes, which may contribute to the different functions of IgD. It has been found that in 
the human upper respiratory mucosa, the constant region of IgD can bind to the protein of 
respiratory bacteria such as Moraxella catarrhalis, while their products can enhance mucosal 
immunity and B cell activation (Chen and Cerutti, 2011).   
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Figure 1.4: Schematic diagrams of Ig molecules. 
IgG subclasses differ in terms of the number of disulfide bonds and the length of the hinge region. 
IgE exists as a monomer and has an extra domain in the constant region. IgD exists only as a 
monomer and has extra amino acids at the C-terminal end for anchoring to the membrane. IgM has 
an extra domain on the chain (CH4) and it has another protein covalently bound via an S-S bond 
called the J chain. IgA is a monomer and when expressed as a dimer, the J chain is associated with it 
(Mayer, 2015 ). 
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Table 1.1. Different IgG isotypes with specialized biological activity and unique distributions. 
+ + + represents the major effector function of each isotype, + + and + represent lesser functions and 
minor functions respectively  and - represents no function.*IgG2 is capable of acting as an opsonizer 
in the presence of Fc receptors (Janeway  et al., 2001). 
Functional activity 
and distribution 
IgM IgD  IgG1 IgG2 IgG3 IgG4 IgA IgE  
Neutralization of 
toxins and 
microbes 
+ - + + + + + + + + + + - 
Opsonization  - - + + + * + +  + + - 
Sensitization for 
killing by NK cells  
- - + + - + + - - - 
Sensitization of 
mast cells  
- - + - + - - + + + 
Activates 
complement 
system  
+ + 
+  
- + + + + + + - + - 
Transport a cross 
epithelium  
+ - - - - - + + + - 
Transport a cross 
placenta 
- - + + + + + + +/ - - - 
Diffusion into 
extravascular sites  
+ /- - + + + + + + + + + + + + + + + 
Mean serum level 
(mg ml -1) 
1.5 0.04 9 3 1 0.5 2.1 3x10-6 
 
 
1.3 T cells  
 
T cells are a form of lymphocytes that play a fundamental role in adaptive immunity. These 
cells can recognize wide ranges of peptide antigens presented by MHC class I or II molecules 
on the surface of APCs. This initiates an activating signalling cascade resulting in 
proliferation, differentiation and effector functions for direct or indirect pathogen clearance 
(Conley et al., 2016, Tewari et al., 2005). T cells differ from other leukocytes in the 
expression of either the αβ or γδ type of TCR on the cell surface (Naito et al., 2011).  
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1.3.1 T cell development, positive and negative selection 
 
T cells are derived from haemopoietic precursors in the bone marrow, enter the bloodstream 
and migrate into the thymus, where they are known as thymocytes. Thymocytes undergo the 
series of maturation processes based on the expression of cell surface markers. The cells here 
lack the expression of CD4 or CD8 receptors and are termed double negative (DN) cells 
(CD4-, CD8-) (Figure 1.5) (Cai et al., 2007). Thymocyte migrants undergo the random 
development of multiple TCRs, which can recognize immunogenic peptides bound to MHC 
molecules. In the thymic cortex, the thymic cortical epithelial cells secrete factors 
(lymphokines) to regulate the development of the T cells. At this stage, two selection 
processes occur. Double positive (DP) (CD4+, CD8+) thymocytes undergo TCR gene 
rearrangement (Romagnani, 2006). Some DP cells undergo positive selection in the cortex. 
These cells receive a survival signal, promoting them for further development to the final 
stage of maturation, which is the single positive TCR+ CD4+ cell (Th-precursor) or CD8+ 
cell (cytotoxic-precursor), based on the appropriate affinity of TCR for MHC-peptide. Most 
of the thymic DP cells die of neglect (no MHC-peptide recognition, no survival signals) 
(Petrović-Đjergović et al., 2007, Romagnani, 2006). The single positive selected cells 
develop further in the thymic medulla; they are then released into circulation and are present 
in peripheral blood. Negative selection eliminates the cells that may react against self-
molecules to avoid the potential cause of autoimmune reactions (Cai et al., 2007).  
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Figure 1.5: Development of T cells in the thymus. 
Early T cells lack expression of CD4 or CD8 and are referred to as double negative (DN) (CD4-, 
CD8-). Double negative cells then progress into double positive (DP) (CD4+, CD8+). DP then further 
develop into either CD4+ or CD8+ single positive cells. In positive selection, thymocytes bind to 
MHC/antigens with sufficient affinity, whereas during negative selection, the binding between 
thymocytes and APC occurs with high affinity and so they receive an apoptosis signal. Self-drawn 
based on  (Yeshanew et al., 2015).  
 
1.3.2 T cell receptors (TCRs) and gene rearrangement  
 
The adaptive immune system has developed two types of T lymphocytes that detect different 
forms of antigen. CD8+ T cells employ cell receptors (TCRs) to recognize short peptides 
derived from cytoplasmic antigens presented by MHC class I. CD8+ undergo clonal 
expansion following the immune response in secondary lymphatic tissues and migrate to the 
site of infection to kill the infected cells, when they then die by apoptosis (Conley et al., 
2016). CD4+ T cells use TCRs to recognize peptides from extracellular proteins presented 
by MHC class II during the immune response, leading to further specialization towards Th 
cells and the secretion of cytokines, and they provide help for CD8+ T cell responses (Milam 
CD4- CD8- 
CD4+ CD8+ 
Capsule 
Cortex 
Medulla 
Pre-TCR 
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and Allen, 2015). Each receptor is produced from a compound gene assembled by the 
somatic recombination of many possible gene segments on one chromosome (Tubo and 
Jenkins, 2014). The powerful diversity of TCRs allows the human T cells to recognize 
various pathogens and initiate a specific immune response. The mechanisms generating TCR 
gene segments are similar to Ig gene rearrangement, generated during thymocyte maturation 
by the recombination of specific V, D and J (Figure 1.6) segments, in the case of TCR  and 
, and V and J segments for TCR  and Toor et al., 2. CDRs are the most variable 
part of the TCR and complement an antigen-MHC’s features. The CDR consists of three 
regions: CDR1 and CDR2 are coded for by the V segment; CDR3 joins a part of the V 
segment and the D segment; J segments undertake incorporation for TCR and parts of the 
V and J segments for TCR(Danska et alThe presence of P- and N-nucleotides in 
all rearranged TCR and TCR VDJ sequences provide further variability and antigen 
recognition capacity for the TCR to recognize non-self and self-peptides (Murphy, 2011). 
 
 
28 
 
 
Figure 1.6: Stages of rearrangement and expression of and -chain genes to generate 
TCRs. 
The generation of the chain occurs through the rearrangement of Vgene segments in a Jα gene 
segment to create a V-region exon. The transcription and splicing of the VJ exon to Cgenerates 
mRNA, which is translated to create a TCR-chain. The chain is encoded by a recombination of 
V, D and J to generate a VDJregion, which is transcribed and spliced to join C, resulting in 
the TCR chain. Both the TCR and  chains are synthesized to generate TCRs (Murphy, 
2011).  
 
Table 1.2. The human TCR gene segments and sources of TCR diversity compared to Ig. 
(Murphy, 2011). 
Element  Immunoglobulin   T-cell receptors  
 +  
Variable segment (V) ~ 40 ~70 52 ~70 
Diversity segment 23 0 2 0 
D segments read in three frames rarely - often - 
Joining segment (J) 6 5()4( 13 61 
Joints with N- and P-nucleotides 2 50% of joints 2 1 
Number of V gene pairs 1.9 ×106 5.8×106 
Junctional diversity ~3×107 ~2×1011 
Total diversity ~5×1013 ~1018 
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1.3.2.1 CD4+ and CD8+ T-cell receptors (TCRs)  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
CD4 and CD8 are receptors expressed on the surface of T cells and act as co-receptors with 
TCRs (Figure 1.7). They interact with the antigen peptide bound to MHC molecules on 
antigen-presenting cells, leading to the enhancement of the T-cell signalling cascade via 
TCRs in association with protein tyrosine kinase p56lck (Lck) for both thymic selection and 
T-cell activation (Gangadharan and Cheroutre, 2004). T cells are polarized into different 
subsets according to priming conditions, including Th1, Th2, Th17 or Treg, whereas CD8
+ T 
cells are chiefly cytotoxic T lymphocytes (CTL) (Li et al., 2013).  
CD4+ is a monomeric type I glycoprotein membrane molecule (58 kDa) expressed on the 
surface of thymocytes and Th lymphocytes, as well as macrophages and monocytes. It 
consists of four extracellular domains of 370 amino acid residues (D1–D4), a hydrophobic 
membrane-spanning region of 25 amino acids, and a short highly charged cytoplasmic tail 
of 38 amino acids (Vermeire et al., 2006). The ligands for αβ TCRs on CD4+ T cells are 
formed from extracellular protein peptides taken up by DCs and macrophages into 
endosomes by micropinocytosis for the fluid phase, and phagocytosis for particles. These 
endosomes contain enzymes such as cathepsins, which digest the internalized proteins into 
small peptides which can then be presented in association with MHCII on the surface of the 
APC to T cells (Tubo and Jenkins, 2014). The interaction between CD4 molecules on T cells 
and MHCII produces further signalling, leading to the production of cytokines by Th cells 
that are required for a full immune response (Yin et al., 2012). 
CD8+ is a glycoprotein surface molecule expressed on the surface of T cells, which exists in 
two isoforms: CD8αβ and CD8αα. CD8αβ is found on αβ TCR thymocytes and CTLs and is 
a heterodimer type I transmembrane glycoprotein member of the IgSF. The α and β chains 
are composed of an Ig variable-like domain connected to the transmembrane domain by a 
stalk and a cytoplasmic tail (Li et al., 2013). It has been revealed that CD8αβ plays a 
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fundamental role in the positive selection of CD8+ T cells in the thymus, and in triggering 
CD8+T cells in the periphery. Meanwhile, the CD8αα homodimer is present on  T cells, 
intestinal intraepithelial T lymphocytes, NK cells and DCs comprising the α chain only (Li 
et al., 2013). It has been shown that CD8αβ functions as an efficient TCR co-receptor due 
to its interaction with the ectodomain of CD8β, enhancing the interaction between 
membrane-bound CD8 and MHCI. The cytoplasmic tail of CD8β increases the association 
between CD8α and intracellular signalling p56lck LAT. These two physical mechanisms of 
the CD8β domain enhance the dependence of CD8 co-receptors on each other (Cheroutre 
and Lambolez, 2008). Unlike CD8αβ, CD8αα is a less effective TCR co-receptor and does 
not enhance the positive selection of conventional MHCI-restricted T cells; it has been 
associated with the negative regulation of intestinal intraepithelial cells (Li et al., 2013). The 
hallmark of CD8αα is as an adhesion molecule able to increase the strength and the affinity 
for MHCI ligands, because it depends only on the interaction of its extracellular region with 
MHCI (Cheroutre and Lambolez, 2008). Although both isoforms have similar affinities for 
MHCI, and the Lck interacts with the cytoplasmic region of CDα, the distinct activity may 
be attributable to the location of CD8αβ in membrane rafts (Rybakin et al., 2011). 
The ligands for CD8+ T cells are generated in the cytosol by the proteasome, through which 
proteolysis degrades intracellular proteins into small peptides. Peptide degradation products 
then translocate into the endoplasmic reticulum through the transporter associated with 
antigen processing (TAP) where they bind with MHCI (Conley et al., 2016). The peptide-
MHCI complex is transported to the cell surface so that MHCI can display intracellular 
proteins to cytotoxic T cells (CTLs). However, MHCI can also display extracellular proteins 
in a process known as cross-presentation, mediated mainly by DCs(Tubo and Jenkins, 2014).  
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Figure 1.7: Schematic diagrams of MHCI and MHCII interactions with T cells. 
The left panel shows antigens processed by target cells and presented to the CD8+ T cell via MHC 
class I in association with CD8+ co-receptors to activate CD8+. The right panel shows APC-digested 
antigens presented via MHCII in association with CD4+ co-receptors to activate CD4+ cells (Parham, 
2009). 
 
1.3.3  Generation of T-cell responses and T-cell subsets  
 
Pathogen recognition begins with the cells of the innate immune system, such as DCs and 
macrophages. These cells recognize potential pathogens through TLRs that are expressed on 
their surface. Stimulation of TLRs via pathogen components induces the secretion of anti-
microbial peptides and proinflammatory cytokines through nuclear factor kappa-light-chain 
(NF-) and mitogen-activated protein kinases (MAPKs). TLR signals activate mature DCs 
to become more efficient in antigen uptake and processing, as well as up-regulating MHCI 
and II on the cell surface (Pei et al., 2012). Following pathogen recognition and uptake of 
pathogen antigen, DCs migrate to the secondary lymph organs where they encounter T cells. 
Furthermore, CD28 on T cells binds to CD80 and CD86 expressed by the activated APC, 
leading to the activation of the co-stimulatory signalling that is necessary for T cell 
proliferation and survival (Leahr and Bevan, 2004). Naïve CD4+ T cells are further polarized 
to differing Th effector subsets, based on the ability of the APC to produce specific cytokines 
in response to TLR signalling. Th1 responses are initiated when DCs are stimulated through 
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their TLRs, leading to the cytokine production of IL-12. The resulting Th1 secretes mainly 
IFN as well as TNFIn contrast, the Th2 response is initiated after DCs interact with 
multicellular parasites and allergens. Th2 cells produce various cytokines, including IL-4, 
IL-5 and IL-13 (Figure 1.8) (Leahr and Bevan, 2004, Romagnani, 2006). Th1 cells control 
cell-mediated responses, such as the activation of macrophages, whereas Th2 cells are 
responsible for stimulating B cells to switch to IgE. Th1 differentiation is regulated by 
cytokines through the activation of signal transducer and activator of transcription 1 (STAT-
1) and T-bet. Thus the production of IL-12 by DCs leads to IFNinductionand the inhibition 
of IL-4 and IL-5. In contrast, the differentiation of Th2 originates by activating the STAT-6 
signalling pathway through IL-4 production. It has been suggested that the early IL-4 may 
either be produced by naïve T cells after interaction between their Notch receptors and the 
Jagged ligand of DCs, or by unknown cell types. The GATA-binding protein 3 (GATA-3) 
and c‐Maf (transcription factor Maf) are also associated with Th2 development and promote 
IL-4, IL-5 and IL-13, as well as inhibiting IFN production (Nicol et al., 2016, Romagnani, 
2006). Thus, cytokines cross-regulate each other’s differentiation (mainly IL-4 and IFN) by 
promoting one type and suppressing the opposite subsets (Anderson et al., 2003, Romagnani, 
2006). 
Activated naïve CD4+ T cells can also differentiate into Th17 cells, which are regulated by 
different cytokines. It has been found that the combination of IL-6 and transforming growth 
factors-β (TGF-β) induces related orphan nuclear receptors (RORt and RORα) transcription 
factors (Nicol et al., 2016). IL-1 and IL-23 have also been shown to have roles in human 
Th17 cell differentiation (Ganjalikhani Hakemi et al., 2011). These transcription factors are 
essential for developing the Th17 lineage. In addition, STAT-3 regulates the IL-6 induced 
expression of both RORt and RORα and the secretion of IL-17, whereas the activation of 
STAT-1 inhibits Th17 differentiation (Kimura and Kishimoto, 2011). Recently, it has been 
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found that these cells express distinct markers, such as the chemokine receptor CCR6 and 
CD161 and CD49d (the α-chain of the integrin VLA-4) (Kleinewietfeld and Hafler, 2013). 
Furthermore, Th17 cells produce various cytokines, including IL-17, IL-17F, IL-21 and IL-
22, which are essential in the defence against various bacteria and fungi, especially at the 
mucosal surface, through the recruiting and activation of neutrophils (Ivanov et al., 2007). 
Cytokines produced by Th17 cells also stimulate fibroblasts, endothelial cells, epithelial cells 
and macrophages to produce chemokines, granulocyte colony-stimulating factors (CSFs) 
and granulocyte-macrophage (Romagnani, 2006). Although under homeostatic conditions 
Th17 cells are detected in the lamina propria of the small intestine, during extracellular 
bacterial or fungal infection these cells also migrate to other tissues (Kleinewietfeld and 
Hafler, 2013).  
 
Figure 1.8: Generation of naïve T cells. 
Following antigen recognition and help from APC, cytokines and co-stimulatory signalling with 
other cells, naive T cells can differentiate into effector subsets, including Th1, Th2, Th9, Th17 and 
Th22. These cells produce different inflammatory responses and cytokine profiles. Adopted from 
(Jutel and Akdis, 2011). 
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1.3.4 T cell activation phenotypes, and potential roles in lung disease 
 
Activated CD4+ cells in particular play a pivotal role in the pathophysiology of bronchiectasis (BR) 
(Gaga et al., 1998), a disease of dilated bronchi (see section 1.6.1). However, the activation of CD4+ 
T cells along with B cells is an important mechanism for inducing high affinity neutralizing 
antibodies. In general, the activation of T cells involves a variety of co-stimulatory molecules which 
provide the second signal that is critical for the enhancement of T cell differentiation, the facilitation 
of TCR signaling and modulation of T cell trafficking (Zhong et al., 2010). These co-stimulatory 
molecules are classified into three groups. The first are the immunoglobulin superfamily members 
including CD28 and CD152 (CTLA-4) and their ligands CD80 and CD86. The second and third 
groups are the tumour necrotic factor receptor (TNFR) superfamily including CD134 (OX40), 
CD137 (4-IBB), CD137L (4-IBBL), CD27 and CD30 (Ki-1); and finally the cytokine receptors such 
as IL-2R, -7R, -15R, -1R and -6R (Giscombe et al., 2006). Many of these stimulatory molecules are, 
therefore, likely to contribute to the T cell pathology seen in BR.  
For instance, CD69+, an early activation molecule, belongs to the natural killer cell gene complex on 
mouse chromosome 6 and human chromosome 12.  It is rapidly expressed on thymocytes during 
positive selection or on cells that have completed this process. Furthermore, CD69 is also expressed 
on neutrophils, eosinophils, epidermal Langerhans cells, and bone marrow myeloid precursors (De 
Maria et al., 1994).CD69 is selectively expressed in chronic inflammation at the sites of active 
immune responses in vivo (Maino et al., 1995, Sancho et al., 2005).  It has been shown that the 
antibody cross-linking of CD69 releases several cellular responses in humans, including nitric oxide 
(NO), monocytes, neutrophil degranulation, T cell proliferation, the production of TNFα and NK cell 
cytotoxicity. Functional CD69 receptors are expressed on the surface of circulating monocytes, and 
signals generated following CD69 cross-linking monocyte activation. This leads to  the production 
of inflammatory mediators and the initiation of cytotoxic activity (De Maria et al., 1994). CD69 is 
therefore likely to have a potential pro-inflammatory role in the pathogenesis of numerous 
inflammatory conditions, including pulmonary fibrosis (Yamauchi et al., 2011).   
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PD-1 (CD279) is an inhibitory receptor on hematopoietic cells which belongs to the CD28/CTLA-4 
receptor superfamily and is expressed on T cells, B cells, NK cells and myeloid cells. During the 
normal effective immune response, PD-1 is up-regulated on T cells to suppress the excessive 
activation of immune cells and thus prevent injury to tissue (MacFarlane et al., 2014). Besides, it 
mediates the signaling which inhibits cytolytic effector cells in the peripheral organs and tissues,  
thereby protecting the tissue from damage (Dolan and Gupta, 2014). Thus, the measurement of PD-
1 may indicate the progression of lung disease and provide useful information on disease stage.  
CD49d (alpha4-integrin) is an important molecule which acts as an adhesive and signaling receptor, 
and it plays an important role in the immune system through leukocyte migration, activation and 
survival. CD49d is also involved in B cell development and mediates the  signalling that up-regulates 
the anti-apoptotic B-cell lymphoma gene (BCL2 family), consequently influencing B-cell survival 
(Majid et al., 2011). Furthermore, the up-regulation of CD49d can aid the recruitment of 
mononuclear leukocytes to sites of inflammation, and it is implicated in the pathogenesis of chronic 
inflammatory diseases including asthma, multiple sclerosis, hypersensitivity and rheumatoid arthritis 
(Majid et al., 2011, Rose et al., 2002).  
OX40 (CD134, TNFRSF4) is a 50‐kDa type 1 transmembrane protein. It is a co-stimulatory molecule 
belonging to the tumor necrosis factor receptor (TNFR) superfamily and is expressed on T cells 
(mainly Th2), as well as on natural killer T cells and neutrophils. OX40 signaling promotes T cell 
proliferation and survival and the expression of IL-4 cytokine (Hirano et al., 2016, Kaur and 
Brightling, 2012, Lane, 2000). OX40 induces co-stimulatory signals that augment the clonal 
expansion of T cells rather than initiating T cell activation (Gramaglia et al., 2000).The OX40 ligand 
OX40L (CD252) is expressed by different cell types, including dendritic cells, B cells, macrophages, 
and Langerhans cells (Siddiqui et al., 2010, Wang and Liu, 2007). The interaction between OX40 
and OX40L is important in T cell activation, survival and inducing memory T cells from the effector 
cells (Ruby et al., 2008, Wang and Liu, 2007). Additionally, OX40L promotes naïve T cells to 
undergo Th2 polarization and the release of cytokines such as IL-4, IL-5, and IL-13. These cytokines 
are associated with the pathogenesis of allergic eosinophilic asthma (Kaur and Brightling, 2012). 
OX40/OX40L interaction is involved in different conditions where both CD4 and CD8 are mainly 
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associated with orchestrating the immune response, including many inflammatory and autoimmune 
diseases (Croft et al., 2009).  
In addition to the role of co-stimulatory molecules in T cell activation and migration, chemokine 
receptors also play a fundamental role in leukocyte activation by controlling the effector functions 
of immune cells and maintaining the adaptive immune response in both physiological and 
inflammatory conditions (Ito et al., 2011). Chemokine receptors are a group of transmembrane (TM) 
proteins of the superfamily of G-protein-coupled receptors that are involved indirectly in leukocyte 
biology throughout the body under both physiological and inflammatory conditions (Choi and An, 
2011). They are categorised as CCR, XCR, CXCR, or CX3CR and numbered according to the order 
of identification (Choi and An, 2011, Szczepanska et al., 2015). For instance, CX3CR is a receptor 
for three chemokines expressing the CXC chemokine family including CXCL9 (a monokine induced 
by interferon-𝛾 (IFN-𝛾), MIG), CXCL10 (IFN-𝛾-inducible protein 10, IP-10) and CXCL11 (IFN-𝛾- 
inducible T cell 𝛼 chemoattractant, I-TAC) (Szczepanska et al., 2015). CCR6 is an important receptor 
that is involved in controlling mucosal immunity by mediating and recruiting immature and mature 
dendritic cells and antigen presenting cells (APCs) to the sites of epithelial inflammation (Ito et al., 
2011).  CCR6 is expressed on immature DCs, most B cells, subsets of CD4+ and CD8+ T cells and 
NKT cells. This receptor can bind only one chemokine ligand, CCL20, which is  expressed by 
different epithelial cells such as keratinocytes, pulmonary epithelial cells, and intestinal epithelial 
cells (Krzysiek et al., 2000, Kucharzik et al., 2002, Reibman et al., 2003). Lung epithelial cells 
express high levels of CCL20, which in turn result in immature CCR6+ DCs being recruited into the 
lung (Lundy et al., 2005). It has been shown that CCL20 regulates the recruitment of DCs in the 
airways of patients with COPD, and the increased expression of CCL20 in patients with COPD 
compared with healthy controls has been demonstrated at the RNA and protein levels in different 
areas of the lungs (Demedts et al., 2007).  
Therefore, it was hypothesized that the analysis of key chemokines produced by different 
inflammatory cell and stimulatory molecules may provide useful evidence in determining the 
immunopathogenesis of patients with BR and other obstructive lung conditions.  
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1.4 The human lungs  
 
The human lungs are complex organs in which the vascular system is combined with 
epithelial-lined tubes and sacs to enable effective gas exchange. The lungs are known to have 
the largest epithelial surface of the body, at the interface between the internal and the external 
environment of the human host (Loscertales et al., 2016, Zhang et al., 2000). The lungs 
consist of different parts known as lobes (Figure 1.9). The right lung comprises three lobes: 
upper, middle and lower. In contrast, the left lung has two lobes: the upper and lower. Human 
lungs are conical in shape and are situated on either side of the mediastinum, surrounded by 
pleural cavities (Seeley et al., 2008). The right lung is larger than the left and weighs an 
average of 620 g, whereas the left lung is generally 560 g in weight. Both lobes of the lung 
have a central region, referred to as the hilum, on the medial surface of the lung, where the 
main bronchus, blood vessels, nerves and lymphatic vessels enter and leave the lung. These 
structures, passing through the hilum, are termed the root of the lung. The bronchi branch 
from the trachea into primary bronchi, which enter the right and the left lungs and then divide 
into small secondary bronchi. These bronchi continuously subdivide into segments and small 
tubes called bronchioles and then terminal bronchioles. The bronchi are supported by 
cartilage in their wall, whereas the bronchioles have smooth muscle tissue; both are lined 
with ciliated columnar epithelial cells. Furthermore, the bronchioles continue to divide, 
terminating in the air spaces of alveoli, where the actual gas exchange occurs between the 
air and the blood (Seeley et al., 2008).   
1.4.1 Alveoli  
 
Alveoli are the main part of the respiratory system and form most of the lung parenchyma. 
Over 350 million alveoli are found in each adult human lung and each alveolus has a 
membrane surrounded by many capillaries facilitating gas transfer to the blood through the 
diffusion process. The surface area of adult human lungs is approximately 60–70 m2, 
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providing an ample surface for gas exchange to be effective. Alveoli are similar to bubbles 
lined with a basement membrane (Figure1.9). Several groups of alveoli are confluent with 
an alveolar duct and terminate at the alveolar sac (Carola et al., 1990). A histological image 
of the respiratory tract shows that most of the upper airway epithelium, from the trachea to 
bronchioles of human lungs, is lined with pseudostratified epithelium, consisting of equal 
proportions of basal cells, secretory cells and ciliated cells (Carola et al., 1990). The smallest 
bronchioles comprise simple columnar or cuboidal epithelia, containing secretary cells 
referred to as goblet cells, and ciliated cells. These cells form the physical barrier against 
foreign substances through the process of mucociliary clearance (Donne et al., 2015). The 
alveolar epithelium is composed of a single layer of epithelial cells – type I and type II 
alveolar epithelial cells, called AEC1 and AEC2 respectively. Airway epithelial cells play a 
critical role in host defence mechanisms, in which they regulate innate immunity and 
produce molecules that interact with immune cells to activate immunity. Furthermore, 
airway epithelial cells (AECs) secrete various microorganism-killing effectors, such as 
mucins, anti-microbial peptides (AMPs) and reactive oxygen species (ROS). These cells also 
produce proinflammatory cytokines, growth factors and chemokines, which recruit and 
activate phagocytes, eliminating pathogens through phagocytosis (Li et al., 2012).  
Type I alveolar epithelial cells (AEC1) are squamous, large, thin cells, which represent 
around 40% of the alveolar lining and combine with other epithelial cells to form an effective 
barrier between the air space and the septal wall (Donne et al., 2015). Type II cells (AEC2) 
are cuboidal cells, smaller than type I cells, which form around 60% of the alveolar lining. 
These secretory cells produce detergent-like phospholipids called surfactant (dipalmitoyl 
lecithin), which is essential for reducing the alveolar surface tension and keeping the alveoli 
inflated. In addition, the surfactant modulates the lung immune response against inhaled 
pathogens (Ross and Pawlina, 2011). Type II cells also have the ability to generate both type 
I and type II cells after lung injuries; thus, they are also an important marker of alveolar 
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injury and the repair of alveoli. Alveolar macrophages, neutrophils and monocytes are also 
found in the alveoli. Alveolar macrophages represent the initial line of phagocytic defence 
against invaders that gain access to alveoli and escape physical defences. These cells have 
the ability to engulf and digest bacteria and initiate the inflammatory immune response 
(Zhang et al., 2000), facilitating the gas exchange between the atmosphere and the blood  
(Carola et al., 1990, Donne et al., 2015, Ross and Pawlina, 2011). In the normal state, an 
array of innate immune receptors, such as TLRs, NLRs and C-type lectins, are expressed by 
the epithelium, as well as microbicidal small cationic peptides, lysozyme, lactoferrin and 
mucins. Epithelial cells also produce cytokines, chemokines and growth factors as a result 
of infection, inflammation, stress and injury (Ramakrishna et al., 2012).  
 
Figure 1.9: Diagrammatic view of the human lung and alveoli. 
Diagrammatic view of the human lung and alveoli. The air pathway consists of the trachea and the 
main, secondary and segmental bronchi, which divide into smaller bronchi and bronchioles, 
terminating in the terminal bronchioles and alveoli. Adopted from (Marieb and Hoehn, 2007). 
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1.4.2 Lung infections  
 
The lungs of the respiratory system are exposed to a large number of microbes and organic 
and inorganic particulate material as a result of the daily inhalation of 10,000 litres of air 
(Bals and Hiemstra, 2004). Healthy individuals are less susceptible to lung infections, 
despite bacteria frequently being inhaled, due to the adequate host defences, which include 
mucociliary clearance, antimicrobial peptides produced by epithelial cells, and the 
sophisticated innate and adaptive immune systems. However, patients with lung disorders, 
such as bronchiectasis (BR), chronic obstructive pulmonary disease (COPD) and cystic 
fibrosis (CF), are characterized by airway inflammation associated with increased mucus 
production and the reduction or inhibition of mucociliary clearance. This is usually 
associated with lung infection -episodes or chronic disease. The recurrent cycles of 
inflammation and tissue damage result in lung damage and reduced lung function and/or 
further respiratory tract infections (RTIs) (Cullen and McClean, 2015).  
RTIs have become the main cause of human morbidity and mortality globally, at great 
economic cost to health care resources (Braido et al., 2007); they are increasing in incidence 
and cases are estimated by the World Health Organisation (WHO) to have exceeded HIV, 
cancer and heart disease (Bomberger et al., 2011). The main cultured pathogens associated 
with RTIs are bacterial infections, such as Pseudomonas aeruginosa (P. aeruginosa), 
Haemophilus influenzae (H. influenzae), Streptococcus pneumoniae (S. pneumoniae), 
Moraxella catarrhalis (M. catarrhalis), Staphylococcus aureus (S. aureus), Chlamydophila 
pneumoniae (C. pneumoniae) and Mycoplasma pneumoniae (M. pneumoniae). Viral 
infections include influenza, parainfluenza viruses and respiratory syncytial virus (RSV). 
Fungal infections are mainly caused by aspergillus and candida (Braido et al., 2007).  
The interaction between pathogens and the host defence depends on factors such as the 
virulence of the pathogen and the susceptibility of the host. The host immune response may 
 
41 
 
eliminate the pathogen and improve immunity against further infection through immune 
memory. However, in the case of bacterial infection with P. aeruginosa, the interaction 
between the host and the bacteria may produce a cycle of infection, allowing the bacteria to 
adhere to the epithelium and colonize the lung in the long term, resulting in tissue damage 
and lung destruction (Bourke, 2002). Obstructive lung diseases associated with frequent 
infections include conditions such as BR, COPD, CF and asthma.  
1.5 Laboratory features 
1.5.1 Lung function test  
 
The lung function test, or pulmonary function test (PFT), is an important diagnostic test in 
the evaluation of patients with different lung diseases, including chronic obstructive lung 
diseases and asthma (Rasam et al., 2015). Spirometry is the most common lung function test 
used to measure limitations in airflow, specifically measuring the volume of air forcibly 
exhaled (forced vital capacity [FVC] and the volume of air exhaled during the first second 
(forced expiratory volume in one second [FEV1] to provide the FEV1/FVC ratio. This is a 
measure simple and has been employed in various clinical studies. PFTs are also defined by 
the Global Initiative for Chronic Obstructive Lung Diseases (GOLD), which is classified 
into four stages: stage 1 (mild, FEV₁ ≥ 80% predicted function); stage 2 (moderate, FEV1 = 
50–80% predicted function); stage 3 (severe, FEV₁ = 30–50% predicted function); and stage 
4 (very severe, FEV1 < 30% predicted function) (Decramer et al., 2012). The ratio between 
FEV1 and slow vital capacity (VC), i.e. FEV1/VC, is also calculated. These measurements 
are then evaluated through comparison with reference data based on age, sex and height  
(Decramer and Vestbo, 2014). Typically, the presence of a post-bronchodilator FEV1/FVC 
less than 0.70 confirms airflow limitation and persistent chronic obstruction (Vestbo et al., 
2013). 
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1.5.2 Bronchoalveolar lavage (BAL) 
 
Bronchoalveolar lavage (BAL) is a research tool in the assessment of the lung diseases that 
are associated with viral and bacterial infections, including COPD, BR and asthma (Garbino 
et al., 2009). BAL is very useful in evaluating airway inflammation, being a safe way of 
investigating the sampling of cells and mediators from the lower airways (Gorska et al., 
2009). This provides reliable data in patients for whom it is difficult to detect 
microorganisms in the sputum (Ratjen, 2006). The analysis of BAL fluid in patients with CF 
has revealed a significant increase in concentrations of local pro-inflammatory cytokines, 
such as IL-1, IL-6, IL-8, and TNF. Elevated inflammatory markers are also observed in the 
BAL fluid of infants with CF in the absence of infection with CF-related pathogens 
(Courtney et al., 2004). Activated neutrophils and macrophages are increased in the sputum 
and BAL fluid of patients with COPD, suggesting their role in airway destruction through 
the secretion of inflammatory mediators, enzymes and reactive oxygen species (Barnes et 
al., 2003). The analysis of BAL fluid has shown higher eosinophil counts in asthmatics 
compared with COPD cases, which may contribute to airway constriction (Gorska et al., 
2009). 
1.6 Respiratory tract diseases 
1.6.1 Bronchiectasis (BR) 
 
Bronchiectasis (BR) was initially described by Laennec in 1819 as a disease of the bronchi 
associated with chronic mucus production and repeated coughing (Neves et al., 2011). BR 
is also defined as a heterogeneous condition characterized by airway inflammation that leads 
to irreversible dilation of the bronchi and persistent sputum overproduction (Boyton, 2008). 
Recently, BR has been diagnosed using high-resolution computed tomography (HRCT), 
which allows diagnosis at earlier stages, thus demonstrating an increase in the prevalence of 
BR. Furthermore, there is an overlap between BR and COPD, where both conditions share 
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common characteristics in terms of their pathophysiology and clinical behaviour. In 2014, 
GOLD described BR as one of the comorbidities of COPD (Du et al., 2016). It has been 
reported that the occurrence rates of BR in COPD are between 29% and 50% (Neves et al., 
2011). Patients with BR may be asymptomatic during the mild phase, but in early-defined 
exacerbations they suffer from a chronic cough, daily mucopurulent sputum production, 
chest pain, weight loss, bronchospasm, dyspnoea, breathlessness, wheezing, tiredness and 
impaired physical performance. Exacerbations are due to viral, or bacterial infections, often 
associated with fever, malaise, increased coughing and sputum production (Boyton, 2012, 
Rademacher and Welte, 2011). The pathophysiology of this disease is defined by infiltrating 
inflammatory cells surrounding the parenchyma, leading to damaged bronchial epithelium. 
The destruction of the elastic and muscular layers of the bronchi leads to the in dilation and 
the impairment of mucociliary clearance, allowing mucus to accumulate and favouring 
bacterial colonization, leading to chronic inflammation. Furthermore, microorganisms 
release inflammatory mediators which cause airway obstruction and progress lung damage 
(Angrill et al., 2002, Rademacher and Welte, 2011).  
1.6.1.1 Aetiology of bronchiectasis (BR)  
 
BR is classified into CF BR, which is  a genetic disease caused by a mutation in the CF 
transmembrane conductance regulator  (King et al., 2006) and non-CF BR (nCFBR), caused 
by multiple conditions. For example, BR may occur following serious infections by fungi, 
viruses and bacteria. BR also progresses due to physical obstruction, producing localized 
areas for disease development (Redding, 2011, Shoemark et al., 2007). Furthermore, the 
incidence of BR is associated with abnormalities in pulmonary host defences, such as 
immune disorders, ciliary dyskinesia and autoimmune disease. In 50% of patients 
(idiopathic), a certain cause is never found (Dogru et al., 2005, Shoemark et al., 2007). 
Whatever the cause, BR leads to a risk of bacterial colonization, a decline in lung function 
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and recurrent exacerbations, resulting in significant morbidity. Some complications 
associated with BR are stated in Table 1.3 (King, 2011, King et al., 2006). The identification 
of causative factors may aid management and the early treatment of the condition (Shoemark 
et al., 2007). 
Table 1.3. Various conditions associated with bronchiectasis (BR). 
(Adopted from (Bandyopadhyay et al., 2004, Whitters and Stockley, 2012)). 
Post infective Viral (adenovirus, measles, HIV) 
Bacterial (pneumococcus) 
Mycobacterium tuberculosis 
Whooping cough 
Host immune defects Allergic bronchopulmonary aspergillosis 
Host immune defects: humoral immune deficiency (IgA, IgG, IgM) 
Selective IgG subclass deficiency 
Specific antibody deficiency 
Mucociliary clearance 
defects 
Primary ciliary dyskinesia 
Kartagener’s syndrome (a genetic disease affecting the airways, 
involving primary ciliary dyskinesia and situs inversus) 
Young’s syndrome (repeated airway infections and congenital 
epididymis obstruction)   
Inflammatory disease Rheumatoid arthritis 
Inflammatory bowel disease 
Chronic obstructive pulmonary disease 
Others Foreign body inhalation 
Middle lobe syndrome 
1-Antitrypsin deficiency 
Toxic inhalation 
 
1.6.1.2 Diagnosis of bronchiectasis (BR) 
 
BR can be diagnosed through the clinical history of patients, in particular childhood and 
respiratory illnesses, and also sputum analysis, pulmonary function tests and biochemical 
analysis of blood samples in association with radiographic changes (Neves et al., 2011). 
High-resolution computed tomography (HRCT) is the best tool for diagnosing BR, allowing 
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detection of the disease at an early stage. This includes ‘tree-in-bud’ abnormalities, 
indicating the distribution of infection in the bronchi (Figures 1.10 and 1.11) (Scullion and 
Holmes, 2013). Bronchoscopy and HRCT demonstrate the structural changes in the airways, 
including in shape, size and separation, and evaluate the quality of lung parenchyma in both 
lungs. Sputum analysis for microbial colonization is also recommended as a diagnostic 
procedure since the disease is characterized by airway inflammation induced by bacterial 
infections (Ibralic and Beslic, 2009).  
Another process for diagnosing BR is spirometry, in which forced expiratory volume in one 
second (FEV1) <80% at ages <14 years at first diagnosis indicates the disease (Rademacher 
and Welte, 2011) . Most, if not all, patients with BR have mild to moderate airflow 
obstruction that worsens over time (King, 2011). The high production of mucus and an 
increase in the thickness of bronchi in the airways also provide markers for BR (Scullion 
and Holmes, 2013). These investigations reveal underlying aetiology and frequently lead to 
a change in disease management (Neves et al., 2011). 
 
Figure 1.10: Transverse image of the lung of a BR patient using HRCT. 
The arrow indicates diseased areas (Rademacher and Welte, 2011). 
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Figure 1.11: Radiograph of a patient with severe non-CF BR. 
Severe cystically enlarged bronchi are marked in the left lung. This radiograph also demonstrates 
crowding of the bronchi, loss of definition of the bronchovascular markings and oligemia (Neves et 
al., 2011). 
 
1.6.1.3 Microbial infection in bronchiectasis (BR) 
 
Patients with BR are often colonized with potentially pathogenic microorganisms. These are 
risk factors for lung disease and they induce inflammatory mediators, leading to bronchial 
wall damage and airway obstruction (Angrill et al., 2002). The hypothesis of a “vicious 
cycle” has been proposed, in which the associated failure of the host defence and induction 
of a host chronic inflammatory response leads to the amplification of the problem (Whitters 
and Stockley, 2012). Pathogens release mediators that can inhibit ciliary function and 
damage ciliated epithelium, leading to the stimulation of chemokines such as IL-8, which 
recruits neutrophils to the site of inflammation in the lung (King, 2011). 
The high production of mucus in the airways of BR patients attracts the growth of bacteria. 
Gram-negative bacteria are the predominant bacteria that have been detected in the sputum 
of patients with BR. These include non-typeable H. influenzae (NTHi), which are non-
encapsulated and found in around 47% of patients. P. aeruginosa and M. catarrhalis are 
found in 12% and 8% of patients respectively(McShane et al., 2013). H. influenza and P. 
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aeruginosa produce mediators that impair ciliary clearance and damage the epithelium. They 
also stimulate chemokines, such as IL-8, to attract neutrophils to the site of inflammation via 
the release of glycoproteins (King, 2011). Once these bacteria are established, it is difficult 
to eradicate them because they have the ability to form robust, antibiotic-resistant biofilms. 
These biofilms make the bacteria more challenging for anti-microbial defences and therapy 
because their hydrated matrix of extracellular polysaccharide and proteins covers the 
organized communities of bacteria and protects them from the host environment. Biofilms 
allow the bacteria to survive in the host through several means. First, within the biofilm, 
there are zones of anoxia, acidity, or nutrient depletion that promote the bacteria, enabling 
them to be increasingly antibiotic resistant. Second, biofilms delay the rate of antibiotic 
diffusion, allowing bacteria more time to sense and respond to their environment. Finally, 
biofilms may protect the bacteria from phagocytosis and various host defences (McShane et 
al., 2013). P. aeruginosa colonization has been shown to correlate with a higher decline in 
lung function and the exacerbation and progression of disease (McShane et al., 2013). Non-
typeable H. influenzae strains, which lack the polysaccharide capsule of a typeable strain, 
have been found to be one of the main bacterial pathogens detected in respiratory secretions. 
This microorganism can cause recurrent or chronic lower airway infection in BR and persists 
in the lung through different strategies. The microorganism expresses multiple adhesions 
with individual specificities for different cell types in the respiratory tract. The ability to 
survive within some innate cells, such as macrophage and epithelial cells, allows the bacteria 
to undergo antigenic drift, thus avoiding adaptive immune responses. Furthermore, the 
bacteria also form biofilms on the mucosal surfaces and effectively resist the host defence 
mechanism. The appearance of M. catarrhalis, also detected in BR, in the respiratory tract 
is due to the capacity of this bacterium to invade respiratory epithelial cells, induce biofilms 
and avoid complement activation (Grimwood, 2011). A recent study found that, in a 
proportion of BR patients colonized by P. aeruginosa, their antibodies surprisingly protect 
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the bacterium from complement-mediated killing (Wells et al., 2014). These bacteria 
produce lipopolysaccharide containing O-antigen and the impaired antibody-mediated 
killing is due to the high production of O-antigen-specific IgG2 antibodies. As the O-antigen 
can be in other Gram-negative bacteria, the failure of IgG to kill the bacteria may be found 
in different Gram-negative bacteria. The depletion of IgG2 to O-antigens increases the 
patient serum’s ability to kill such strains. These findings are important in understanding the 
protection produced by natural infection and the design of vaccines (Wells et al., 2014). 
1.6.1.4 Innate and adaptive immunity in bronchiectasis (BR) 
1.6.1.4.1 Neutrophils    
     
Neutrophils are the most abundant cells found in the pulmonary tissues of BR patients. They 
rapidly migrate into the site of inflammation and provide effector mechanisms, such as 
phagocytosis, reactive oxygen mediators and other anti-microbial properties. Activated 
neutrophils also release proteases, neutrophil elastase and pro-inflammatory mediators, 
including IL-1, IL-8 and TNF. Neutrophils and epithelial cells express TLRs. Once TLRs 
encounter specific pathogen-associated molecules, they provoke a signalling cascade, 
leading to the activation of nuclear factor (NF)-kB and other transcription factors (Fuschillo 
et al., 2008). Furthermore, neutrophils release matrix MMPs, which may augment the 
inflammation and cause airway remodelling. High levels of MMPs which have been found 
in the BAL fluid of patients with CF and non-CF BR may contribute to the progression of 
the disease (Bergin et al., 2013). 
1.6.1.4.2 Macrophages  
 
Although the role of macrophages in patients with BR is still unclear, there is a higher 
proportion of macrophages within the entire lamina propria of patients compared to healthy 
controls. Also, higher numbers of macrophages are seen in patients with regular sputum 
production, suggesting macrophages may be implicated in disease activity (Fuschillo et al., 
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2008). Moreover, increased TNF levels have been observed in the airway lamina propria 
of these patients. This is attributed to the activation and stimulation of macrophages by LPS 
from bacteria (Zheng et al., 2001).  
1.6.1.4.3 Lymphocytes   
    
Infiltrating T cells have been found in the lamina propria and the epithelium of both humans 
with BR and in experimental models of idiopathic BR (Fuschillo et al., 2008). Increased 
CD4+ and CD8+ T cells found in the lungs and BAL fluid of patients with BR may contribute 
to the inflammatory response (Boyton, 2008, Fuschillo et al., 2008). The principal role of 
cytotoxic T cells in idiopathic BR is supported by observation of bare lymphocyte syndrome 
type 1, which is caused by a mutation in the gene of MHCI molecules. Consequently, these 
patients lack expression of MHCI and CD8+ T cells, which leads to recurrent respiratory 
infections and airway damage, resulting in BR (Fuschillo et al., 2008).  
Furthermore, research has revealed an association between idiopathic BR and the human 
leukocyte Class II antigen HLA-DR1, DQ5. This suggests that the recognition by CD4+T 
cells of these MHC molecules presenting antigen from respiratory bacterial pathogens is 
affected, thus increasing susceptibility to lung infections (Grimwood, 2011). 
Th17 cells are also important, as the airway submucosa shows greater levels of IL-17+ cells  
which may correlate with neutrophil numbers, leading to the vicious cycle of infection and 
inflammation (Boyton et al., 2012). It has been found that patients with BR have higher pro-
inflammatory cytokines, such as tumour necrosis factor α (TNF), IL- 6 and IL-8 in the 
sputum, BAL fluid and plasma (Martínez-García et al., 2008). Primary antibody deficiency 
syndromes (PADS) have been implicated in BR, in which there is inability to mount a proper 
and competent antibody response to pathogen antigens. This can involve either the partial or 
complete absence of one or more Ig classes or subclasses (Whitters and Stockley, 2012), 
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including IgM, IgG, IgA and the IgG subclasses: IgG1, IgG2, IgG3 and IgG4. Furthermore, 
a reduction in the antibody response to encapsulated pyogenic bacteria, such as H. influenzae 
and S. pneumoniae (pneumococcus), has also been found in patients with BR (Stead et al., 
2002). In response to H. influenzae, Th2 was the predominant T cell response in patients with 
BR, rather than the Th1 found in healthy controls (Grimwood, 2011). 
1.6.2 Chronic obstructive pulmonary disease (COPD) 
 
Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death 
throughout the world. It affects around 10% of the general population, with increasing 
incidences of morbidity and mortality (Cosio et al., 2009). COPD has become the fourth 
leading cause of death in industrialized countries and is expected to be the third leading cause 
of death worldwide by 2020 (Kheradmand et al., 2012). COPD is characterized by a 
limitation of air flow, which is not fully reversible, in association with an abnormal 
inflammatory response of the lungs to noxious particles and gases such as those found in 
cigarette smoke  (Dutta, 2013, Gadgil and Duncan, 2008). The structural abnormalities that 
are found in bronchioles with a diameter of less than 2 mm are characterized by increased 
airway wall thickness with peribronchial fibrosis, and by luminal reduction (Hogg, 2006). 
Exposure to smoke promotes inflammatory infiltrates in the mucosa and alveolar walls, 
increased mucus secretion, epithelial cell hyperplasia and the destruction of alveoli (Figure 
1.12). These factors appear to contribute to recurrent bacterial infections and inflammatory 
responses (Decramer et al., 2012, Hogg, 2006, Kheradmand et al., 2012).  
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Figure 1.12: Histological image of airways of a healthy subject and a subject with COPD. 
(A) clear normal airways; (B) airways affected by COPD have inflammatory cell infiltration, 
mucosal hyperplasia and increased thickness of connective tissue in the peribronchiolar space. 
Modified from (Decramer et al., 2012). 
 
1.6.2.1 Aetiology of COPD  
1.6.2.1.1 Smoking risk factors 
 
Cigarette smoke is the main risk factor for COPD, which probably accounts for ∼80–90% 
of COPD cases in the US (Yoshida and Tuder, 2007). Cigarettes contain a mixture of 
carcinogens, irritants and free radicals and when these components are introduced into the 
lungs, excessive inflammatory responses disturb the normal lung defence mechanisms 
(Nikota and Stämpfli, 2012). The chemical components of cigarettes generate reactive and 
unstable free radicals, such as superoxide anion, nitric oxide, peroxynitrite (ONOO-) and 
hydroxyl radicals, leading to a series of chain reactions resulting in tissue damage due to 
oxidation (Figure 1.13). Several studies have shown the presence of oxidative stress and free 
radical biomarkers in patients with COPD. High levels of 8-hydroxy-deoxyguanosine have 
been found in the urine of COPD patients and increased levels of 3-nitrotyrosine and F2α 
isoprostanes have been detected in the lungs. These biomarkers are associated with disease 
severity (Yao and Rahman, 2011). The gas and tar phase of cigarette smoke contains reactive 
oxygen and nitrogen species (ROS, RNS), as well as phenols and quinone (Yoshida and 
Tuder, 2007). ROS/RNS are also induced by the inflammatory immune response of cells 
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such as epithelial cells, resident macrophages, neutrophils, monocytes, B and T lymphocytes 
amplified by cytokines, and chemokines. The main ROS-generating enzyme in 
inflammatory cells is nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) and 
other enzymes are involved, such as xanthine oxidase. Likewise, RNS in the form of nitric 
oxide (NO) is generated by nitric oxide synthase. A study of a mouse model showed that 
NADPH oxidase causes enlargement of the airspace, suggesting that ROS derived from 
NADPH oxidase actively contributes to the signalling pathway of tissue homeostasis. 
Therefore, the use of an NADPH oxidase inhibitor to alter the oxidant/antioxidant imbalance 
in COPD may be damaging (Yao and Rahman, 2011). Cigarette smoking has various effects 
on the mechanical barrier of the lung, reducing the frequency of ciliary beat and promoting 
squamous metaplasia. This may lead to a reduced number of ciliated cells and the stimulation 
of goblet cell and submucosal gland secretions. The high production of mucus in the airways 
and impaired mucociliary clearance promotes bacterial growth and colonization in the 
airways (Beasley et al., 2012). Once bacteria have become established, they increase mucus 
secretion, disrupting the ciliary activity and amplifying the chronic cycle of infections. 
Chronic bacterial infection, which produces inflammation, contributes to progressive airflow 
obstruction and lung destruction. Cigarette smoking also impairs the ability of innate 
immune cells, such as macrophages and neutrophils in the airway, to eradicate pathogens by 
phagocytosis (Beasley et al., 2012, Sethi, 2010). 
Pulmonary emphysema is the key feature of COPD and it is much more likely to be found 
in cigarette smokers than in non-smokers. Emphysema is defined as a permanent 
enlargement of air space distal to the terminal bronchioles. It is associated with  the 
irreversible destruction of alveolar walls and contributes directly to airflow reduction (Horio 
et al., 2017). The process includes the disruption of the epithelial barrier and thus interfering 
with mucociliary clearance, resulting in an increase of inflammatory mucous in the small 
conducting airways and accumulations of connective tissue in the airway wall (Hogg, 2004).  
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Emphysema is  characterized by different inflammatory cells including neutrophils, alveolar 
macrophages, CD4+ and CD8+ lymphocytes and imbalances of proteinase and anti-
proteinase within alveolar space, leading to the permanent loss of airspace and destruction 
of alveoli (Cheng et al., 2009, Goldklang et al., 2012). 
It has been shown that activated macrophages and neutrophils produce proteases, including 
matrix metalloproteinases (MMPs), which degrade elastin, collagen, proteoglycans and 
other structural proteins leading to alveolar wall damage and contributing to the aetiology of 
emphysema (Cheng et al., 2009, Ostridge et al., 2016). The expression of MMP is also found 
in the airways of COPD subjects (Ostridge et al., 2016).  
 
Figure 1.13: The pathogenesis of COPD. 
Cigarette smoke induces inflammatory responses, which in turn activate macrophages (1) and 
neutrophils (2) to release proteases. The chemical components of cigarette smoke generate oxidants, 
resulting in parenchymal lung damage (3) and over time induce emphysema. In addition, activated 
epithelial cells stimulate fibroblast activity, resulting in chronic bronchitis (5). Adapted from (Wood 
and Stockley, 2006). 
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1.6.2.1.2 Non-smoking risk factors 
 
Although the major environmental risk factor for COPD is tobacco smoke, the cellular and 
molecular mechanisms that are involved in the pathogenesis of the development of COPD 
have not fully been explained. It has been suggested that genetic factors are major 
contributors, such as the rare hereditary deficiency of α 1-antitrypsin (AAT), a disintegrin, 
metalloproteinase 33 (ADAM33), antioxidant superoxide dismutase (SOD) and pro-
inflammatory mediators, such as TNFα (D'hulst et al., 2005, Yao and Rahman, 2011). AAT 
is a serine protease inhibitor, which is synthesized in the liver and belongs to the group of 
acute phase proteins associated with inflammatory infection. It is elevated in 1–3% of 
patients with COPD (Mannino and Buist, 2007, Wozniak et al., 2015). Other factors, such 
as indoor air pollution from burning biomass fuels, are also associated with an increased risk 
of COPD in developing countries (Cosio et al., 2009). Indoor air pollution is probably 
responsible for an estimated 2 million deaths and 4% of the global health burden in 
developing countries. Exposure to various levels of indoor pollutants released from cooking, 
baking and heating with a biomass fuel, such as coal, straw, animal dung and wood, suggests 
that this chronic exposure is associated with chronic airflow obstruction in adults and acute 
respiratory infection in children (Liu et al., 2007). Furthermore, exposure to dust, chemicals 
and fumes in the workplace is another risk factor that is associated with COPD (Mannino 
and Buist, 2007).  
1.6.2.2 Diagnosis of COPD 
 
In terms of diagnosis, the examination of medical history and spirometry are critical steps. 
Patients with COPD complain of a cough, sputum production, dyspnoea and wheezing. 
Spirometry is used to measure airflow limitation, which is helpful in assessing the severity 
of COPD. To increase the accuracy of spirometry, the test should be performed when the 
patient is stable or 8 weeks following exacerbation (Dutta, 2013). Chest X-rays are useful to 
 
55 
 
show pockets of trapped air that are associated with emphysema. Sputum production analysis 
is not very useful in diagnosing patients with COPD because the majority of patients produce 
a small amount of sputum with coughing (Dutta, 2013). 
1.6.2.3 Innate and adaptive immune cells in COPD  
1.6.2.3.1 Neutrophils  
 
Neutrophils are short-lived cells and the first line of defence recruited from the circulation 
to the airways of the lungs. The role of neutrophils in the pathogenesis of COPD has been 
established. Activated neutrophils are increased in the sputum and the BAL fluid of patients 
with COPD. These cells produce serine proteases, including neutrophil elastase (NE), 
cathepsin G, proteinase‐3, matrix metalloproteinase (MMP)‐8 and MMP‐9, which in turn 
leads to inflammation and alveolar destruction (Barnes et al., 2003). Neutrophils also 
contribute to the production of mucosal metaplasia in chronic bronchitis and the destruction 
of lung tissues in emphysema. Studies focused on the analysis of airway smooth muscle have 
found an association between neutrophil infiltration and both computed tomographic 
measurements of air trapping and the severity of airflow. Such studies explain that exposure 
to inflammatory mediators leads to smooth muscle contraction, mucus induction and 
peripheral airway dysfunction in COPD (O’Donnell et al., 2006).  
1.6.2.3.2 Macrophages  
 
Macrophages are part of the innate immune system, playing a major role in the airway 
defence mechanism against infections and potentially contributing to the pathophysiology 
of COPD. Macrophages are markedly increased in the airways, lung parenchyma, BAL fluid 
and sputum of COPD patients (Barnes et al., 2003). Macrophages release inflammatory 
compounds, such as reactive oxygen species, chemotactic factors, inflammatory cytokines, 
smooth muscle constrictors, mucus gland activators, extracellular matrix proteins and a 
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range of matrix metalloprotease enzymes (MMPs). These mediators are stimulated by the 
components of cigarette smoke. Specifically, alveolar macrophages induce elastolytic 
enzymes, including MMP-2, MMP-9 and MMP-12, resulting in emphysema. It has been 
shown that alveolar macrophages from COPD patients have a high level of elastolytic 
activity at baseline compared with normal smokers (O’Donnell et al., 2006).  
1.6.2.3.3 Epithelial cells  
 
Airway epithelial cells are the first line of defence and provide a physical barrier preventing 
invasive infection, as well as producing a range of antimicrobial compounds, such as 
defensins and other cationic peptides. These cells have numerous PRRs that are necessary 
for pathogen recognition. In addition, these cells secrete antioxidants and antiproteases, such 
as secretory leukoprotease inhibitor (SLPI) (Barnes et al., 2003, Parker and Prince, 2011). 
Airway epithelia can be affected by environmental stimuli, such as airborne pollutants, 
allergens, cigarette smoke and microbes, leading to a change in epithelium defence 
mechanisms, such as the secretion of mucus and reduced efficiency of ciliary beating. Once 
the epithelial cells are activated, they produce IFNand TNF. These mediators prompt 
epithelial cells to release secondary mediators, including lipid mediators, reactive oxygen 
species (ROS), IL-1, GM-CSF and IL-8, all of which increase inflammation and contribute 
to the pathophysiology of COPD (Barnes et al., 2003, Pettersen and Adler, 2002).  
1.6.2.3.4 T lymphocytes  
 
T lymphocytes have a variety of activities involved in protective immunity against lung 
infection. They provide help for proliferation and functioning of other cell types. There are 
different subsets of T cells involved in COPD including CD8+, CD4+, T regulatory cells and 
Th17+ T cells, all potentially contributing to the pathogenesis of COPD (Grumelli et al., 
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2004). Tobacco smoking with COPD also stimulates the humoral and cellular components 
of the adaptive immune response (D'hulst et al., 2005).  
In COPD, CD8+ lymphocytes secrete a predominantly Th1 cytokine pattern that includes 
increased production of IFNγ, interferon-inducible protein-10 (IP-10) and monokine 
produced by interferon-gamma (MIG). These mediators can lead to tissue injury through the 
up-regulation of matrix metalloproteinase (MMP) (Brusselle et al., 2011, Gadgil and 
Duncan, 2008). Furthermore, CD8+ T cells can cause cell death by secreting cytotoxic 
mediators such as granzyme and perforins, suggesting a potential role in COPD 
pathophysiology (Brusselle et al., 2011). Various studies have reported high levels of CD8+ 
in the sputum of smokers with and without COPD compared with non-smokers, and that 
these cells are highly active in producing lytic substances such as perforin. Increased levels 
of CD8+ T cells have also been reported in the lung parenchyma and within the smooth 
muscle of airways of COPD patients (Sohal et al., 2013). 
CD4+ T cells are also important in the release of activating cytokines and in focusing and 
increasing inflammatory responses by other immune effectors such as macrophages, 
neutrophils and NK cells. CD4+ T cells provide help for the activation of B cells and may 
facilitate the production of IgG autoantibodies in COPD. They also provide help for isotype 
switching from IgM to strong and avidly binding IgG antibodies, in particular against protein 
antigens (Gadgil and Duncan, 2008). Grumelli et al. (2004) found that reduced lung function 
in COPD patients is strongly associated with CD4+ and CD8+ T lymphocytes expressing a 
specific repertoire of chemokine receptors, such as CCR5 and CXCR3 (markers for Th1 but 
not Th2). Furthermore, peripheral lung lymphocytes from ex-smokers with COPD show that 
both CD4+ and CD8+ T cells are polarized to the Th1 phenotype compared to cells from the 
lung tissue of normal individuals. The destruction of alveolar tissue observed in the lungs of 
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patients suggests an autoimmune component involving CD4+T cells in the pathogenesis of 
COPD (Vargas-Rojas et al., 2011). 
It has been shown that, in a COPD cohort, TNFα, IL-13 and IL-17 are produced by peripheral 
T cells in response to non-typeable H. influenzae (NTHi). These pro-inflammatory mediators 
have been proposed to contribute to inflammation (King et al., 2013). Th17 cells are a critical 
component of the adaptive immune response, which is implicated in chronic inflammatory 
and autoimmune diseases. These cells are important in the clearance of pathogens that are 
not cleared by Th1 and Th2 cells, such as extracellular bacteria and fungi. It has been shown 
that the differentiation of naive T cells into Th17 depends on the presence of TGFβ1 and IL-
6. Elevated levels of TGFβ1 in the serum of COPD patients and increased IL-6 in both serum 
and sputum during COPD exacerbation may lead to higher Th17 cells observed in patients 
with COPD compared to smokers without COPD and healthy individuals. Also, a large 
number of Th17 cells may predict the severity of airflow, as the decline in lung function is 
associated with increased Th17 cells (Cazzola and Matera, 2012). 
1.6.2.4  Exacerbation of BR and COPD  
 
An exacerbation of BR and COPD are defined as an acute worsening of respiratory 
symptoms associated with events of physiological instability, including dyspnoea, cough, 
sputum production, large volumes of purulent sputum and wheezing, and may include 
systemic complaints such as fever and fatigue for >24 h. These symptoms contribute to the 
progressive decline in lung function and accelerate morbidity, mortality and poor health 
status (Dickson et al., 2014, Metaxas et al., 2015). Acute exacerbation (AE) is more common 
in older individuals with COPD, who experience worsening of symptoms for >48 hours 
leading to the acceleration of lung function decline, respiratory failure and often death (Liao 
et al., 2015). The causes of exacerbation are not well-defined and are described as 
heterogeneous events because various factors are implicated, such as respiratory virus and 
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bacterial infections of the airway, often associated with the progression of airflow 
obstruction (Gompertz et al., 2001, Wedzicha and Seemungal, 2007). In COPD, the most 
frequent viruses associated with an exacerbation are rhinoviruses, coronavirus, respiratory 
syncytial virus, influenza and parainfluenza viruses. It has been found that exacerbations 
caused by respiratory viral infection are more severe and require a longer recovery time 
(Wedzicha and Seemungal, 2007) than those caused by other factors. Traditional culture-
based methodologies have demonstrated that approximately 50% of COPD exacerbations 
are associated with bacterial infections, such as S. pneumoniae, H. influenzae and M. 
catarrhalis, leading to increased symptoms of coughing, sputum production and 
inflammatory changes, particularly in acute exacerbations. However, these pathogens can 
also colonize the airways between exacerbations (Han et al., 2012 , Mohammad and 
Dhanashree, 2012, Pragman et al., 2012). Tissue deterioration and inflammation in the lung 
impairs local immune responses and provides a suitable microenvironment for additional 
complicated pathogens, such as P. aeruginosa and Stenotrophomonas maltophilia (S. 
maltophilia) (Lode et al., 2007). These bacteria stimulate inflammatory mediators, such as 
neutrophils, IL-8 and TNFα, in the sputum (Beasley et al., 2012). However, recent studies 
have suggested that bacterial and viral infections may not be the main causative factor in the 
development of BR exacerbations (Guan et al., 2015, Metaxas et al., 2015). P. aeruginosa 
colonization has predominantly been associated with a higher number of exacerbations, poor 
quality of life and increased hospital admissions compared with patients colonized with other 
bacterial infections, accelerating lung function decline (Chawla et al., 2015). 
1.6.3 Asthma 
 
Asthma is a long-term chronic inflammatory condition, comprising airway limitation, in which many 
cells and cellular elements play a critical role (Gillissen and Paparoupa, 2014). Globally, asthma 
affects more than 300 million people, with approximately 250,000 annual attributable deaths (Kudo 
et al., 2013). The Health and Social Care Information Centre 2013 showed that asthma affects an 
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estimated 3.8 million individuals in the UK and incidence has increased worldwide in the past 30 
years (Hazeldine, 2013). Asthma often starts in childhood, both due to inherited genetic traits and in 
association with exposure to common inhaled allergens. Around one million children in the UK have 
been diagnosed with asthma (Reed and Neil, 2013). It is characterized by recurrent episodes of 
shortness of breath, coughing, chest tightness, sputum production and wheezing. These symptoms 
increase at night or in the early morning, as well as after exposure to environmental antigens or 
stimulus (Racusin et al., 2013). The predominant cause of asthma is genetic disposition, together 
with exposure to environmental antigens and factors such as house dust mites, plant pollens, animal 
dander, airborne pollutants, viral infections, physical factors (i.e. exercise and cold air) and some 
drugs, such as aspirin (Clancy and Blake, 2013). Despite some similarities between asthma and 
COPD, there are obvious differences in the airway physiology, pathogenesis and different patterns 
of inflammation. COPD shows persistent airflow limitation that is not fully reversible (Kitaguchi et 
al., 2016, Tzortzaki et al., 2011). However, asthma is characterized by chronic inflammation and 
airway remodeling leading to airflow obstruction that is often reversible spontaneously or by 
treatment (Tzortzaki et al., 2011).  
The chronic inflammation within the respiratory  tract are associated with the involvement 
of different inflammatory cells and cytokine expression (Aoshiba and Nagai, 2004). 
1.6.3.1 Pathology of asthma  
 
The clinical hallmarks of the pathogenesis of asthma are airway inflammation with 
reversible airflow limitation, collagen deposition under the epithelium, increased airway 
smooth muscle and thickening of the sub-mucosal basement membrane (Barnes, 2008). 
Collagen types I and III are produced by activated fibroblasts, such as myofibroblasts, 
resulting in significant structural changes in the airways (Chanez et al., 2004). The loss of 
ciliated epithelium cells is also associated with asthma, as well as increased mucous gland 
hypertrophy in the submucosa. Airway obstruction in asthmatics can affect both the large 
and the small airways and lead to the early closing of the smaller airways and a decrease in 
expiratory flow rates (Fireman, 2003). The main feature of asthma is declining lung function, 
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with a reduction in peak expiratory flow (PEF) or forced expiratory volume in 1 second 
(FEV1) (Edwards et al., 2012). Abnormalities in the general immune response and local 
immune dysregulation in the mucosal surface are also implicated in asthma. Airway 
remodelling occurs in asthmatic patients because of repeated episodes of inflammation and 
through the production of matrix proteins and growth factors induced by inflammatory cells. 
Recurrent epithelial damage followed by tissue repair is another cause of airway remodelling 
(Barrios et al., 2006).  
1.6.3.2 Immunopathogenesis 
 
Asthma is an inflammatory disorder of the pulmonary airways associated with the innate and 
adaptive immune response that involves both cellular and humoral immunity result in the 
clinical expression of reversible lower airway obstruction (Fireman, 2003, Holgate, 2012). 
It is classified into several phenotypes, including an allergic asthma phenotype characterized 
by allergen sensitization and involving an adaptive immune response resulting in the 
induction of allergen-specific Th2 and IgE responses (Holgate, 2012). In contrast, non-
allergic asthma phenotypes are associated with exposure to environmental factors such as 
air pollution and cigarette smoke, involving innate immunity. These include macrophages, 
neutrophils, natural killer T cells and innate lymphoid cells (Yu et al., 2014). The airway 
epithelium contains a large population of airway epithelial cells that interact with inhaled 
allergens and pathogens and can activate the immune response by influencing antigen-
presenting cells such as DCs. These cells express various extracellular and intracellular 
PRRs, such as TLRs. Mature DCs that have taken up allergens migrate to draining lymph 
nodes, where they process the allergens into small peptides, and then present them via MHC 
class I and MHC class II to T cells (Papazian et al., 2015). Co-stimulatory molecules and 
epithelial-derived cytokines and chemokines such as IL-33, IL-25, CCL17 and CCL22 
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induce the activation of DCs and Th2 maturation, which then migrate into the mucosa 
(Holgate, 2012).  
Group 2 innate lymphoid cells (ILC2s), another population of innate cells associated with 
Th2 responses, are similar to lymphocytes but they lack expression of T-cell or B-cell antigen 
receptors. These cells produce signature cytokines associated with Th1, Th2, or Th17 cells, 
including IL-5 and IL-13. It has been shown that ILC2 are implicated in lung inflammation 
and mediate allergic inflammation in response to the papain allergen (Papazian et al., 2015). 
Furthermore, humoral immune responses play a critical role in the immediate allergic 
response upon exposure to allergens. Isotype switching from IgM to IgE involves both 
cytokines (IL-4 or IL-13) and ligation of CD40 and CD40L modulated by Th2 cells (Holgate, 
2012).  
The eosinophils, mast cells, T cells (in particular Th2 CD4
+) and macrophages are the major 
cells described in asthma aetiology (Aoshiba and Nagai, 2004). Mast cells are also important 
in the pathology of asthma, in which Fc receptors bind with high affinity to IgE. Upon 
exposure to antigen, binding mast cells are stimulated to release histamine and tryptase and 
to synthesize leukotrienes, prostaglandins and platelet-activating factor. These mediators 
promote smooth muscle contraction and increase secretion from mucus glands (Fireman, 
2003) (Figure 1.14). Studies in animal models of asthma have shown that Th2 cells are 
associated with the pathogenesis of asthma through the recruitment of eosinophils and 
induce goblet cell hyperplasia. Th2 cytokines such as IL-5, IL-9 and IL-13 activate 
eosinophils to produce inflammatory mediators, such as leukotrienes, platelet-activating 
factor and major basic protein. These derived mediators damage the mucosa and accelerate 
pulmonary obstruction (Lacy and Moqbel, 2000). Furthermore, IL-5 is essential in 
eosinophil proliferation, differentiation and maturation, migration to tissue sites and 
survival. Thus, in the case of asthma associated with eosinophils, targeting IL-5 inhibition 
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(through neutralizing mAbs) may be an effective method for treatment of especially severe 
asthma (Garcia et al., 2013).  
 
Figure 1.14: Histological image of bronchial mucosa in a normal individual (A) and a patient 
with asthma (B). 
Obvious differences in the asthmatic compared to the healthy individual are the goblet cell 
hyperplasia in the epithelial cell lining, the thickening of the sub-basement membrane and the 
collagen deposits and cellular infiltration (Busse and Lemanske, 2001). 
 
1.6.3.3 Microbial infections in asthma  
 
Bacterial and viral infections are associated with the exacerbation of asthma by impairing 
mucociliary clearance and inducing increased mucus production. S. aureus, H. influenzae 
and Chlamydia pneumoniae (C. pneumoniae) are pathogens often isolated from the sputum 
of asthmatics. The persistence of these bacteria is perhaps due to the reduced phagocytic 
capacity of macrophages in eradicating bacteria, leading to accelerated chronic inflammation 
and exacerbations (Liang et al., 2014). S. aureus is frequently isolated from the respiratory 
tract and is found in 87% of patients with intrinsic asthma (Stentzel et al., 2016). Infection 
with these bacteria is characterized by the high production of inflammatory mediators such 
as TNFα, IL-8 and IFNγ; these mediators activate local immune cells such as Th2 and 
macrophages, leading to structural changes in the airways through the regulation of MMPs 
(Liang et al., 2014). Mycoplasma pneumoniae has been identified in respiratory samples of 
adults and children affected with asthma and is associated with the severe persistent acute 
exacerbation of asthma. M. pneumoniae infection promotes the host inflammatory response 
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via the activation of neutrophils, lymphocytes and plasma cells, resulting in pulmonary 
injury. The protein membrane components of M. pneumoniae activate PRRs, including TLR-
1, TLR-2 and TLR-6, and increase the production of proinflamatory cytokines such as IL-8 
and TNFα (Chaudhry et al., 2016). C. pneumoniae also inhibits the apoptosis of the infected 
cells, which ensures the longevity of the host cells and increases chronic inflammation due 
to persistent infection (Gillissen and Paparoupa, 2014). Furthermore, viral infections such as 
respiratory syncytial virus (RSV) are very common in individuals with asthma. RSV causes 
an imbalance between Th1 and Th2, with high levels of IFNγ and low levels of IL-4. 
Increased levels of IL-4 and IFNγ in cord blood are associated with a diagnosis of asthma at 
6 years of age, so the measurement of cytokines may be helpful in diagnosing individuals at 
risk of asthma (Castro et al., 2008).     
1.6.4 Cystic fibrosis (CF)       
 
CF is one of the most common life-threatening autosomal recessive conditions in Caucasian 
populations (Milagres et al., 2009). Genetically, CF is caused by a mutation in the gene that 
codes for the CF transmembrane conductance regulator (CFTR) protein. The defective gene 
was cloned in 1989 and is located on the long arm of chromosome 7 (Jackson and Pencharz, 
2003). CF is also defined as a disease of exocrine gland function, initiating several 
pathological and clinical complications (Jacquota et al., 2008).  The main function of the 
CFTR protein is the transport of chloride ions and the regulation of other ion channels 
through the epithelial cell membrane, such as the inhibition of the transport of sodium ions 
through the sodium channel, the regulation of adenosine triphosphate (ATP) channels, the 
exchange of bicarbonate-chloride and others (O’Sullivan and Freedman, 2009). The failure 
of chloride ion transport into the bronchial mucosa leads to abnormally high viscosity 
secretions and mucus plugging, resulting in an impaired volume of ciliary movement and 
the inhibition of mucociliary clearance, which promotes bacterial colonization and 
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significantly reduces life expectancy in CF (Bourke, 2002, Henrique, 2007). Structural 
abnormalities found in CF lungs include BR, the accumulation of airway mucus, 
peribronchial inflammation and fibrosis associated with high levels of MMPs and 
glycosaminoglycan (Cigana et al., 2016).  
1.6.4.1 Microbial infections in CF  
 
The hallmarks of CF lung disease are acute and chronic bacterial infection and subsequent 
excessive inflammatory immune responses. High sodium chloride levels on the airway 
surface disrupt mucociliary transport and may inhibit anti-microbial molecules, such as 
lysosome and β-defensins, thus enhancing bacterial growth (Ratjen, 2006). The most 
commonly isolated pathogens in CF are S. aureus, P. aeruginosa, Burkholderia cepacia 
complex (B. cepacia), S. maltophilia and non-tuberculous mycobacteria (de Vrankrijker et 
al., 2010). It has been suggested that S. aureus is the main pathogen colonizer during early 
CF infection, whereas P. aeruginosa is eventually established and persists for decades 
because of its ability to survive in various environments and develop resistance to different 
antibiotics (Nguyen et al., 2016). Furthermore, early P. aeruginosa infection together with 
S. aureus colonization significantly influences the progress of CF pathology due to its 
virulence factors and the ability to evade immune responses and antibody treatment (Yonker 
et al., 2015). Group members of B. cepacia have also been isolated from older CF patients 
and can cause nosocomial infections in people with CF. This group is highly resistant to 
antimicrobial compounds and antibiotic treatment. Therefore, it is necessary to identify the 
strains early on and to ensure that patients colonized with B. cepacia are isolated from other 
patients to reduce the risk of transmission (Baldwin et al., 2005). Several studies have shown 
that most of the bacteria isolated in biofilms contain exopolysaccharides and host mucin. It 
is suggested that airway inflammation caused by these pathogens is induced by the release 
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of bacterial components, which access the airway epithelium and stimulate immune cells in 
the lung, rather than by direct contact between organism and host cells (Sadikot et al., 2005).  
The acquisition of fungal species also occurs in the respiratory tract of patients with CF. 
Candida species and Aspergillus fumigatus (A. fumigatus) are the most common fungi 
isolated from the airways of CF patients, with a prevalence of A. fumigatus ranging from 
16% to 45.7% and Candida dubliniensis being present in 11.1% in CF patients (Bouchara et 
al., 2009).  
1.6.4.2 Inflammatory cells and cystic fibrosis  
 
The inflammatory response in CF involves both innate and adaptive responses. Neutrophils 
migrate to the site of infection and release inflammatory mediators and pro-inflammatory 
cytokines, such as TNFα, IL-8, and IL-1β, causing lung injuries (Figure 1.15). Neutrophils 
also release oxidants and protease mediators, such as neutrophil elastase. Neutrophil elastase 
can digest the elastin fibres and other matrix proteins in the airway, increasing mucus 
secretion, stimulating the generation of chemoattractants and promoting degradation and 
tissue damage (Courtney et al., 2004). CFTR dysfunction results in impaired human 
macrophages and increases pro-inflammatory cytokine released by macrophages, such as 
IL-1α, IL-6, G-CSF and IL-8 (Yonker et al., 2015). IL-8, TNFα and IL-1β produced by 
macrophages in response to bacterial LPS may activate neutrophils and aid development of 
Th1 or Th2 response in CF (Conese et al., 2003). 
The role of T lymphocytes against infections is pathogen-specific (Yonker et al., 2015). 
Most patients with CF and chronic P.aeruginosa colonization have increased antibody 
responses and are dominated by Th2 immune responses, characterized by IL-4, IL-5, IL-6 
and IL-10 production, as well as IgG1 and IgE antibody (Song et al., 2003). Furthermore, a 
high anti-Pseudomonas-specific IgG response associated with defective STAT1 signalling 
is found in CF respiratory epithelium. Increased levels of IgG response appear insufficient 
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to clear the bacteria from the lung or prevent the further acquisition of new P. aeruginosa. 
However, specific IgG is likely to be important in preventing the systemic spread of P. 
aeruginosa, as infected patients rarely develop pseudomonal bacteremia or sepsis (Amin et 
al., 2010). T-cells from the peripheral blood cells of CF patients colonized with P. 
aeruginosa produce high TNF and interferon- levels. Thus, T cell responses to P. 
aeruginosa potentially contribute to the progression of respiratory disease and failure (Dubin 
et al., 2007).  
 
Figure 1.15: Neutrophil infiltrate in the sputum of a patient with CF. 
Activated neutrophils recruited to the site of infections release pro-inflammatory cytokines 
(Courtney et al., 2004). 
 
Recent studies have shown that Th17 are present in the airway submucosa of young CF 
patients. These cells produce the signature cytokine IL-17, which is critical in the activation 
and migration of neutrophils in the lung. However, other IL-17-related cells, such as 
neutrophils, T cells and natural killer T cells, have also been found. The IL-17 protein is 
important for the eradication of some pathogens that fail to be cleared by Th1 and Th2 (Tan 
et al., 2011). IL-22, a member of the IL-10 family of cytokines produced by both Th cells 
and innate lymphoid cells, is involved in mucosal host defence, including in the lung, by 
inducing various antimicrobial peptides and promoting epithelium surface protection and 
repair (Bayes et al., 2016). It has been found that healthy individuals and CF patients have 
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similar levels of Th22 specific to P. aeruginosa. These cells have been found to be positive 
for mucosal chemokine receptors, CCR6+, but lack the skin-homing receptors CCR4 and 
CCR10 that have previously been detected on human Th22 (Bayes et al., 2014). 
The infected lungs of CF patients also show elevated proteolytic enzyme activity and high 
levels of chemokines such as IL-8 (Jacquota et al., 2008). Although the main source of IL-8 
in the airway is still unclear, several studies have shown that in response to some stimulus 
(i.e. bacteria-derived or autocrine stimulus TNFα), respiratory epithelial cells may be the 
predominant source, as bronchial epithelial cells from CF patients produce detectable levels 
of IL-8 and IL-6 compared with healthy controls (Gwyer Findlay and Hussell, 2012). 
 
Table 1.4. Summary of the characterization of chronic obstructive lung diseases 
Diseases  BR COPD Asthma CF 
Features Chronic lung 
disease 
Chronic conditions mostly 
caused by smoking   
  
Inflammatory 
condition 
Genetic disease  
Microbial 
infection  
P. aeruginosa  
H. influenzae 
H. influenzae 
P. aeruginosa 
S. aureus  
H. influenzae 
P. aeruginosa  
S. aureus 
Sputum 
production 
High  Low  Low High  
BAL 
content  
Neutrophils and  
pro-
inflammatory 
cytokines 
Neutrophils and 
macrophages 
Eosinophils  Neutrophils and  
pro-
inflammatory 
cytokines 
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1.7 Hypothesis and Aims 
 
1.7.1 Research hypothesis 
 
It has been shown that microbial infection is involved in the pathogenesis and exacerbation 
of obstructive lung diseases. This study hypothesizes that microbe-specific immune 
responses (T cell and antibody) are biomarkers, having a positive association with 
colonization, disease severity (lung function) and the exacerbation of obstructive lung 
diseases. It is expected that patients with chronic obstructive lung disease (COPD) will have 
higher anti-Haemophilus responses, cystic fibrosis (CF) patients have higher anti-
Pseudomonas responses and bronchiectasis (BR) patients have a mixture of responses; 
moreover, exacerbation and severity are associated with higher immune responses for all 
groups.  
1.7.2 Aims and objectives 
  
The aim of this PhD research project is to investigate specific immune responses, both T cell 
and antibody, against colonizing microorganisms in patients with obstructive lung diseases 
– BR, COPD, non-infectious lung disease (asthma) and CF – compared to healthy controls. 
The data generated may provide a useful indication of colonization and severity, as well as 
of infection-induced disease exacerbation if the quality and quantity of specific responses 
correlate with microbiological analysis of sputum samples for the patients and their clinical 
parameters. Through the detailed phenotyping of reactive T cells, their contribution to the 
immunopathology of obstructive lung diseases will be explored. 
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2 Chapter Two: General Materials and Methods 
 
2.1 Ethical approval 
Ethical approval for the project was granted to Dr Anthony De Soyza, Department of 
Respiratory Medicine, Freeman Hospital by the local NHS Research Ethics Committee, the 
NRES Committee North East – County Durham & Tees Valley (ref 12/NE/0248) (see 
Appendix I). Internal ethical approval was obtained from Northumbria University, the 
School of Applied Sciences Ethics Committee (RE-HLS-HLS-12-100513). The ethical 
approval for the Manchester specimens was given to the Manchester Allergy, Respiratory 
and Thoracic Surgery Biobank Ethics Committee (REC reference: 10/H1010/7).  
2.2 Human samples  
 
Patients with BR and COPD, and healthy controls, were recruited by Dr Anthony De Soyza 
at the Chest Clinic, Freeman Hospital, Newcastle upon Tyne. Heparinized blood samples 
were taken from patients attending the Chest Clinic and transferred directly to the tissue 
culture lab at Northumbria University for processing. The sputum samples were analysed 
using the culture-based technique in the Microbiology Department at the Freeman Hospital. 
Sputum samples from BR patients were also subjected to genomic analysis for microbial 
colonization by Dr Clare Lanyon, Northumbria University.  
Blood samples from CF patients were obtained by Dr Stephen Bourke from patients 
attending an adult CF clinic at the Royal Victoria Infirmary, Newcastle upon Tyne. In 
addition, sputum samples were collected and submitted to the Microbiology Laboratory for 
microbial analysis.  
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2.2.1 Clinical data  
Patients were clinically stable at the time of assessment. They underwent spirometry testing 
to obtain forced expiratory volume in 1 second (FEV1), FEV1 % Pred, VC, FEV1/VC % and 
VC % Pred. The bronchiectasis severity index (BSI) score was assessed for 86 BR patients; 
these patients were classified as either hospitalized (>5 exacerbations) or as outpatients (2–
3 exacerbations). (Appendix 11). The exacerbations were determined for the preceding 12 
months. All clinical data were obtained by the research team at the Sir William Leech 
Clinical Trials Centre and calculated during routine medical follow up of the patients.  
2.2.2 Separation of peripheral blood mononuclear cells (PBMCs) and plasma 
  
15 ml of Lymphoprep (Axis-Shield, Norway) was added to sterile Leucosep tubes (Greiner 
Bio-One, Stonehouse.UK) and centrifuged for 20 second at 1500 rpm to obtain the 
Lymphoprep below the glass filter. Heparinized peripheral blood obtained from patients and 
healthy volunteers was added to the tube, on top of the glass filter, and the tube was 
centrifuged for 12 min at 2100 rpm. The tube then has three layers (Figure 2.1): the plasma 
as a yellow liquid at the top, the peripheral blood mononuclear cells (PBMCs) forming a 
cloudy layer located between the plasma, and Lymphoprep underneath and the other denser 
white blood cells and erythrocytes collected at the bottom of the tube. The plasma is 
removed, aliquoted and stored at −20 oC. The PBMCs layer is carefully removed using a 
plastic pipette and washed in supplemented RPMI-1640 (R0, Appendix 6) by re-suspending 
and centrifuging at 1700 rpm for 10 min. If not used immediately, the cell pellet is re-
suspended in freezing medium.  
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Figure 2.1: Separation of blood into different layers. 
(1) Before centrifugation and (2) after. The top yellow layer is plasma, while the opaque layer is 
PBMC and the red layer at the bottom is composed of red blood cells. 
 
2.2.3 Freezing the cells  
 
The freezing medium was prepared by adding 90% of Fetal Bovine Serum (FBS) (Biosera, 
E. Sussex.UK) (Appendix 6) and 10% Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich, 
Poole.UK) in a 7ml bijou tube. For 2 vials, 1.8 ml of FBS plus 0.2 ml of DMSO was 
prepared. The freezing medium was then added to the re-suspended pellet of the PBMCs and 
mixed gently using a sterile pipette. The cells and the freezing medium were aliquoted in 
labelled micro tubes and placed in a Mr Frosty controlled freezing box at -80 oC for 24 h. 
The frozen cells were then transferred to longer storage in a freezer at -150 oC (Thermo 
Scientific, Loughborough, UK).  
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2.2.4 Thawing the cells  
 
When needed, the micro tubes containing the frozen cells were taken from -150 oC and 
quickly thawed by gently swirling in a water bath at 37 °C. The cells were then transferred 
to a sterile universal tube containing 10 ml of R0 and centrifuged at 1500 rpm for 5 min. The 
supernatant was decanted and the cell pellet re-suspended in 1 ml of R10 (Appendix 6) and 
then counted using a CASY® cell counter (Roche Diagnostics, Burgess Hill, UK). 
2.2.5 Setting the CASY counter for cell counting 
 
The CASY® cell counter (Roche Diagnostics, Burgess Hill, UK) (Figure 2.2) was used to 
count the PBMCs obtained from patients and healthy volunteers. Once the device is switched 
on, all required initialisation procedure is automatically performed. The system then 
completes a self-test with all memory modules. After the initialisation procedure is 
completed the CASY then displays a blank size distribution on the screen. Measurement of 
the PBMCs is initiated by filling a CASY cup with clean CASYton solution and by selecting 
the appropriate setting according to the parameters for the selected measuring capillary that 
contains the external electrode. The CASYton solution under the measuring capillary is used 
to monitor the background and clean the cell counter system before and after each sample 
run through the CLEAN key holding down 3 times. Once the background is clear, a new 
CASY cup containing 10 ml CASYton and 10µl of cell suspensions was placed on the 
measuring capillary and measurement is started by pressing the key ENTER. The cell size 
ranges for counting are: Lymphocytes 5.4-9.2 µm and Monocytes 9.3-20 µm as validated by 
the flow cytometer’s scatter of lymphocytes and monocytes. All cell counts were adjusted 
to 8x106cells/ml to obtain optimal T cell responses and maintain consistency among samples.  
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Figure 2.2: The CASY® cell counter for PBMCs counting. 
Adopted from  (Sabanci University Nanotechnology Research and Application, 2013) 
 
2.2.6 Cell counting 
 
The CASY® cell counter was first cleaned with CASY®clean (Roche Diagnostics GmbH, 
Mannheim, Germany) to remove any residual cells. The cells were re-suspended in 1 ml of 
R10 thoroughly to disperse any clumps. Subsequently, 10 µl of the cell suspension was 
transferred into a CASY cup containing 10 ml of CASY®ton (Roche), which was mixed 
thoroughly and run on the CASY counter. Lymphocytes, monocytes and total PBMCs were 
measured based on the cell diameter with a readout of cells per ml.  
2.3 Preparation of bacterial lysate  
 
Bacterial strains were provided by Dr John Perry, Microbiology Department, Freeman 
Hospital, cultured with the help of Dr Andrew Nelson, Northumbria University. The strains 
were cultured from a single colony in 10 ml of broth, the type depending on the species 
(Table 2.1) and incubated with shaking at 200 rpm overnight at 37 oC. Then, 1 ml of the 
culture (Appendix 2) was transferred into broth in a 200 ml flask and incubated with further 
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shaking for 2 h at 37 ºC until the optical density (OD) of the culture reached 0.8. This culture 
was then decanted into 50 ml universal centrifuge tubes and the cells harvested by 
centrifugation at 4000 rpm for 15 min at 4 ºC. The supernatant was removed to leave the 
bacterial cell pellets and 50 ml sterilized PBS (Appendix 5) was added to the pellets to wash 
them. This wash was repeated 3 times and the final pellet was suspended in 5 ml of PBS. 
Using the Sonicator (Soniprep 150, Henderson Biomedical, UK), equipped with a microtip, 
the suspension was sonicated on ice in 10 seconds bursts at high intensity with 10 seconds 
cooling periods on ice between each burst. The cells lysate was decanted into microfuge 
tubes and centrifuged at 13000 rpm at 4 ºC for 20 min to remove debris. The soluble lysate 
was aliquoted and stored at -20 ºC.  
2.4 Determining protein concentration using the Bradford assay 
 
The concentration of protein in the lysate was measured using the Bradford assay. A 50 µl 
aliquot of the original lysate was diluted in PBS. 10-fold dilution steps of bovine serum 
albumin (BSA – Sigma-Aldrich, Poole. UK) in 500 µl of PBS, ranging from 0.1 mg/ml to 
1.4 mg/ml produced the series of standards. Then 50 µl of this protein standard and 50 µl of 
lysate samples were added to a 96-well plate. Subsequently, 200 µl of Bradford Dye Reagent 
(B6916 – Sigma-Aldrich, Poole. UK) (Appendix 2)was added to each well. The plate was 
incubated for 30–45 min at room temperature (RT) and then read on an ELISA Plate Reader 
(EL808, Bio-Tek Vermont, USA) at 595 nm. The concentration of unknowns was read from 
the standard curve.  
2.5 Separation of protein using SDS-PAGE electrophoresis  
 
The components of the SDS-PAGE 12% resolving gel (Appendix 3) were combined, mixed 
and poured between two clean glass plates of the dimensions 10.1x8.2 cm, separated by a 
1 mm spacer ridge on the larger of the two plates. The plates were held together with clamps 
and checked to ensure the bottom edges of the plates were flush. The resolving gel was then 
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slowly pipetted into the space between the plates. A layer of deionized water was added to 
cover the top of the resolving gel to prevent oxygen from inhibiting polymerization. The 
resolving gel was then allowed to polymerize for 45 min. Once the gel was set, the water 
was removed from the top of the gel by means of absorption with filter paper. The 
components of the stacking gel (Appendix 3) were then combined, mixed and loaded on the 
top of the resolving gel. A 10-toothed comb (1.1x0.75 cm) was then inserted carefully into 
the gap between the plates at an angle to prevent air bubbles being trapped between the comb 
and the stacking gel and was allowed to set for 45 min. The comb was then removed to reveal 
the wells, which were immediately rinsed with deionized water to remove any gel debris. 
The gel was placed vertically in the electrophoresis rig (Bio-Rad). SDS-PAGE (1X) 
(Appendix 3) running buffer was added to the tank with caution to ensure that the level of 
the buffer in the space between the two gels was higher than the level on the outside of the 
gels. Loading samples were prepared for SDS-PAGE by adding 5 µl of loading buffer to 
20 µl of each sample. The samples were boiled for 5 min. 
Then, 20 µl of samples and 10 µl of the molecular weight markers were loaded into the wells 
using a P20 pipette. The apparatus was connected to the power supply at 120 mA and run at 
150 V for 45 min. Once all the protein migrations had completed, the power supply was 
turned off and the gel was removed from the plate and placed in Coomassie blue for 5–
10 min on a rocking table and stained with Coomassie blue (Appendix 3). The gels were 
then immersed in de-staining buffer (Appendix 3) and left overnight on a rocking table at 
RT until bands appeared. The gels were photographed using a gel documentation system 
(Bio-Rad Gel Doc2000) using Quantity OneTM software. Hard copies of the gel photographs 
were printed using a Mitsubishi video copy processor (Model P91, attached to the gel doc 
system). 
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Table 2.1. Microbial species used for antigens in the antibody and T cell assays 
Number  Abbreviation 
code 
Species Gram  Strain ID and/or source 
1 BPT Bordetella pertussis  Neg NCTC15434 
2 BCEN Burkholderia cenocepacia Neg LMG18829 
3 BMULTI Burkholderia multivorans Neg LMG18822 
4 MCAT Moraxella catarrhalis  Wild9 (in house) 
5 PINT Provetella intermedia Neg Wild (in house) 
6 CF2 Pseudomonas aeruginosa  Neg Wild CF2 (in house) 
7 CF3 Pseudomonas aeruginosa Neg Wild CF3 (in house) 
8 PSA Pseudomonas aeruginosa Neg NCTC10662 
9 SPN Streptococcus pneumoniae  Pos  DMSZ11865 
10 NT Hi Non-typeable Haemophilus 
influenzae 
Neg MQCL 491 
11 HBO Haemophilus influenza 
serotype type B 
Neg (HbO-HA antigen) 
NIBSC, Potters Bar,UK 
12 ASP Aspergillus fumigatus fungus ALK-Abello Ltd, Reading, UK 
13 ALT Alternaria .alternata  fungus ALK-Abello Ltd, Reading, UK 
Note: Strains either were taken from the National Collection of Typed Cultures (NCTC), Laboratory 
of Microbiology, University of Ghent (LMG) Belgium, or were fully identified wild in-house isolated 
and characterized strains. 
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2.6 Measurement of lipopolysaccharides (LPS – Endotoxin) in antigens 
  
A procedure was carried out to detect LPS in Gram-negative bacteria using Escherichia coli 
(E. coli) endotoxins as controls. 
2.6.1 Preparing the standard stock solution 
 
The solution of (endotoxin unit) 1.0 EU/ml of endotoxin standard (Thermo Scientific, 
Leicester, UK) in vial (A) was reconstituted by adding 0.05 ml of E. coli endotoxin standard 
stock to endotoxin-free water (Thermo Scientific) according to the endotoxin concentration 
of the vial (e.g. if the concentration is X/ml, the volume of endotoxin-free water is (X-1)/20).  
A 0.25 ml of the 1.0 EU/ml standard from vial (A) was transferred to 0.25 ml of endotoxin-
free water in a small eppendorph tube (B), which was then vortexed for 1 min (Appendix 4). 
Then, 0.25 ml from the standard vial (A) was transferred into 0.75 ml of endotoxin-free 
water to prepare 0.25 EU/ml in vial (C). 0.1 ml of vial (A) was then transferred to 0.90 ml 
of endotoxin-free water to prepare vial (D).  
2.6.2 Microplate assay 
  
A sterile 96-well microplate (Greiner Bio-one) was labelled for the standard and unknown 
samples. A 40 µl of endotoxin-free water (Thermo Scientific) was added to appropriate well 
of the blank wells. 40 µl the standard from the (A), (B), (C) and (D) vials was added to the 
appropriate well. Then 50 µl of the unknown samples (1in5 and 1in500) was added to each 
well of the plate and incubated for 5 min at 37 oC. Limulus Amebocyte Lysate (LAL) 
(Thermo Scientific) was reconstituted in 3.4 ml of endotoxin-free water and 50 µl volumes 
were added to wells of the plate. The plate was then incubated for 10 min at RT. 
Subsequently, 100 µl of chromogenic substrate solution (Thermo Scientific) was added to 
the plate prior to incubation for 10 min at RT (Appendix 4). Then, 50 µl of stop reagent 
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(25% acetic acid) was added and the absorbance was read at 405 nm using the plate reader 
(Synergy HT lab tech).  
2.7 The basic protocol of Enzyme-Linked Immunosorbent Assay (ELISA) for serum 
antibody detection  
 
An indirect enzyme-linked immunosorbent assay (ELISA) method was used to determine 
the antibody specificity and the optimal dilutions for the coating of microbe-derived 
antigens, to initiate screening and undertake titration for total IgG and for the measurement 
of other subclasses.  
ELISA with 96-well plates (Nunc Maxisorp, Sigma-Aldrich, UK) were coated with selected 
antigen diluted in PBS, and incubated overnight at 4oC (Figure 2.2). The plates were washed 
3 times with PBS containing 0.05% Tween 20 (PBST) (Appendix5). Washing was always 
followed by blotting on tissue paper. The plates were then blocked with 100 µl of 5% milk 
powder in PBST (Appendix5) for 30 min at RT. Next, the plates were washed 3 times and 
incubated with100 μl of diluted sera in PBST containing 0.5% milk powder (diluent) for 2 h 
at RT. After 6 washes, the plates were incubated for 1 h at RT with 50 μl of anti-human 
IgG/HRP (Dako polyclonal Rabbit P0214 Dako, Ely, Cambridgeshire) at a dilution of 
1in5000 diluent. Following 6 washes, 100 µl of OPD substrate solution (Appendix 5) was 
added to each well and the reaction was stopped after 10 min by adding 25 µl of 2M 
sulphuric acid (Sigma-Aldrich, UK). Absorbance was read at 490 nm in the ELISA reader 
(EL808, Bio-Tek Instrument, US) using KC Junior software. 
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Figure 2.3: Schematic diagram of the indirect ELISA procedure for antibody screening and 
titration. 
The plate is coated with appropriate antigen and incubated at 4 ˚C overnight. The plate is washed 
and blocked. Diluted sera are added and any antibody present binds to the antigens. The plate is 
washed again and the secondary (detection conjugate) antibody is added. After incubation and 
another 6 washes, the substrate is added and the reaction is stopped with 25 µl of 2M sulphuric 
acid. E = enzyme, S = substrate. Adapted from (Chhabra, 2014). 
 
2.7.1 Optimal coating concentration for each antigen used in the project 
 
Each antigen was diluted in PBS in microfuge tubes through double dilution starting from 1 
in 20.  100 µl of each of diluted antigen was added to 96-well ELISA plates in triplicate. A 
serum containing specific antibody activity was added in a single dilution. The ELISA 
procedure was then carried out as described in section 2.7 and the results were expressed 
graphically as absorbance vs coating concentration.  
2.7.2 Screening of sera against antigens to establish starting titration 
 
Serum dilution ELISA showed that absorbance at a single dilution was not sufficient to give 
an accurate measurement of the antibody level. It was decided to carry out a 4-step process 
for each serum sample and obtain an end-point titre. Screening of sera at a 1in 25 dilution 
was initially carried out to establish the starting dilution of the sera. Table 2.2 shows the 
initial dilution for sera titration based on the mean of absorbance obtained in the screening.  
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Table 2.2. Establishing the initial dilution for titration 
The starting sera dilution for titration was estimated by calculating the mean absorbance for sera at 
1 in 25 dilutions with the mean of the blank subtracted. 
Absorbance Initial dilution  
<0.2 1/25  
0.2–0.4 1/50  
0.4–0.6 1/100  
0.6–0.8 1/200  
0.8–1.0 1/400  
>1.0 1/800  
 
2.7.3 Antibody titration for all groups in the study 
 
Extended serum dilution was undertaken to establish the linear part of the curve from which 
the endpoint titre can be extrapolated. Serum titration was performed to determine the 
endpoint titre of antigen-specific antibodies. The 96-well plates were coated, blocked and 
washed as described in section 2.7. In this assay, sera were diluted based on the results of 
the previous screening, as shown in Table 2.2. The initial dilution was placed in the first 
column in duplicate and the sera were double diluted down the plates 4 times in total. The 
diluted serum was mixed 6 times before moving down to the next titration wells. The 
washing and incubation steps were as described in section 2.7. The same procedure was 
carried out for all antigens.  
2.7.4 Measurement of antibody specificity by inhibition ELISA 
 
The inhibition experiments determining cross reactivity are described using the example of 
Pseudomonas antigen. Pseudomonas lysate antigen was diluted at 1in 2000 in PBS and 
added to each well of the 96-well ELISA plate. The plate was incubated overnight at 4 ºC. 
The plate was washed and blocked as described in section 2.7. Six microfuge tubes were 
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labelled for antigen inhibitors, including lysate of Pseudomonas (same as coated), 
Pseudomonas LPS, Haemophilus influenzae type b lysate, Bordetella pertussis lysate, 
Burkholderia cenocepacia lysate and Streptococcus pneumonia lysate. These were diluted 
in 2-fold dilutions from 1in10 up to 1in640 in 250 µl of diluent. Serum samples were diluted 
at 1in 250 in diluent. A high IgG responding serum to the Pseudomonas antigen was selected. 
250 µl of diluted serum was added to each antigen inhibitor and incubated for 30 min at RT. 
Then, 100 µl of each sample was added to the plate and incubated at RT for 1 h. The plate 
was then washed and developed as described in section 2.7. The inhibition assay was shown 
graphically as an absorbance versus inhibitor concentration and expressed as the percentage 
inhibition of the non-inhibited serum. The inhibition assay was also carried out for the other 
antigens. 
2.7.5 Ig subclass measurement in ELISA 
 
Measurement of Ig subclasses was performed by ELISA as described in section 2.7. 
However, the secondary detector antibody (Sigma-Aldrich, UK) was substituted to allow 
detection of the subclasses, including IgG1, IgG2, IgG3 and IgG4, as well as the other 
classes, such as IgA and IgM. The dilutions of the secondary antibody used are shown in 
Table 2.3. In some instances, in which the secondary antibody was biotin-conjugated, an 
extra step was required, adding a dilution of Avidin–Peroxidase (Sigma-Aldrich, UK) at 1in 
40000 and incubating for 1h at RT. After washing, the substrate was added and the reaction 
was stopped with 25 µl of 2M sulphuric acid as usual. Absorbance was read in the ELISA 
reader at 490 nm. Only the absorbance (minus blank) value at a fixed serum concentration 
of 1in 25 was used for the Ig subclasses. 
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Table 2.3. Antibody isotype detection. 
Antibody conjugates for the detection of antibody isotypes were diluted in diluent and used at the 
dilutions indicated 
Number  Antibody isotypes Dilutions used  Details  
1 IgG1 1:2000 Monoclonal Anti-Human IgG1-Biotin 
antibody produced in mouse 
2 IgG2 1:8000 Monoclonal Anti-Human IgG2-Biotin 
antibody produced in mouse 
3 IgG3 1:4000 Monoclonal Anti-Human IgG3- Biotin 
antibody produced in mouse 
4 IgG4 1:10000 Monoclonal Anti-Human IgG4-Biotin 
antibody produced in mouse 
5 IgA 1:5000 Anti-Human IgA (µ-chain specific) 
peroxide antibody produced in goat 
6 IgM 1:5000 Anti-Human IgM (α-chain specific) 
peroxide, produced in the goat 
 
2.7.6 Stability of the sera  
 
Experiments were carried out to assess the effect of multiple freeze–thaw cycles on the 
antibody activity levels of human sera against bacterial antigens. A series of 11 aliquots of 
serum samples were included, comprising BR (n=5), COPD (n=4) and healthy subjects 
(n=2). These sera had been previously screened and titrated for antibody against Moraxella 
catarrhalis. The same sera were tested after 5 freeze–thaw cycles against M. catarrhalis 
using ELISA as described in section 2.7. 
2.8 Determining T cell responses to panels of antigens 
 
2.8.1 Dilution of the cells  
 
To adjust the cell counts to the required concentration, an appropriate volume of R10 was 
added to cells to achieve the optimum concentration of 8×106 PBMC/ml, thus allowing a 
sufficient cell response but avoiding high background or black out in the ELIspot results. 
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2.8.2 ELIspot protocol  
 
Sterile 96-well ELIspot plates (Millipore, Watford.UK) were coated with 10 µl of capture 
anti-human IFN (Mabtech, Nacka Strand, Sweden) per ml of bicarbonate buffer, resulting 
in a concentration of 10 µg/ml. Coating with 50 µl of capture antibody was undertaken 
overnight at 4oC. The plate was washed 3 times with sterilized PBS and blocked with 100 µl 
of R10 medium (Appendix 6) for 1h at RT. Then, 50 µl of stimulus (Table 2.5) and 50 µl of 
8×106/ml PBMCs (set up at 8x106/ml) were added to the plate. The plate was incubated for 
18–20 h at 37°C in a 5% CO2 incubator. The plate was then washed 6 times with PBS before 
adding 50 µl of biotinylated-anti-IFN detector antibody (Mabtech, Nacka Strand, Sweden) 
diluted at 1in1000 in PBS. The plate was incubated for 2 h at RT. The plate was then washed 
6 times and 50 µl of streptavidin ALP (Mabtech, Nacka Strand, Sweden) diluted at 1in1000 
in PBS was added to the plate and incubated for 1h at RT. The plate was then washed 6 times 
and 50 µl of the substrate from AP Conjugate Substrate kit 170-6432 (Bio-Rad Laboratories 
Inc,) (Appendix 6) was added. The reaction was stopped by washing the plate thoroughly 
with tap water after approximately 10 min. The plate was dried overnight and spot-forming 
cells were counted using an Immuno-Spot reader (Auto-immun Diagnostika- AID, GmbH, 
Strassberg, Germany). The frequency of IFN-γ-producing cells was calculated by the 
number of spots in the wells after background subtraction and multiplied by the cell 
concentration factor (2.5 for 8x106). The results are expressed as spot-forming cells 
(SFC)/106(M) PBMC.  
2.8.3. Setting the ELIspot reader  
 
Autoimmune diagnostic GMBH (AID) ELIspot reader takes high resolution images with 95 
megapixel connected digital camera. Once the machine is switched on and a plate is inserted, 
the plate is adjusted in order to see the rim of the well before calibrating the stage in which 
wells are centred properly, thus the size of counting area of the spots is determined. The 
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properties of counted spots (Table2.4) is also determined. Once the calibration is saved, the 
read and counting function is then followed with speed of reading at maximum. Therefore, 
counts of spots are determined based on spot size, intensity and gradient of edge (Figure2.4). 
Table 2.4. Thresholds for spot counting 
  Intensity Size Gradient 
MIN 4 3 1 
MAX 255 500 90 
  
 
Figure 2.4: Example of a well of an ELIspot plate, showing positive spots. 
Adopted from  (Roche Innovatis AG CASY, 2002). 
 
2.8.4 Depletion of CD4+ T cells to confirm adaptive response  
 
CD4 Dynabeads (Invitrogen, Paisley, UK) were pulse-vortexed for 30 seconds. 1×108 CD4 
beads (25 µl) were transferred into a sterile FACS tube (Falcon, Corning, Sigma-Aldrich, 
UK). Then, 1 ml of R0 medium was added to wash the beads: the tube was placed in a 
magnet (Dynal) for 1 min and the supernatant was discarded. The tube was then removed 
from the magnet. 0.35 ml of cells (PBMCs) and 0.15 ml of R10 were added to the beads in 
the tube. The mixture was incubated for 30 min at 4 oC, mixing every 5 min. The tube was 
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placed in the magnet for 1 min and unbound cells were taken and transferred into another 
FACS tube. Subsequently, 0.7 ml of R10 medium was added to the cells. The cells were then 
used to investigate immune responses against a panel of antigens using ELIspot (see 2.8.2). 
Table 2.5 illustrates the stimuli used for stimulating PBMCs to produce cytokines such as 
IFNin ELIspot 
Table 2.5.  Antigens and stimulus used for ELIspot and flow cytometry 
 Antigen and 
stimulants label 
Antigen name Details  
F1 Medium (R10) RPMI-1640 containing 5 ml penicillin-
streptomycin, 10% of FBS and 5 ml of glutamine 
F2 Positive control Anti-CD3 monoclonal antibody (mAb) 1:200 
(Mabtech) 
F3 B. pertussis Lysate + 1 peptide 
F4 P. aeruginosa 
(NCTC) 
48 μl Lysate + 30 μl peptides 
National collection of typed cultures  
F5 S. pneumoniae Lysate + 6 peptides 
F6 Mycobacterium 
tuberculosis (TB) 
Purified protein derived (PPD) + 6 peptides 
F7 H. influenzae serotype b 
(HBo) 
102 μl Lysate + 30 μl peptide, Oligosaccharide–
human serum albumin conjugate NIBSC, Potters 
Bar, UK 
F8 Respiratory Syncytial 
Virus (RSV) 
Lysate + 4 peptides 
F9 Influenza virus 55 peptides 
F10 Burkholderia cepacia 
complex  
2 lysates + 4 peptides, also termed (2) 
F11 Mycoplasma pneumonia Lysate (Native Antigen Company) 
F12 M. catarrhalis Lysate  
F13 Cytomegalovirus (CMV) 
 
Lysate + CD4 and CD8 epitope peptides 
Lysate from The Native Antigen Company 
(Upper Heyford, Oxfordshire, UK) 
F14 A. fumigatus Lysate (ALK-Abello Ltd, Reading, UK) + 1 
peptide 
PHA Phytohaemagglutinin 5 ml of R10, 50 μl of PHA = 5 μl/ml 
PMAI Phorbol myristate acetate  50 μl of Phorbol myristate acetate, 1 μl of 
Ionomycin in 2 ml of R10 = 20 ng/ml 
and 1μg/ml, respectively 
EBV Epstein-Barr virus all          EBV-CD8+ and EBV-CD4+ antigens 
        2.5 ml    
Candida   Candida.  sp Lysate (ALK-Abello Ltd,         Reading, UK) and 
1 peptide 
Burkholderia (1) B. cepacia complex (1) Lysates 
Notes: * All other peptides found sequences of epitopes: Immune Epitope Database (IEDB) National 
Institute of Allergy and infection, Bethesda, USA. The peptides were synthesised by Mimotopes, 
Victoria, Australia. All lysates were produced in house unless otherwise indicated.  
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2.8.5 Frozen and fresh cells for ELIspot  
 
Experiments were performed to investigate the differences between fresh and frozen cells in 
response to the same antigens. Here the ELIspot plate was divided into two parts: one part 
for the fresh cells and the other for frozen cells stimulated with the same antigens. The 
procedure was carried out as described in section 2.8.2.  
2.8.6 Inhibition with anti-class II antibody to confirm adaptive response  
 
 Sterile 96-well ELIspot plates was coated with anti-human IFN as described in section 
2.8.2. Following blocking, 25 µl of fresh cells were added, plus 25 µl of anti-class II 
antibody (L243, gift from Martin Glennie, Southampton) was also added to give a final 
concentration of 10 µg/ml. The plate was incubated for 30 min at 37 oC, 5% CO2. A mixture 
of 50 µl of appropriate antigens and stimuli were added to the plate. The experiment was 
then carried out as described in section 2.8.2.  
 2.9 Flow Cytometry  
 
2.9.1 Optimizing the fluorescence compensation settings  
 
Tubes were labelled for each fluorochrome as in Table 2.6. 2 μl of each antibody was added 
to the corresponding tubes. One drop of negative compensation beads and one drop of Anti-
Mouse Ig, κ positive compensation beads – BDTM CompBeads (BD Biosciences, Oxford 
UK) (Appendix 7) were then added to each tube to optimize the fluorescence compensation 
settings and distinguish the positive and negative background for multicolour analysis. Two 
populations of micro particles were thus used: the BD™ CompBeads Anti-Mouse Ig, κ 
particles bind to any mouse κ light chain-bearing Ig and the BD™ CompBeads Negative 
Control has no binding capacity. As a negative control, one drop of negative beads was also 
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added to another empty tube. Tubes were then pulse-vortexed and incubated for 15 min in 
the dark at RT. Subsequently, 2 ml of 1X PBS was added to each tube and centrifuged at 
1500 rpm for 5 min. The supernatants were discarded and the beads were re-suspended in 
300 μl of 1X PBS. To calculate the spectral overlap for each fluorochrome, beads were 
acquired on a BD FACSCantoTM II flow cytometer (BD Biosciences, Oxford, UK), using 
the automated compensation program, which is part of the BD FACSDivaTM software.  
Table 2.6. Fluorochrome labelled antibodies used in this study 
Fluorochromes Cell 
markers  
Function Clone Laser (nm) 
Excitation  
EM-maxa 
(nm) 
(detection)  
FITC OX40b Co-stimulation ACT35 488 525 
PE CD49db Homing  9F10 488 575 
PerCP-Cy5.5 CXCR3c Chemokine receptor 
(Th1) 
IC6/CXCR
3 
488 695 
PE-Cy7 CCR6b Chemokine receptor 
(Th17) 
B6H 488 785 
APC PD-1b  Energy marker eBioJ105 633 660 
APC-Cy7 CCR5c Chemokine receptor 
(inflammatory) 
2D7/CCR5 633 785 
BV421 CD69c Activation marker  KN50 405 421 
BV510 CD4c Th cell marker SK3 405 510 
Notes: a Maximum emission wavelength; b eBioscience (Affymetrix - eBioscience, Hatfield, UK); c 
BD Biosciences (Oxford, UK). 
 
2.9.2 Cell activation and surface staining  
 
Frozen PBMCs samples were thawed quickly in a 37°C water bath and washed by adding 
10 ml of R0 prior to centrifuging at 1500 rpm for 5 min. The supernatants were discarded 
and cells re-suspended in 1ml of R10 and counted using a CASY counter as described in 
section 2.2.4. Then, 250 μl of 8×106 PBMCs was incubated with 250 μl of medium, 
polyclonal anti-CD3mAb, or lysates + peptides from P. aeruginosa or H. influenzae type b 
(Table 2.5). The cultures were incubated overnight at 37°C, 5% CO2. The cells were then 
washed with 1X PBS and incubated (15 min, at RT, in the dark) with the antibody 
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combination shown in Table 2.7 and 50 μl of Brilliant Stain Buffer (BD Horizon™). The 
stained cells were washed with 2 ml of 1X PBS and re-suspended in 300 μl of 1X PBS prior 
to immediate acquisition on the flow cytometer. Data were analysed using BD FACSDivaTM 
software. For isotype control, stimulated cells were stained with isotype controls as in Table 
2.7 and incubated for 15 min at RT. The stained cells were washed and re-suspended in PBS 
prior to immediate acquisition on the flow cytometer (BDFACSCantoII) and analysed using 
BD FACSDivaTM software. 
2.9.3 Staining for intracellular molecules by flow cytometry 
 
An experiment was performed to determine the number and phenotype of IFNproducing 
cells. To activate T cells, 250 μl of 8×106 PBMC was stimulated with 250 μl of medium, 
anti-CD3, or lysates of P. aeruginosa, or left unstimulated, for 20 h, the last 18 h of which 
were in the presence of 0.1 µg/ml Brefeldin A (Golgi plug, BD Bioscience, Oxford, UK) 
(Appendix 7) to allow the cytokines to accumulate inside the cells. The cells were then first 
stained for surface antigens, as described in section 2.9.2, prior to being fixed with 100 μl of 
IC Fixation Buffer (Affymetrix eBioscience, Hatfield, UK). Cells were incubated for 20 min 
in the dark at RT. Cells were then washed twice with 2 ml 1X Permeabilization Buffer 
(Affymetrix eBioscience, Hatfield, UK) and re-suspended in 100 ml 1X Permeabilization 
Buffer (Appendix 7). 2 μl of IFN PE (Affymetrix eBioscience) was added to the cells and 
incubated for 30 min in the dark at RT. The cells were washed twice: once in 1X 
Permeabilization Buffer and once in 1X PBS. The cells were then re-suspended in 1X PBS 
and acquired on the flow cytometer (BD FACSCantoTM II). Data were analysed using BD 
FACSDivaTM software. 
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Table 2.7. Antibody and isotype controls used in the flow cytometry protocol. 
Antibody  Concentration 
 (μg/ml) 
Concentratio
n/test 
(μg/2 ml) 
Isotype Concentration 
 (μg/ml) 
Amount isotype/ 
test 
CD134 FITCa 100 0.2 IgG1a 500 4 μl of 1:10 diln 
CD49d PEa 25 0.05 IgG1a 200 2.5μl 0f 1in10 
diln 
CXCR3 PerCP-
Cy5.5b 
100 0.2 IgG1b 200 1 μl 
CCR6 PE-Cy7a 25 0.05 IgG1b 50 1 μl 
PD-1 APCa 200 0.4 IgG1a 200 2 μl 
CCR5 APC-
Cy7b 
200 0.4 IgG2b 200 2 μl 
CD69 BV421c 12 0.024 IgG1d 100 2.4 μl of 1in 10 
diln 
CD3 BV510 c 100 0.2 IgG1d 100 2 μl 
Notes: a eBioscience(affymetrix eBioscience, Hatfield, UK); b BDPharmingen (BD Bioscience, 
Oxford ,UK); c BDHorizon (BD Bioscience, Oxford, UK); d BioLegend (London, UK). 
 
2.10 Measurement of cytokines for culture supernatant using multiplex ELISA 
 
Cytokines in supernatants were measured in 10 BR patients and 4 healthy volunteers using 
the Mesoscale Scale Discovery (MSD) (Meso Scale Diagnostic, LLC, Gaithersburg, USA). 
Multiplex kit – pro-inflammatory panel 1 (IFN, IL-2, IL-4, IL-10, IL-12p70 and IL-13) and 
cytokine panel 1 (IL-5 and IL-17A) were used. For each panel, 1 ml of diluent 1 was added 
to 1 g of blocker B. Serial dilutions of 1in100 were made for each standard for both panels. 
Then, 25 μl of these standards were added to the appropriate 96-well plate (Meso Scale 
Diagnostic, LLC, Gaithersburg, USA). 25 μl of culture supernatant samples from previously 
stimulated PBMCs were added to each well of the 96-well plates. The plates were covered 
with an adhesive cover (Thermo Scientific, UK) and incubated for 2 h at RT on a plate shaker 
(100 rpm). A 25 μl of detector antibodies (Meso Scale Diagnostic, LLC, Gaithersburg, USA) 
were diluted in diluent 100 at 1X (MSD) and added in pro-inflammatory panel 1 (human 
calibrator blend) including anti-human IL-13, IFN- antibody, anti-human IL-10 antibody, 
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anti-human IL-2, anti-human IL-4 and anti-human IL-12P70. A 25 μl of detector antibodies 
also added to cytokine panel 1X (human calibrator blend), including anti-human IL-5 
antibody and anti-human IL-17A, antibody (Sulfo-TAG). The plates were incubated for 2 h 
at RT on a plate shaker (100 rpm). The plates were washed 6 times with 150 μl of PBS 
−0.05% Tween-20. Then, 150 μl of read buffer 4X with surfactant (MSD) diluted in 
sterilized water (50:50) was added to each well of the plates. The plates were read on MSD 
sector imager. Data were analysed immediately in MSD Software and Excel. 
2.11 Calculation and statistical analysis  
 
ELISA data were always run in duplicate or triplicate and therefore the average absorbance 
for each set of replicate samples was calculated. The absorbance value of the blanks was 
then subtracted from the average values. These gave the screening values for determining 
the starting point for titration. Furthermore, antibody titres were expressed as the reciprocal 
of the highest dilution in which the absorbance value of a serum differed from zero. The 
calculation of the endpoint was obtained by plotting the mean absorbance on the x-axis 
versus dilutions on the y-axis in the standard curve and the end point was obtained from the 
equation y=mx+c, where c is the end point on the x-axis. In this project, Microsoft Excel 
was used for calculating both screening and titration values.  
Statistical analysis was carried out using Graph Pad Prism5, Minitab17 and IBM SPSS-22. 
The data for antibody and T cells responses were found to be non-normally distributed, so 
the Mann-Whitney U-test was performed to compare the differences in antibody and T-cell 
levels between patients and healthy volunteers, as well as FEV1% predicted and microbial 
colonization, in which p<0.05 was considered statistically significant. Correlations were 
analysed using Spearman’s test.  
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3 Chapter Three:  Measurement of Anti-microbial Antibody 
Responses in Chronic Obstructive Lung Diseases 
 
Abstract 
Aim: This chapter investigates antibody responses in patients with chronic obstructive lung 
diseases, namely bronchiectasis (BR), chronic obstructive pulmonary disease (COPD) and 
asthma, against antigens derived from bacteria and fungi found within the lung microbiota. 
The responses were compared to those of healthy volunteers to determine if there were any 
significant differences between the clinical groups and healthy subjects.  
Methods: Plasma was separated from the heparinised blood of stable BR patients (n = 119), 
COPD (n=58), and asthmatic (n=14) patients attending an outpatient clinic at the Freeman 
Hospital, Newcastle upon-Tyne, who were recruited in this study. Healthy volunteers (n=28) 
were recruited from the staff of Freeman Hospital.  An indirect ELISA was setup and used 
to investigate the Igs against bacteria, virus and fungi-derived antigens. Anti-Pseudomonas 
Ig isotypes were also examined in BR (n=20) and COPD (n= 20) patients.  
Results: Antibody titres in each clinical group were different from those of healthy 
volunteers. BR patients had significantly higher IgG titres against P. aeruginosa, S. 
pneumoniae polysaccharide, H. influenzae, H. influenzae polysaccharide and S. maltophilia, 
whereas patients with COPD had significantly higher IgG titre against S. pneumoniae 
polysaccharide. In contrast, reduced IgG titres were observed in patients with asthma in 
which healthy volunteers have significantly higher antibody response against S.pneumoniae 
and M.catarrhalis.  Investigation of antibody Ig isotypes against P. aeruginosa showed that 
IgG1 was the predominant isotype in BR patients, whereas IgM was the main isotype 
detected in patients with COPD.  
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Conclusion: The increased magnitude of a specific antibody may be an indication of 
infection with P. aeruginosa and other pathogens in patients with BR and COPD.  In 
contrast, the low level of IgG antibody responses in patients with asthma may be related to 
infrequent microbial infections or possibly the switching of antibody to IgE in this group. A 
variation in the antibody isotypes was seen among patients with BR and COPD, suggesting 
different exposure patterns.   
3. 1 Background  
 
A major cause of both morbidity and mortality for individuals worldwide are respiratory 
conditions such as bronchiectasis (BR), chronic obstructive pulmonary disease (COPD), 
cystic fibrosis (CF) and asthma (Cullen and McClean, 2015). BR, COPD and CF are 
associated with an intense inflammatory response as a result of recurrent microbial infections 
including bacteria and viruses (King, 2011). Antibody-mediated immunity is critical for host 
defence against pathogens, and individuals with underlying defects in humoral immunity are 
more susceptible to bronchiectasis and bacterial sinopulmonary infections. The process of 
antibody production in the respiratory tract in response to bacterial infection can occur 
rapidly via the activation of resident memory B cells and specific IgG secretion if there was 
previous exposure to the pathogens (Twigg, 2005). If the host is naïve to the pathogen, the 
antibody is produced more slowly, with IgM prominent followed by specific IgG and IgA in 
order to eliminate the infection. The production of antibody depends on the antigen exposure 
site. For instance, IgA responses occur in the upper airways, whereas the production of 
pathogen-specific IgG occurs once the pathogens reach the lower airways. Indeed, IgG 
utilises opsonizing properties for aiding phagocytic cells and for activating complements in 
the elimination of pathogens and the provision of effective immune responses against 
microorganisms (Twigg, 2005). T cells are also activated and contribute to antibody 
formation in response to cognate antigens of the pathogen. CD4+ T cells are crucial in 
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antibody production where they promote the activation and differentiation of B cells to 
undergo class-switching from the production of IgM to the more efficient and avidly-binding 
IgG isotypes against protein antigens (Gadgil and Duncan, 2008). Isotype switching requires 
cytokine signals that are produced by T helper cells such as IFN IL-4, IL-5, and signals by 
stimulatory molecules CD40L with CD40 on B cells (Garraud and Nutman, 1996).  
However, the inflammatory cells also contribute to the inflammation and pathogenesis of 
chronic obstructive lung diseases. Neutrophils, macrophages and other innate and adaptive 
cells are recruited into the airways and release pro-inflammatory cytokines leading to the 
irreversible dilation of bronchial walls and the destruction of lung parenchyma resulting in 
impaired mucocilary clearance and promoting bacteria colonization (Whitters and Stockley, 
2012). The predominant pathogenic bacteria isolated in such lung diseases are P. aeruginosa,  
H. influenzae, S. aureus, S. pneumoniae and M. catarrhalis (Kadowaki et al., 2015). In 
contrast, asthma is an inflammatory disease of the airways not primarily associated with 
microbial infection and therefore these groups were used as a control to see if lung 
inflammation alone gives any antibody responses.  
In this part of the study, the aim is first to prepare or collate the antigens derived from 
microbes associated with the lung disease to be utilised in antibody ELISA. Second, the 
measurement of antibody responses against lung organism antigens was carried out to 
determine whether or not variations in antibody levels between the clinical groups are a 
biomarker for colonization and if they reflect immune protection from infections. It is 
important to know that all patients were stable and no patients receiving steroids during the 
study.  
3.2 Results  
 
3.2.1 Demographic characteristics of participants  
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Patient cohorts consisting of 119 patients in the BR group (45 males, 74 female), 58 patients 
in the COPD group and 14 asthmatics were recruited in this study. A healthy volunteer group 
of 28 was recruited from the staff of the Freeman Hospital. Due to the cross-sectional and 
practical nature of the study, some clinical data sets of the COPD group, asthmatics and 
healthy volunteers were not available. A summary of the demographic and clinical 
characteristics of the patient cohorts is shown in Table 3.1. As shown, at the time of 
assessment the mean ages of patients were BR 65±1.08, COPD 69±1.23, asthmatics 57±3.45 
and healthy volunteers 54±3.0 years cross-cohort. Symptoms scores were determined as 
described by Jones (2009) 
Exacerbations were determined in the preceding 12 months, for which BR patients had more 
episodes over this period (4) followed by COPD patients (3) and asthmatics (2).  
The mean value of smoking history (pack years) is higher among COPD patients, thus 
confirming that COPD is mostly caused by smoking thus, increased the rate of admission 
due to acute exacerbation. The mean of forced expiratory volume in one second (FEV1 % 
predicted) was less than 50% in patients with COPD, demonstrating severe airflow 
obstruction, while BR patients achieved a mean value of less than 70% representing 
moderate airflow obstruction compared to a cohort of similar age. Asthmatics showed mean 
of FEV1 71%, indicating better lung function test compared to BR and COPD.  Healthy 
volunteers also underwent the lung function assessment, which showed a mean FEV1 higher 
than 100% of the predicted value. The mean vital capacity (VC % predicted) in BR patients 
was 82%, whereas for COPD patients it was 77%. Asthmatics reported 90% and healthy 
volunteers showed a high level of 118%. Patients with COPD showed deterioration of the 
FEV1/FVC ratio at 50% followed by BR patients (66%) and asthmatics (77%). However, 
healthy volunteers gave results of 83%. A summary of the patient demographic data is shown 
in Table 3.1. 
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Table 3.1. Demographics of the subjects included in this part of the study 
   
Characteristics  
BR 
n=119 
COPD 
n= 58 
Asthma  
n=  14 
HV 
n=28 
Sex (no.) 
Male/female ) 
45/74  
Not av. 
 
Not av. 
 
Not av. 
Age (y) 65  ±   1.08                                           69   ± 1.23 57 ±3.45 54±3.0 
Symptom score 64    ±   2.19 68  ±   2.56 54  ± 6.4 Not app. 
Exacerbations 
(per year) 
4     ±  0.296 3    ±   0.38 2   ± 0.70 Not app. 
Smoking history 
(pack years) 
8    ±  1.33 47  ±   4.08 10  ± 3.92 Not av. 
FEV1 (% 
predicted) 
68     ±  2.68 49  ±  2.70 71 ± 7.44 113±2.83 
VC (% 
predicted) 
82     ± 2.478 77  ±   2.40 90 ±7.63 118± 2.7 
FEV1/FVC ratio  66    ±  1.52 50  ±  2.17 77 ±5.05 83±1.75 
Values are presented as means ± SEs, where chronic bronchitis is defined as the presence of chronic 
productive coughing for more than 6 months, and exacerbations represents the number per year. 
FEV1 represent forced expiratory volume in the first second and FVC, forced vital capacity. Not av, 
indicates the data are not available whereas not app means that the category was not applicable.  
 
3.2.2 SDS-PAGE (Sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
analysis of bacterial protein  
 
The bacterial lysates were prepared as described in section 2.3. The distributions of 
molecular weights of bacterial proteins were determined by SDS–PAGE, as described in 
section 2.5. The standard contains highly purified proteins of molecular masses of 15-250 
kDa. The results shown in Figure 3.1 indicate the position of 9 distinct samples on SDS–
PAGE alongside the standard molecular weight marked in lane 1. Lane 3 is B. pertussis, 
Lane 4 is B. cenocepacia and Lane 8 is K. pneumoniae, and these had higher protein intensity 
bands compared to the other samples. A further gel shown in Figure 3.2 also shows Lane 6 
P. aeruginosa (NCTC) to have numerous protein bands with differing  
molecular weights. Overall, the analyses of bacterial lysate showed multiple bands of 
protein.  
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Figure 3.1: Visualisation of unknown protein bands with bacteria lysates by 12%SDS-PAGE. 
Lane1, the Mw ladder; Lane 2 B. fragilis controls; Lane 3 B. pertussis, Lane 4 B. cenocepacia, Lane 
5 C. difficile control, Lane 6 E. faecalis control, Lane7 E. coli, Lane 8 K. pneumoniae, Lane 9 B. 
multivorans. Proteins were visualised by Coomassie blue and destained as described in section 2.5.   
 
Figure 3.2: Visualisation of unknown protein bands within bacteria lysates by 12% SDS-
PAGE.  
Lane1, Mw ladder; Lane 2 M. catarrhalis, Lane 3 P. intermedia, Lane 4 P. aeruginosa (wild type), 
Lane 5 P. aeruginosa (wild type), Lane 6 P. aeruginosa (NCTC), Lane 7 S. typhimurium control, 
Lane 8 S. aureus, Lane 9 S. pneumoniae. Bacterial proteins visualised by Coomassie blue and 
destained as described in section 2.5. 
 
 
3.2.3 Measurement of protein concentrations of lung bacteria antigens  
 
The protein concentrations of each bacterial antigen were measured by Bradford assay as 
described in section 2.4. Figure 3.3 demonstrates the standard curve used to obtain the 
protein concentrations. The amount of protein in the unknown samples was calculated in 
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µg/ml from the standard curve equation. The concentration obtained from the curve was 
multiplied by the dilution factors of the samples.   
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Figure 3.3: Standard curve for the Bio-Rad Bradford protein assay. 
The curve is produced by the addition of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 1 mg/ml BSA in 
500 µl of PBS to 250 µl of Bradford dye reagents.  
 
Table 3.2 shows the protein concentrations and lipopolysaccharide (LPS) content of each 
sample of the lung bacterial antigens as described in sections 2.4 and 2.6 respectively.  S. 
pneumoniae lysate (SPN) has the highest protein concentration (33.06 mg/ml) whereas B. 
pertussis (BPT) has the lowest protein concentration (0.88 mg/ml). Furthermore, different 
strains of P. aeruginosa have differing protein concentrations. On the other hand, the content 
of LPS was low in most organisms except for E. coli, which contained the highest 
concentration of LPS (89.0 ng/ml). 
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Table 3.2. Protein and lipopolysaccharide concentrations of microbe-derived antigens used in 
this study. 
 
Note: in case of PSA one antigen for several different infections from different P. 
aeruginosa because lysate represents all strains of Pa and it contains vast majority of 
conserved antigens  
3.2.4 Optimal coating concentration for antigens  
 
Number Abbreviation Species Protein 
concentration 
(mg/ml)  
LPS  
(ng/ml)  
1 BPT Bordetella pertussis 0.88 0 
2 BCEN Burkholderia cenocepacia 15.74 0.28 
3 BMULTI Burkholderia multivorans 16.54 0.48 
4 MCAT Moraxella catarrhalis 16.65 0.11 
5 PINT Provetella intermedia 1.21 0 
6 CF2 Pseudomonas aeruginosa 13.63 0 
7 CF3 Pseudomonas aeruginosa 22.01 0 
8 PSA (NCTC) Pseudomonas aeruginosa 16.2 0 
9 SPN lysate Streptococcus pneumoniae 33.06 0 
10 NT Hi Non-typable Haemophilus 
influenzae 
56.6 Not av. 
11 HBo Haemophilus influenzae Type B 
polysaccharide 
1.0 Not app 
12 SM Stenotrophomonas  maltophilia 6.8  
13 ALT Alternaria alternata Not av.  Not app. 
14 SPN poly  Streptococcus pneumoniae  Not app Not app 
15 ECO Escherichia coli 3.05 89.0 
16 Hib Haemophilus influenzae lysate 3.7 Not app 
17 ASP Aspergillus fumigatus  Not av. Not app 
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In order to establish the optimal coating dilution of each lysate to carry out ELISAs, the 
titration of coating dilutions was performed as described in section 2.7.1. The results of 
coating dilution for each antigen for coating ELISA plates are shown in the Figure 3.4.  
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Figure 3.4(A-L): The optimal coating dilution of each antigen as determined by ELISA. 
The graphs showed the plate-coating concentrations for each antigen in the study. The x-axis 
represents the log10 antigen dilution while the y-axis represents the absorbance at 490nm. The result 
are represented by the mean ± SEM, (n =3) replicates per sample. (A)  P. aeruginosa, (B) H. 
influenzae b polysaccharide (HbO), (C) A. fumigatus, (D) S. pneumoniae, (E) P.intermedia (F) RSV, 
(G) B. pertussis, (H) A. alternata, (I) S. maltophilia, (J) S. pneumoniae polysaccharide, (K) M. 
catarrhalis, and (L) NTH. influenzae. The arrows indicate the selected coating dilution. 
 
Plate-coating concentration subsequently used was selected based on being on the plateau in 
the absorbance reading and on there being sufficient antigen for the entire project.  
Table 3.3 shows the optimal coating dilutions of 15 microorganism species used as antigens 
in the ELISA technique to measure antibody response. These organisms were either bacteria 
lysates, polysaccharides or extracts from fungi or viruses. The results show that the optimal 
antigen dilutions differ between organisms, with P. aeruginosa being at a high dilution of 
1in 2000, whereas, H. influenzae b, S. pneumoniae, A. fumigatus, P. intermedia, M. 
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catarrhalis, RSV, B. cenocepacia, B. multivorans and S. maltophilia were at 1 in 1000, A. 
alternata and S. pneumoniae polysaccharide were 1 in 500, B. pertussis was 1 in 250 and 
non-typeable H. influenzae was at the lowest dilution of 1 in 100.  
Table 3.3. Optimal coating dilutions of microbe-derived antigens.  
 
This determined by indirect ELISA for all antigens utilised in the study (with their sources indicated). 
 
Organism 
number  
Species  Abbreviation  
(Code) 
Nature and source of 
antigens 
Antigen 
coating 
dilutions 
1 P.aeruginosa PSA Cell lysate (in-house) 1in 2000 
2 H.influenzae b  HBO 
polysaccharide 
Polysaccharide NIBSC, 
NIBSC, Potters Bar, UK 
1in 1000 
3 S. pneumoniae SPN Lysate (in-house) 1in 1000 
4 A. fumigatus ASP Extract  (Soluprick, 
Horsholm, Denmark) 
1in 1000 
5 P. intermedia PINT Lysate (in-house) 1in 1000 
6 M. catarrhalis MCAT Lysate (in-house) 1in 1000 
7 B. pertussis BPT Lysate (in-house) 1in 250 
8 A. alternata ALT (Soluprick, ALK, 
Horsholm, (Denmark) 
1in 500 
9 Respiratory 
Syncytial Virus 
RSV Lysate (Gift from Geoff 
Toms, Newcastle 
University)  
1in 1000 
10 S. pneumoniae  SPN-
Polysaccharide  
Polysaccharide conjugate 
vaccine Prevenar 
13(Wyeth pharmaceutical 
Inc, USA) 
1in 500   
11 B. cenocepacia  BCENO Lysate (in-house) 1in 1000 
12 B. multivornas  MULTI Lysate (in-house) 1in 1000 
13 S.maltophilia SM Lysate (in-house) 1in 1000 
14  NTH. influenzae NT-Hi Lysate (in-house) 1in 100 
15 H. influenzae b Hib Lysate (in-house)  
 
3.2.5 Inhibition ELISA to assess antibody specificity  
Inhibition experiments were carried out to ascertain the IgG cross-reactivity and specificity 
against cognate antigen, as previously described in section 2.7.4, to ensure that the antibody 
is directed against the target antigen. The percentage of inhibition was calculated using the 
formula (No inhibition-max inhibition) ÷ (no inhibition) ×100. Figure 3.5 shows the 
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inhibition of coated P. aeruginosa lysate (NCTC) by P. aeruginosa lysate (91%), LPS of P. 
aeruginosa (7%), H. influenzae b (6%), B. pertussis (3%), B. cepacia (0.8%) and S. 
pneumoniae (0.9%). Figure 3.6 displays the inhibition of coated NTH. influenzae, by NTH. 
influenzae (90%), H. influenzae lysate (88%) and H. influenzae polysaccharide (1%). The 
results indicate that cross-reactivity is unlikely. 
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Figure 3.5: Inhibition ELISA for IgG against P. aeruginosa. 
Six antigen inhibitors were tested, including P. aeruginosa, LPS of P. aeruginosa, H. influenzae b, 
B. pertussis, B. cepacia and S. pneumoniae. Absorbance at 490 nm was plotted against the protein 
concentration of the bacterial lysate (mg/ml).  The percentages of inhibition of antibody binding for 
the antigens are shown in the key. 
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Figure 3.6: Inhibition ELISA for IgG against NTH. influenzae. 
Three antigens were used as inhibitors, including NTH. influenzae, H. influenzae lysate and H. 
influenzae polysaccharide against coated NT H. influenzae. Absorbance at 490 nm was plotted 
against the protein concentration of NTH. influenzae (mg/ml). The percentages of inhibition of 
antibody binding for the antigens are shown in the key. 
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3.2.6 IgG ELISA for antibody screening in all groups against the antigens  
 
Screening of the sera was performed to determine the magnitude of serum responses and to 
establish the starting dilution of antibody titre against the key antigens in the study, as shown 
in Table 3.3. BR patients (n=103/119) were investigated for antibody screening and titration, 
where 5 sera samples were not included (missing samples) and 11 samples were excluded 
from the analysis because the patients have immunodeficiency. COPD patients (n=57/58) 
were also investigated as well as asthmatics (n=14) and healthy volunteers (n=27/28).  Each 
clinical group was initially screened at 1 in 25 dilutions in diluent for their responses as 
described in section 2.7.2. Absorbance was read at 490 nm for each patient serum. An 
example of the screening of each group against P. aeruginosa is shown in Figure 3.7(see 
Appendix 9 for more results of antibody screening). Figures 3.7-3.10 illustrate the IgG 
screening of sera against P. aeruginosa in patients with BR, COPD, and asthma as well as 
healthy volunteers.  The results show that most patients and controls exhibited high antibody 
responses to P. aeruginosa. Similar patterns of IgG responsiveness were observed for the 
other antigens tested.     
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Figure 3.7: Screening profile of BR sera against P. aeruginosa. 
Patient sera were initially screened at 1in 25 dilution for their response against the antigen to establish the starting point for antibody titration. Absorbance values for each 
BR patient are given.   
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Figure 3.8: Screening profile of COPD sera against P. aeruginosa. 
Patient sera were initially screened at 1in 25 dilution for their response against the antigen to establish the starting point for antibody titration. Absorbance values for each 
COPD patient are given.  
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Figure 3.9: Screening of asthmatic sera against P. aeruginosa. 
Patient sera were initially screened at 1in 25 dilution for their response. Absorbance values for each 
asthmatic are given. 
 
Figure 3.10: Healthy volunteers sera screened against P. aeruginosa. 
 Healthy volunteers sera were initially screened at 1in 25 dilution for their response. Absorbance 
values for each healthy volunteer are given.  
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Table 3.4 demonstrates the absorbance range at screening, indicating which subsequent 
starting sera dilution was used to obtain the end-point titre.  
Table 3.4. Establishing initial dilution for titration. 
Starting sera dilutions for titration were estimated from the mean optical density of sera with blank 
subtracted 
Absorbance for 1 in 25 
screening   
Subsequent sera starting dilution  
   < 0.2   1:25 
0.2-0.4 1:50 
0.4-0.6  1:100 
0.6-0.8        1:200 
0.8-1.0   1:400 
> 1.0 1:800 
 
3.2.7 Strategy for obtaining end-point titre  
 
A long series of dilutions of serum against antigen shows a typical S-shaped curve. 
Absorbance measurements in the upper plateau of the curve do not discern differences in 
antibody concentration. Hence, the linear parts (Figure 3.11) of the curve in this example 
between a dilution of approximately 1 in 100 to 1 in 1000, is used to extrapolate the dilution 
where the absorbance in zero. This is the end-point titre. 
3.2.8 IgG antibody titre of patient’s sera against antigens 
 
Doubling dilution was carried out on patient sera, which were diluted according to the results 
of the first screening as shown in Table 3.4 and as described in section 2.7.3. Antibody titres 
were expressed as the reciprocal of the highest dilution in which the absorbance value of a 
serum differs from zero. Calculation of the end-point was obtained from the equation 
y=mx+c, where c, the intercept on the y- axis (dilution) is the extrapolated end-point titre 
Figure 3.12.   
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Figure 3.11: Long titration for IgG against P. aeruginosa. 
Serum sample were used to assess the titration values against P. aeruginosa. Results were calculated 
and represented as the mean± SEM.  The oval indicates linear part of serum dilution. 
 
 
 
Figure 3.12: Calculation of each patient end-point titre obtained from the graph using the 
equation y=mx+c. 
The dilution was plotted against absorbance and, in the example for PSA, the value of 2281 was 
found to be the end-point titre. 
y = -2519.4x + 2281.1
R² = 0.9867
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3.2.9 IgG titre against absorbance  
 
Due to constraints on samples, reagents and time to perform serum dilution series for every 
sample, an analysis was performed to see if absorbance was a sufficient measurement of Ig 
levels rather than having to carry out titration for every test. Figure 3.13 below demonstrates 
the relationship between the screening and titration of anti-Pseudomonas IgG titres to see if 
screening absorbance is a sufficient measurement of antibody magnitude. The results 
showed a significant correlation between the titre and the screening absorbance (p=0.0001).  
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Figure 3.13: Titration versus absorbance to P. aeruginosa for the patients and healthy 
volunteers. 
Anti-Pseudomonas IgG absorbance was plotted against the titration of the same cohort to see the 
association between them. The relationship was assessed using Spearman correlation. (n=147)   
 
3.2.10 Stability of the sera 
  
Since sera and plasma samples had to be kept frozen (and thawed when needed), an 
experiment was carried out to investigate the effect of repeating the freeze-thaw cycles of 
human sera on the activity of IgG antibody to a bacterial antigen. M. catarrhalis was selected 
as an example for testing antibody activity (Figure 3.14). Sera were used after 5 freeze-thaw 
cycles as described in section 2.7.6. The results showed no significant difference (p=0.947) 
between levels of antibody in first thawing sera and after 5 freeze/thaw cycles. These 
findings imply that the antibody levels are stable even after 5 freeze-thaw cycles.  
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Figure 3.14: Activity of the sera before and after 5 freeze-thaw cycles. 
Anti- M. catarrhalis IgG was used as an example to determine the effect of repeated freezing-thawing 
cycles on the antibody. Results represent the mean of absorbance. 1st represent the first use and 5X 
shows results after 5 freezing-thawing cycles. No significant difference was found (p=0.9476). 
  
3.2.11 IgG titre in bronchiectasis patients (BR) compared to healthy volunteers (HV) 
   
Indirect ELISA and end-point titration as described in section 2.7.3 was used to measure IgG 
titres against the key antigens shown in Table 3.3 for patients with bronchiectasis (BR) 
compared to healthy volunteers (HV). The findings showed significant differences between 
BR patients and healthy volunteers for P. aeruginosa (p=0.0002), S. pneumoniae 
polysaccharide, H. influenzae (p<0.0001), H. influenzae polysaccharide (p=0.05) and S. 
maltophilia (p=0.032). Conversely, S. pneumoniae titres were significantly higher in healthy 
volunteers compared to BR patients (p=0.027). There were no significant differences 
between BR patients and healthy volunteers with respect to the other bacterial antigens, 
including NTH. influenzae, M. catarrhalis, and A. alternata (p>0.05). In addition, a similar 
response among patients with BR and healthy volunteers to A. fumigatus was seen. Overall, 
the antibody responses of BR patients against most antigens were higher than those of 
healthy volunteers. 
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Figure 3.15: IgG titre against the key antigens included in the study in bronchiectasis patients 
and healthy volunteers. 
Higher antibody titres were detected in BR patients compared to the healthy volunteers (HV). *** 
indicates highly significant p≤0.001. * indicate p ≤ 0.05.  The data is represented by the mean ± SEM 
(n=103 for BR and 27 for HV). 
 
3.2.12 IgG titre in COPD patients compared to healthy subjects 
 
IgG titres of patients with COPD measured by indirect ELISA and end-point titre were 
compared to those of healthy volunteers as explained in section 2.7.3 to determine if there 
were any significant differences between these groups. The results showed that the COPD 
group had highly significant anti-S. pneumoniae polysaccharide (p= 0.0047) compared to 
healthy individuals. Meanwhile healthy volunteers had higher anti-S. pneumoniae IgG titres 
when compared to COPD patients (p=0.014). The results showed no significant differences 
between COPD patients and healthy subjects to P. aeruginosa, NTH. influenzae, H. 
influenzae b lysate, M. catarrhalis, S. maltophilia, A. fumigatus, A. alternata and H. 
influenzae b polysaccharide. 
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Figure 3.16: IgG titre against the key antigens in the study in COPD group and healthy 
volunteers. 
*** indicates highly a significant difference between the COPD and HV (p=0.0047), and * indicates 
(p= 0.014). The results are represented by the mean ± SEM (n=57 for COPD and 27 for HV). 
 
3.2.13 IgG titres in asthma patients compared to healthy volunteers 
 
 Specific IgG titres versus antigens included in the study were also measured as described in 
section 2.7.3 among asthmatics compared to healthy volunteers. The findings showed that 
asthmatics had significantly lower IgG titre against S. pneumoniae lysate (p=0.046) and M. 
catarrhalis (p=0.032). The results showed no significant differences in patients with asthma 
against S. pneumoniae polysaccharide, A. alternata and H. influenzae b compared to healthy 
controls. 
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Figure 3.17: IgG titre against the key antigens in the study in asthmatics and healthy 
volunteers (HV). 
* indicates p≤0.05. The results are represented by the mean ± SEM (n= 14 for asthma and 27 for 
HV).  
 
3.2.14 IgG subclass 
 
Sub groups of 20 BR patients and 20 COPD patients were tested for anti-P. aeruginosa Ig 
isotypes including IgG1, IgG2, IgG3, and IgG4, as well as the IgA and IgM classes. These 
samples were high IgG antibody titre responders to P. aeruginosa as determined previously 
in antibody screening and titration.  Absorbance at 490 nm was plotted against the Ig 
isotype for serum dilution at 1 in 25. The isotype levels for BR and COPD patients are 
shown in Figures 3.18 and 3.19, respectively. IgG1 response was highest in BR patients 
followed by IgA and IgM. In contrast, COPD patients demonstrate higher IgM followed 
by IgG1. Other IgG isotypes were at low levels among patients with BR and COPD. Three 
healthy volunteers and three asthmatics were also measured for isotypes, IgA, and IgM 
against PSA. The results are shown in (Appendix 10).   
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Figure 3.18: Antibody isotype levels against P. aeruginosa in BR patients. 
Comparison of antibody isotypes in patients with BR showed that the predominant isotype was 
IgG1. Data are shown as mean ± SEM.  
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Figure 3.19: Antibody isotype levels against P. aeruginosa in the COPD group. 
Comparison of antibody isotypes in patients with COPD showed that the predominant isotype in 
COPD was IgM.  Data are shown as mean ± SEM.   
 
3.3 Discussion  
 
Bronchiectasis and chronic obstructive pulmonary disease are the most common conditions 
leading to progressive lung damage and loss of lung function. Both conditions are 
characterised by an abnormal dilation of airways that is not fully reversible. Bacterial 
infection and inflammatory response are the main determinants for promoting disease 
progression (Vestbo et al., 2013, Whitters and Stockley, 2013). Recruited neutrophils are 
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found to be a major factor in the causation of airway inflammation, disruption of the local 
immune response and eventually damage to the bronchi (Shum et al., 2000). It has been 
shown that high titres of antibody against P. aeruginosa are found in CF patients. The role 
of anti-Pseudomonas antibody is important for eliminating the bacteria and may provide an 
early indication of microbial colonization (Caballero et al., 2001, Milagres et al., 2009). In 
this study, it is hypothesised that microbial infection is the main cause of eliciting higher 
antibody titre in patients with obstructive lung disease. Therefore, the elevated antibody may 
be a sufficient marker for microbial colonization.   
The aim of this section was to investigate the immune responses against different lung 
antigens among patients with chronic obstructive lung diseases (BR, COPD and asthma) 
compared to healthy volunteers, and to identify any significant differences between these 
groups. In this study, different forms of lung antigens were used, including a lysate of 
bacteria, polysaccharides, viruses and extracts of fungi, to ascertain the presence of 
antibodies specific to each antigen. The cross-reactivity of P. aeruginosa and NTH. 
influenzae were tested with other related bacteria to determine the specificity of IgG using 
an inhibition assay (see Figures 3.5 and 3.6). For P. aeruginosa, the inhibition assay showed 
minimal inhibition by the other antigens tested (Figure 3.5). The procedure of the inhibition 
assay is based on the hypothesis that the incubation of antigen and positive sera will allow 
the interaction between the antigen and the antibody and the formation of an antibody-
antigen complex. Once the mixture is added to the ELISA plate coated with the same antigen, 
only free antibody will react with the restrained antigen in the plate. Therefore, the antibody 
specific to the soluble antigen cannot bind to the immobilized antigen and as a result will be 
washed away. The remaining antibodies that react with the immobilised antigen can then be 
determined by the assay (Bergmann et al., 2006).  Therefore, the results show that no cross-
reaction was observed in P. aeruginosa with other Gram-negative bacteria, indicating that 
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the antibody is specific for the cognate antigen. However, a cross-reactivity was observed 
between H.influenzae lysate and NTH.influenzae.  
In this study, the stability of the sera was also examined after multiple freeze-thawing to 
monitor the sustained quality of sera during the study. The results demonstrated that the 
antibody activity was not affected even after multiple freeze/thaw cycles. This finding 
supports those of a previous study conducted to measure the antibody activity of IgG, IgA 
and IgM, which showed the antibody to be stable even after 30 freeze-thaw cycles 
(Rastawicki et al., 2012).   
 3.3.1 Antibody response in patients with BR and HV  
 
Antibody analysis revealed that patients with BR had significantly higher IgG titres 
compared to healthy volunteers against P. aeruginosa (p=0.0002), S. maltophilia (p=0.032), 
H. influenzae polysaccharide (p=0.05), H. influenzae and S. pneumoniae polysaccharide 
(p<0.001). These patients are more susceptible to persistent microbial infections. The most 
common pathogens isolated from the respiratory tract of non-cystic fibrosis bronchiectasis 
(nCFBR) patients include H. influenzae, P. aeruginosa, S. pneumoniae, and M.catarrhalis 
(Angrill et al., 2002, Pasteur et al., 2000). Therefore, increased antibody levels against these 
organisms in BR patients are expected to be due to multiple boosting. Furthermore, higher 
antibody titres were also observed in BR patients than in healthy volunteers against NTH. 
influenzae, and A. alternata. However, the differences were not significant (p>0.05). The 
reason for these responses may be the immunological stimulus from the antigens in the 
airways in combination with the PAMPs (such as LPS) leading to inflammatory responses 
and increased magnitude of antibody (Caballero et al., 2001, Stead et al., 2002). It has been 
suggested that detectable levels of IgG against NTH. influenzae in both bronchiectasis and 
healthy controls may be due to healthy volunteers having a Th1 response and protective 
immunity against these bacteria, whereas patients with bronchiectasis develop a Th2 
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response with associated antibody production but weaker immunity against infection (King 
et al., 2003, Murphy, 2003). The data also shows a similar magnitude of response of the 
antibody between BR and healthy volunteers against A. fumigatus and this may be because 
both groups have a similar degree of exposure to A. fumigatus. A study has demonstrated 
that the culture of sputum from patients with CF underestimates colonization by A. 
fumigatus, and no correlation was found between the antibody titre and A. fumigatus 
colonization (Máiz et al., 2008).  
A previous study has shown decreased antibody response to Pneumococcus polysaccharide 
in patients with BR (Stead et al., 2002). This result is contrary to our finding, which showed 
significantly higher antibody titres against S. pneumoniae polysaccharide in BR and COPD 
patients. This may be because the patients responded to natural infections or they had 
previous immunisation against Pneumococcus, which is boosted by infection. Interestingly, 
healthy volunteers showed significantly higher IgG titres against S. pneumoniae lysate, 
suggesting that the protective immune response among healthy volunteers arises from 
exposure to this bacterium rather than by vaccination (King et al., 2003).  
3.3.2 Antibody response in patients with COPD and HV  
 
The COPD group contained 57 patients compared to 27 healthy volunteers. Similarly to BR 
patients, a significant difference was observed in COPD patients against S. pneumoniae 
polysaccharide (p=0.0047). This implies that these patients may have had previous 
immunization or exposure to the bacteria as discussed above for BR patients. However, only 
slightly increased antibody titres were observed in COPD patients against P. aeruginosa, H. 
influenzae b, S. maltophilia and A. alternata, but the differences were not significant, 
suggesting that levels of bacterial infection eliciting inflammatory and antibody responses 
among patients with COPD, were less than in BR (Millares et al., 2014). In contrast, a lower 
antibody titre was found in COPD subjects against S. pneumoniae lysate, NTH. influenzae 
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and M. catarrhalis. Decreases in IgG antibody titre in COPD compared to BR may be 
influenced by smoking in COPD patients. Smoking is thought to inhibit the activation of B 
cells and immunoglobulin secretion, leading to the impaired ability of the host to clear 
infection (Al-Ghamdi and Anil, 2007, Voss et al., 2015). Furthermore, as a component of 
cigarette smoke nicotine promotes bacteria replication and decreases the production of 
cytokines, including IL-6, IL-12, TNFα and IFN(Matsunaga et al., 2001). A similar 
response to A. fumigatus between COPD patients and healthy subjects was observed, as seen 
among patients with BR.  
3.3.3 Antibody response in patients with asthma and HV 
  
Fourteen patients with asthma were included in the antibody analysis. The findings 
demonstrated that asthmatics had lower antibody responses against S. pneumoniae lysate, 
NT. H. influenzae, M. catarrhalis, S. maltophilia and A. fumigatus and the differences for 
both S. pneumoniae lysate and M. catarrhalis were significant (p= 0.046 and p=0.032 
respectively) compared to healthy controls. Reduced antibody levels observed among 
asthmatics may be related to rare microbial infections that are necessary to activate humoral 
responses. In contrast, the antibody levels against S. pneumoniae polysaccharide, A. 
alternata and H. influenzae b were slightly higher among patients with asthma. However, no 
statistical significance was found (p>0.05). This contrasts to a previous study, which showed 
that antibodies against S. pneumoniae polysaccharide were lower in patients with asthma 
compared to non-asthmatics. The reason behind this may be the limitations of statistical 
power as reported in the previous study (Zhao et al., 2013).  The lower levels of IgG antibody 
in patients with asthma against most antigens may be explained by the fact that the 
presentation of allergen peptides to TCR via MHC II in combination with costimulatory 
molecules and a high level of IL-4 may lead to Th2 cell differentiation and B cell isotype 
switching to IgE (Holgate, 2012).  
 
120 
 
3.3.4 IgA, IgM and IgG subclasses in COPD and BR 
 
The study sought to examine the IgG sub classes and other classes including, IgM and IgA 
in BR and COPD groups against P. aeruginosa as described in section 2.7.5. A sub group of 
20 patients was selected from each clinical group; these patients had higher total anti-
Pseudomonas IgG. The findings showed that the level of IgG1 was greater among BR 
patients compared to the other sub classes (IgG2, IgG3 and IgG4) and classes (IgM and IgA). 
Increased IgG1 in patients with BR seems to be associated with the biochemical nature of 
the Pseudomonas antigens itself, since the protein antigens are associated with the T cell-
dependent elicitation of IgG1, whereas the polysaccharide increases the response of IgG2 
(Obukhanych and Nussenzweig, 2006, Twigg, 2005).  
Additionally, the level of anti-Pseudomonas IgA was slightly higher compared to the other 
sub classes. IgA is the main humoral immune response against bacterial infection at the 
mucosal surface of the lungs. Its role is to inhibit the organism binding to the mucosal 
surface, neutralising extracellular pathogens and clearing infections (Blutt et al., 2012, Brett 
et al., 1988, Twigg, 2005). Therefore, as BR is associated with P. aeruginosa infections, 
increased IgA production is expected for the clearing of the Pseudomonas and to protect 
against re-infection. It has been reported that increased anti-Pseudomonas IgA may occur 
before the anti-Pseudomonas IgG response in patients with cystic fibrosis colonized by P. 
aeruginosa (Brett et al., 1988). Specific IgA against exotoxin A, lipopolysaccharide, alginate 
and whole cells of P. aeruginosa have been previously demonstrated in the serum of CF 
patients (Cukor et al., 1983, Pedersen et al., 1990). Here the elevated level of anti-
Pseudomonas IgA in patients with BR may provide an indication of P. aeruginosa 
colonization in the lung mucosa.  
In contrast to BR, the results showed that patients with COPD had higher anti-Pseudomonas 
IgM responses. This may be due to a disruption in T cell responses that would promote IgM 
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to IgG class switching. A previous study revealed that increased IgM antibody against NTH. 
influenzae in both sera and saliva reduced infections and chronic respiratory disease in 
patients with hypogammaglobulinemia (Micol et al., 2012). Anti-Pseudomonas IgG1 levels 
also increased compared to other sub classes in patients with COPD, indicating a role of the 
T cell-dependent antibody response.     
Low levels of IgG sub classes, including IgG2, IgG3 and IgG4, in patients with BR and 
COPD have been found in this study. Bacterial whole cell lysates were used in which the 
protein is the most antigenic component which therefore provides cognate antigen for T cell 
help. High levels of IgG2 and IgG3 against Pseudomonas in patients with cystic fibrosis have 
been associated with worsening clinical condition (Pressler et al., 1990). In the same study, 
the authors reported that the investigation of antibody sub classes should be restricted to 
certain antigen components, and that IgG sub class production occurs in response to the 
particular protein or polysaccharide (Pressler et al., 1990). Low levels of anti-Pseudomonas 
IgA in patients with COPD may be due to the low extent of Pseudomonas colonization in 
the lungs of COPD patients compared to BR, which is investigated in the next chapter.   
4 Conclusion 
  
The study described in this chapter demonstrated that increased IgG antibody titres in BR 
and COPD patients in comparison to healthy volunteers may be the result of microbial 
exposure and infections. In contrast, patients with asthma have lower IgG antibodies. This 
suggests that elevated IgG levels are associated with bacterial infection. IgA may also 
provide an indication of pulmonary infections among patients with BR and COPD. 
Investigation of IgG isotypes against further specific antigenic components in patients with 
BR and COPD is needed.     
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4 Chapter Four: Relating Antibody Responses to Microbial 
Colonization and Disease Severity in Patients with 
Bronchiectasis (BR) and Chronic Obstructive Pulmonary 
Disease (COPD). 
 
Abstract  
Aim: The aim of this chapter is to compare the microbiological results from sputum, and 
disease severity, with antibody responses against corresponding antigens in BR and COPD. 
In the whole cohort, 119 patients with BR and 58 patients with COPD were recruited into 
this study. Out of these, 116 BR and 48 COPD subjects contributed to the sputum analysis. 
Asthmatics were excluded from the microbial analysis.  
Methods: IgG titres against microbial derived-antigens were measured by indirect ELISA 
end point titre. Lung function assessment was performed on patients and healthy volunteers. 
Culture-based microbiology was carried out to detect the presence of pathogens in the 
sputum of patients with BR and COPD.   
Results: Culture-positive isolates were obtained from 108 and 27 patients for BR and 
COPD, respectively. The remaining BR (n=8) and COPD (n=21) samples were classified as 
no pathogen isolated. Non-typeable H. influenzae was the predominant bacterial species 
isolated in both groups, followed in abundance by P. aeruginosa detected in BR and S. 
pneumoniae in COPD patients. Increased magnitude of antibody was associated with the 
degree of microbial colonization when it was categorised according to standardised clinical 
criteria. Lung function (FEV1% predicted) was significantly reduced in patients who had 
chronic infection compared to those for whom it was intermittent. By contrast, no 
relationship between antibody titre and lung function was observed.   
 
 
 
123 
 
A significant difference was observed in antibody titres against P. aeruginosa, M. 
catarrhalis and S. maltophilia at different scores of exacerbations.  
Conclusion:  Polymicrobial colonization was detected among patients with BR and COPD. 
These pathogens induce humoral immune responses and elevated levels of IgG which are in 
part dictated by levels of exposure.  Bacterial infections also promote lung function 
deteriorations and exacerbations, but these are not predicted by level of specific antibody.   
4.1 Background  
 
Ever since the Human Microbiome Project (HMP) omitted the lung from the list of priority 
organ systems, much work has focused on the communities of micro-organisms in healthy 
and diseased conditions, shedding light on the pathogenesis of lung infections (Beck et al., 
2012, Dickson et al., 2013). Recent studies have found microbial communities in the airway 
of healthy humans, confirming that the lung is not a sterile organ (Yonker et al., 2015).  
Bacterial colonization is associated with reduced mucociliary clearance in the lower 
respiratory tract, and it promotes the hyper-inflammatory response, airway destruction, 
further supporting microbial colonization. This phenomenon is termed the “vicious cycle 
hypothesis” as described by Cole (1986). 
Bronchiectasis is strongly associated with chronic airway infection leading to progressive 
damage to the bronchial wall and impaired lung function. Previous studies investigating the 
pathogenic microorganisms of BR from sputum samples have identified H. influenzae and 
P. aeruginosa as the most common pathogens isolated, and further analysis of H. influenzae  
found it to be the non-typeable (NT) strain (King et al., 2007). Other lung isolates include S. 
pneumoniae, M. catarrhalis and non-tuberculous mycobacteria (NTM). S. aureus is less 
frequently isolated and its isolation suggests the possibility of cystic fibrosis.  P. aeruginosa 
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has antibiotic resistance particularly due to the formation of mucoid biofilm, which results 
in severe damage to the underlying airway. It has been shown that H. influenzae is isolated 
from patients with moderately declining lung functions, whereas P. aeruginosa is implicated 
in worsening lung function, exacerbation, and hospitalization (King, 2011).    
Microorganisms are the main aetiological factors contributing to the pathogenesis of COPD 
in both stable and exacerbation conditions. In stable conditions, the chronic infections 
promote airway inflammation, leading to increased frequency of exacerbation and impaired 
lung function. Furthermore, studies have shown that 70% of COPD exacerbation is 
associated with respiratory infections, the most frequently isolated bacteria from COPD 
patients being NTH. influenza, S. pneumoniae and M. catarrhalis. Other Gram-negative 
bacteria, including P. aeruginosa and S. maltophilia, are also present in patients with severe 
exacerbation (Matkovic and Miravitlles, 2013, Sethi and Murphy, 2001).  
Culture-independent approaches are becoming an important technique in the clinical field 
and in conjunction with routine culturing. The technique has shown that, for example, 
patients with cystic fibrosis have more diverse polymicrobial communities than is found 
using culture-dependent methods (Tunney et al., 2013).  
In response to microbial infection, serum antibody titre typically rapidly elevates after 
infection followed by stabilization then decreases towards a baseline over the following 
years. For several infections, such as HIV and CMV, this process is termed 
“seroconversion”, which is used to ascertain the level of infection. Thus, the antibody level 
is boosted by re-exposure or repeated contact with the organisms (Teunis et al., 2012, Teunis 
et al., 2002). Considering the role of the immune response against infection, the aim in this 
study is to investigate antibody levels in relation to infection status by pathogenic 
microorganisms. The frequency of microbial colonization and specific antibody levels are 
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also compared to lung function to see if the acquisition of bacteria is associated with lung 
function decline and disease exacerbation. Ultimately, the aim is to ascertain if antibody 
responses serve as biomarkers for lung disease.  
4.2 Results  
4.2.1 Microbial community detected in bronchiectasis and chronic obstructive lung 
disease patients 
 
From the whole cohort of sputum samples, 108 BR and 27 COPD patients were culture-
positive for pathogenic microorganisms. The remaining BR (n=8) and COPD (n=21) 
samples were classified as having no pathogens isolated. The following Figure 4.1 and Table 
4.1 show the abundance of microorganisms in the sputum of patients with BR and COPD 
patients. The results demonstrated that the most common pathogenic organisms isolated 
from the sputa of BR and COPD patients were H. influenzae, found in 65.5% and 37.5% of 
patients respectively, followed by P. aeruginosa found in 57.7% and 14.5%. S. pneumoniae 
was isolated from 45.6% of BR and 20.8% of COPD patients. M. catarrhalis was found in 
38.7% of BR and 29% of COPD patients. The percentage of patients with no pathogen 
isolated was 6.8% in BR and 43.7% in COPD. Multiple infections, in which more than two 
or more pathogens were isolated, were observed among many of these patients, particularly 
BR, and hence the percentages add to greater than 100. 
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Figure 4.1: The abundance of identified microorganisms in sputum samples collected from 
clinically stable patients with BR and COPD. 
The culture-dependent technique was performed to examine the sputum for pathogenic 
microorganisms. The most common pathogenic organisms isolated were NTH. influenzae in BR and 
COPD followed by P. aeruginosa in BR and M. catarrhalis in COPD. NPI indicates the percentage 
of no pathogens isolated.  
.  
Table 4.1. Shows the abundance of microorganisms isolated from the sputum of patients with 
BR and COPD. 
Microorganism  Bronchiectasis 
patients (%) 
Chronic obstructive 
pulmonary disease patients 
(%) 
NT. H.influenzae 65.5  37.5 
P. aeruginosa 57.7 14.5 
 
S. pneumoniae 45.6 20.8 
M. catarrhalis 
 
38.7 29 
A. fumigatus 23.2 4 
S. maltophilia 
 
16.3 4.1 
Candida. sp 14.6 8.3 
S aureus 31 2 
 
E.coli 20.6 6.2 
NPI 6.8 43.7 
  
0
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350
BR COPD
NPI
E.coli
S aureus
Candida
S.maltophilia
S. pneumoniae
M. catarrhalis
A. fumigatus
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4.2.2 Classification of patients according to frequency of infections  
 
Patients were classified into four groups based on the frequency of isolation of 
microorganisms from the sputum samples. Total of 116 of the BR patients and 48 COPD 
patients were either culture-negative or culture-positive for pathogenic microorganisms. The 
negative samples for BR (n=8) and COPD (n=21) were categorized as no pathogen isolated 
(NPI). The culture-positive BR (n=108) and COPD (n=27) samples were classified into three 
groups. Occasionally isolated, where they had only one microbial isolate per year. Chronic 
infection is defined by the isolation of pathogenic microorganisms in the culture on two or 
more occasions in one year, and this category is further subdivided into chronic previously 
and chronic currently based on the date of isolation (being the same as date of sample) (see 
Table 4.2). 
Table 4.2. Classification of patients based on microbiological results 
0
  
No pathogen isolated (NPI)  
1 Occasional  
 
1 isolation in a year 
 Chronic, divided into 2 and 3  
 
 
Chronic colonization is defined by the 
isolation of potentially pathogenic 
bacteria in sputum culture on 2 or more 
occasions, at least 3 months apart in a 1 
year period 
2 Chronic previously A period of 1997-2013 
 
3 Chronic currently 
 
All of 2013 and 2014 
 
4.2.3 Antibody response associated with microbial colonization in bronchiectasis (BR) 
patients   
 
IgG titres against microbe-derived antigens, including P. aeruginosa, S. pneumoniae, A. 
fumigatus, M. catarrhalis, NTH. influenzae and S. maltophilia, were measured by ELISA 
for bronchiectasis patients. IgG titre was compared to the results of the incidence of 
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colonization as classified in Table 4.2. P. aeruginosa showed a significant difference when 
compared to non-colonized and currently colonized (p<0.001) and between occasionally and 
currently colonized (p<0.001). Significant differences were also seen between non-
colonized and chronic previously (p=0.001) as well as between occasional and chronic 
previously (p=0.003).  Similarly, a significant difference was seen between those who were 
non-colonized compared to currently colonized by S. maltophilia (p= 0.036). Conversely, 
no significant difference was found between the groups for other pathogens in the study, 
including S. pneumoniae, A. fumigatus, M. catarrhalis and NTH. influenzae, although there 
was a trend for increased titre with increased exposure.  
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Figure 4.2: Antibody titres compared to the results for pathogens microbiologically isolated 
from the sputum of BR patients. 
The serum IgG responses against six microbe-derived antigens were compared to the results of 
incidence of colonization. The colours match with the frequency of colonization as indicated in the 
chart. *** indicates highly significant differences were found between no pathogen isolated, 
occasionally group and chronic colonization category for P. aeruginosa (p < 0.001). * indicates 
significant difference p<0.05 S. maltophilia. Data are represented by mean ± SEM.  
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4.2.4 Antibody response associated with microbial colonization in chronic 
obstructive pulmonary disease (COPD) patients.  
 
IgG titres against lung antigens in the study were also compared to incidence of microbial 
colonization for COPD; patients showed a significant difference (p=0.04) between non-
colonized and currently colonized patients for M. catarrahlis.  Meanwhile, patients who had 
no NTH. influenzae isolation (non-colonized) had significantly higher antibody titres 
compared to those with occasional colonization (p= 0.04).  Similarly, for S. pneumoniae, 
non-colonized patients displayed higher but not significant antibody titre compared to those 
chronically colonized by this bacterium. Furthermore, patients who were occasionally 
colonized by P. aeruginosa had higher antibody compared to patients with no isolation of 
these bacteria. In contrast, no obvious difference was found between non-colonized patients 
and patients with chronic isolation for A. fumigatus.  
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Figure 4.3: Antibody titres compared to the result of pathogens isolated from the sputum of 
COPD patients. 
The serum IgG responses against six microbe-derived antigens were compared to the results of 
incidence of colonization. The colours match the frequency of colonization as indicated in the chart. 
Significant differences were found between the non-pathogen isolated category and chronic 
colonization in M. catarrhalis and between non-pathogen isolated and occasionally in NTH. 
influenzae with p=0.04 for both. Data are represented by the mean ± SEM. (np that indicates no 
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culture+ patients were identified, 1p indicates only 1 patient was identified, and so no error bars are 
shown). 
 
4.2.5 Lung function associated with colonization in BR and COPD  
 
Patients with BR and COPD underwent spirometry testing during their clinical assessment 
(see chapter 2). Lung function as measured by FEV1% predicted were assessed in order to 
determine the severity of the disease in each patient.  It was seen that both clinical groups 
had progressive lung function decline and loss of FEV1% overtime.  
Figure 4.4 shows the relationship between FEV1% predicted and the incidence of microbial 
colonization in patients with bronchiectasis. Patients with no-pathogen colonization were 
compared to those with current microbial colonization. An inverse relationship was broadly 
observed between microbial colonization and lung function. The results show a significant 
reduction in FEV1% predicted in BR patients curently colonized by P. aeruginosa, and M. 
catarrhalis (p=0.02) compared to the non-colonized group. A significant decrease was also 
observed between those with chronic current isolation and those where S. maltophilia had 
not been colonizing (p=0.006). No significant reductions were found between the groups 
who were non-colonized or colonized by S. pneumoniae, A. fumigatus, and NTH. Influenza. 
 
 
 
131 
 
P.
ae
ru
gi
no
sa
S.
pn
eu
m
on
ia
e
A
.fu
m
ig
at
us
 
M
.c
at
ar
rh
al
is
N
T
H
.in
flu
en
za
e
S.
m
al
to
ph
ili
a
0
20
40
60
80
100
Non
Occasionally
Chronic previously
Chronic currently
*
* *
Pathogens
F
E
V
1
%
p
re
d
 
Figure 4.4: Lung function assessment compared to the results of microbial colonization in 
BR. 
The results of FEV1% predicted were compared to the incidence of colonization for each potentially 
pathogenic microbial species. The data are represented by the mean± SEM. Significant differences 
between non-pathogen isolated and chronic currently colonised, with p ≤ 0.05. 
 
Figure 4.5 shows the relationship between the presence of bacterial infection and FEV1% 
predicted in patients with COPD. The results demonstrate a significant reduction in FEV1% 
predicted between patients who are non-colonized and currently colonized by P. aeruginosa 
(p=0.019). However, significantly decreased FEV1% predicted (p=0.02) was observed 
among patients who had negative culture for S. pneumoniae compared to those with previous 
colonization. The data did not show any significant reduction in FEV1% for M. catarrhalis, 
NTH. influenzae  and A.fumigatus colonization. 
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Figure 4.5: Lung function assessment compared to the results of microbial colonization in 
COPD. 
The results of FEV1% predicted were compared to the incidence of colonization for each potentially 
pathogenic microbial species. The data are represented by the mean± SEM. Significant differences 
were found between non-pathogen isolated, chronic and occasionally infected categories. (np 
indicates no patients were analysed,1p indicates only 1 patient was analysed and no error bars are 
shown). 
4.2.6 Lung function in BR exacerbated patients and healthy volunteers  
 
BR exacerbating patients were classified into three subgroups according to the 
Bronchiectasis Severity Index (BSI) (see Appendix11) as either <3 exacerbations or >3 
exacerbations per year, or hospitalised. The FEV1% predicted was assessed in these 
exacerbation groups and compared to healthy volunteers (Figure 4.6). Significant lung 
function decline was observed among patients with different scores for exacerbation 
compared to healthy volunteers (p=0.006). In addition, the one-way ANOVA showed high 
statistical significance (p<0.0001). 
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Figure 4.6: FEV1% predicted assessment was tested in variously-exacerbated BR patients 
compared to healthy subjects. 
Data are represented by mean± SEM. (The number in each group is indicated).   
 
4.2.7 Antibody response in exacerbated patients with bronchiectasis   
 
IgG titres against the main bacteria associated with lung function decline, including P. 
aeruginosa, S. maltophilia and M. catarrhalis, were compared for BR patients with different 
exacerbation scores in order to see if there is a significant difference in the antibody titres 
between these groups and whether or not antibody responses may associate with disease 
severity and exacerbation. Figure 4.7 shows that significant differences between the >3 
exacerbation and hospitalised (p=0.037) and between the >3 and <3 groups (p=0.040) 
against P. aeruginosa were seen. Similarly, significant differences were found between >3 
and <3 exacerbations (p=0.010 and p=0.040) against M. catarrhalis and S. maltophilia 
respectively. The results indicate that the antibody could be a biomarker for disease severity 
and exacerbation.  
 
 
 
134 
 
<3 exacerbation >3 exacerbation Hospitalised
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
p=0.037p=0.04
A
Excerbation scores
A
n
ti
-P
se
u
d
o
m
o
n
as
 I
g
G
 t
it
re
 
<3 exacerbations >3 exacerbation Hospitalised
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
p=0.01
B
Excerbation scores
A
n
ti
-S
.m
a
lt
o
p
h
il
ia
 I
g
G
 
<3 exacerbation >3 exacerbation Hospitalised
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
p=0.03
C
Exacerbation scores
A
n
ti
-M
.c
a
ta
r
r
h
a
li
s
 I
g
G
 
Figure 4.7 (A-C): IgG titres against (A) P. aeruginosa; (B) S. maltophilia and (C) M. 
catarrhalis compared for each exacerbation score. 
A significant difference was found between > 3 and < 3 exacerbations against these antigens. A 
significant difference was also found between >3 and hospitalised against P. aeruginosa. The Mann-
Whitney test was used to obtain p-values. Data are represented by mean ±SEM. 
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4.2.8 Correlation between antibody responses and lung functions in BR and COPD 
patients  
 
IgG titre against P. aeruginosa, S. maltophilia and M. catarrhalis was plotted against FEV1% 
predicted to see if there is a significant correlation between antibody response and 
deterioration of lung function, and whether or not immune response can be a biomarker to 
predict lung function decline.  The results show no significant correlation between antibody 
response and lung functions in the BR and COPD groups (Figures 4.8 and 4.9 (A-C)).  
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Figure 4.8 (A-C): Spearman correlation analysis for BR patients of IgG titre and FEV1% 
predicted. 
(A) IgG response against P. aeruginosa; (B) IgG titre against S. maltophilia and (C) IgG titre against 
M. catarrhalis. No significant differences were found (p>0.05).  
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Figure 4.2(A-C): Spearman correlation analysis for COPD patients of IgG titre and FEV1% 
predicted. 
(A) IgG response against P. aeruginosa; (B) IgG titre against S. maltophilia; and (C) IgG titre against 
M. catarrhalis. No significant differences were found (p>0.05).    
 
4.3 Discussion  
 
In this study, it was found that NTH. influenzae is the most common pathogen isolated from 
BR and COPD patients (Figure 4.1). This finding agrees with those of previous studies found 
that it is the most common pathogen isolated from patients with bronchiectasis (Angrill et 
al., 2002, King et al., 2007, Pasteur et al., 2000), followed in frequency by P. aeruginosa 
for patients with BR and M. catarrhalis of patients with COPD. H. influenzae can stimulate 
mucus production, adhere in the submucosa, invade cells and damage the epithelium of the 
airway. This bacterium may produce biofilms for protection from antibody and immune 
cells, resulting in colonization in the airways (King, 2011). A previous study of children with 
CF bronchiectasis showed that there was an inverse correlation between P. aeruginosa and 
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H. influenzae in microbial analysis suggesting that P. aeruginosa may inhibit the growth of 
H. influenzae (Klepac-Ceraj et al., 2010). Therefore, the interaction between these 
microorganisms needs more investigation in patients with lung disease.   
4.3.1 Microbial infections and IgG titre  
 
In this study, IgG titres were investigated in BR and COPD patients and analysed based on 
microbial isolation as shown in Table 4.2. Those currently chronically colonized by different 
pathogens showed higher antibody titre among patients with bronchiectasis. More 
specifically, there were significantly higher antibody titres in patients who had current 
colonization compared to being non-colonized for P. aeruginosa and S. maltophilia 
(p<0.001 and 0.036 respectively). Significant differences were also observed between non-
colonized patients and those with chronic previously category (p=0.001) as well as patients 
occasionally colonized and those with previous chronic colonization (p=0.003) for P. 
aeruginosa.  
It has been shown that increased antibody titres are correlated with P. aeruginosa 
colonization in patients with cystic fibrosis (Brett et al., 1987, Brett et al., 1986, Cordon et 
al., 1992). Bacterial infections promote the inflammatory response and increase the specific 
antibody response, which may be unable to clear the infections but may form immune 
complexes and activate inflammatory mediators that lead to lung damage (Caballero et al., 
2001). Increased antibody titre may perhaps be useful as an indicator of microbial infections, 
especially for diagnosing young children who are unable to expectorate sputum, and for 
determining the need for antibiotic treatment  (Cordon et al., 1992). These findings support 
those of a  previous study conducted to detect anti-Pseudomonas antibodies in patients with 
non-cystic fibrosis bronchiectasis by Western blot (Caballero et al., 2001). Significant 
differences were also observed among COPD patients between non-colonized and those who 
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were currently colonised by M. catarrhalis (p=0.04). Interestingly, COPD patients who had 
no NTH. Influenzae isolation had significantly higher antibody titre (p=0.04) compared to 
those with occasional isolation, although the antibody titre was also higher in patients 
chronically colonized by this bacterium. Likewise, detectable antibody against S. 
pneumoniae was also observed among the patients with no isolation of this bacterium in the 
corresponding sputum.  Increased antibody titre with the negative culture isolation seen in 
patients with COPD may be due to the specific antibiotic treatment, especially if these 
patients had chronic exacerbations and worsening lung functions (Cordon et al., 1992). In 
addition, existing antibodies may be providing immune protection in this group. An elevated 
level of antibody observed in patients with COPD against P. aeruginosa and S. maltophilia 
in those who had occasional isolation of these bacteria may be an indication of the degree of 
bacterial exposure.   
4.3.2 Microbial infections and deterioration of lung function 
  
Concerning the relationship between bacterial infection and the deterioration of pulmonary 
functions in both BR and COPD clinical groups, the results demonstrated significantly lower 
lung function (p= 0.02) with those currently colonized by P. aeruginosa and M. catarrhalis 
than non-colonized in BR patients. Similarly, a significant reduction was seen in FEV1% 
(p=0.006) in patients chronically colonized by S. maltophilia than non-colonised patients. 
Lower FEV1% predicted was also observed among BR patients at different categories of 
chronic colonization by S. pneumoniae, A. fumigatus and NTH. influenzae, but no significant 
differences could be detected. A significant decrease in FEV1 % predicted was seen in COPD 
patients chronically colonized by P. aeruginosa (p= 0.019). In contrast, a significant 
decrease in FEV1% predicted was found in COPD patients who had no S. pneumoniae 
isolation in the corresponding sputum sample, suggesting that other factors such as quality 
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of life, a previous history of exacerbation, and childhood pneumonia may be associated with 
lung function decline (Kim et al., 2016).  
These findings corroborate those of previous studies conducted on patients with 
bronchiectasis and the role of Pseudomonas in progressive lung function decline (Davies et 
al., 2006, King et al., 2007, Ma et al., 2015, Martinez-Garcia et al., 2007). Colonization with 
P. aeruginosa in non-cystic fibrosis bronchiectasis is strongly associated with an accelerated 
decline of lung function, and even antibiotic treatment for an exacerbation shows no 
improvement in FEV1  and FVC compared to other microorganisms (Murray et al., 2009). 
Impairment of lung functioning is associated with pathogenic bacterial load and species 
changes, and the best-preserved lung function is most likely to have no pathogenic bacteria 
isolated (King, 2009, Marin et al., 2010). The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) stated that the severity of airflow obstruction should be categorised as 
follows: patients with stage I: mild 80% or above, stage II: moderate 50-79%, stage III: 
severe 30-49%, and stage IV: very severe below 30% (Decramer et al., 2012). Thus, at the 
time of sampling in this study, BR patients colonized by P. aeruginosa, S. pneumoniae, A. 
fumigatus, and NTH. influenze presented with GOLD stage II, whereas patients who had 
current chronic colonisation by M. catarrhalis and S. maltophilia presented at GOLD stage 
III.  
Furthermore, COPD patients who had current colonization by P. aeruginosa and A. 
fumigatus as well as occasional colonization by S. maltophilia and previous colonization by 
M. catarrhalis presented with GOLD stage IV (i.e. very severe below 30%). The data 
suggests that bacterial infections in patients with BR and COPD are the main factor 
associated with airflow obstruction.  
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4.3.3 Lung function and exacerbated BR patients  
 
When lung function (FEV1 % predicted) was assessed in the exacerbated patients with 
different scores, the deterioration of lung function was associated with exacerbation 
frequency and a considerable variation in FEV1 was observed during the course of 
exacerbation. It has been shown that recurrent exacerbation strongly contributes to lung 
function decline in patients with CF (Amadori et al., 2009, Sanders et al., 2011).  
4.3.4 Antibody responses and exacerbations 
  
IgG titre was also investigated in exacerbated patients at different scores to find out if the 
higher antibody titres correlated with exacerbation. The findings showed that patients 
with >3 exacerbations have significantly higher antibody titre against P. aeruginosa, M. 
catarrhalis and S. maltophilia compared to patients with <3 exacerbations (p=0.04, 0.03 and 
0.01 respectively). A significant difference was also seen versus P. aeruginosa in >3 
exacerbations and hospitalised patients (p=0.037). It is likely that microbial infections 
stimulate the inflammatory and antibody responses resulting in destruction of lung tissues, 
and subsequent deterioration of lung function and induction of exacerbation. Thus, 
occurrence of exacerbation is a result of the vicious cycle of inflammation rather than the 
microbe itself (Perera et al., 2007). Nevertheless, data in non-CFBR patients remain 
inadequate (Brett et al., 1986). Thus, further studies to understand the mechanism of 
microbial infection and inflammatory response (particularly T cell responses) and their role 
in inducing exacerbations are required. In contrast, no correlation between IgG titre and lung 
function was observed in patients with BR and COPD.  T cell responsiveness is the subject 
of the next chapter.     
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5 Conclusion  
 
In this study, culture-based methods enabled the characterization of the lung microbiome in 
the lower airways of BR and COPD cohorts. The findings reveal that the lower airways of 
BR and COPD patients are colonized by poly-microbial communities that perpetuate 
immunological responses. In agreement with previous studies, it has been show that NT. H. 
influenzae was the main organism isolated from the sputum of patients with BR and COPD, 
followed by P. aeruginosa in BR and M. catarrhalis in COPD. Measurement of antibody 
against lung pathogens may be helpful in differentiating between early infection and chronic 
colonization as well as being useful in monitoring the progress of infection. The results 
demonstrated that microbial infection induces airflow obstruction and is associated with 
recurrent exacerbations. In addition, anti-microbial antibody titres are also increased in 
patients with persistent exacerbation.  Hence, antibody titre can be a useful indication of 
disease severity and exacerbations in patients with BR but not sufficient for FEV1% 
predicted.  
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5 Chapter Five: Measurement and Significance of Anti-microbial 
T Cell Responses in Chronic Obstructive Lung Diseases 
 
Abstract   
Aim: T cell responses against microbial infections are thought to contribute to the 
pathogenesis of chronic obstructive pulmonary diseases, since infiltrating T cells have been 
found in the lamina propria and lung epithelium of patients with BR and COPD. 
Nevertheless, they remain poorly understood. The aim of this chapter is to investigate the 
nature of T cell responses against lung microbes as a potential clinical biomarker of disease 
progression.  
Methods: Peripheral blood mononuclear cells (PBMCs) were separated from heparinised 
blood collected from BR (n=119), COPD (n=58) and asthmatic (n=14) patients. Healthy 
volunteers (n=28) were also included in this study. PBMCs were used in ELIspot to 
investigate the magnitude of T cells in the form of IFN responding to lysates and peptides 
obtained from bacteria, viruses and fungi.     
Results: Lower T cell responses were observed among patients with BR, COPD and asthma 
compared to healthy volunteers against most antigens derived from bacteria, viruses and 
fungi that colonize the lung. T cell responses were not associated with microbial infections 
or lung function, but it is associated with exacerbation for M. catarrhalis in patients with 
BR.   
Conclusion:  This study demonstrated the reduced response of IFNproducing T cells to 
lung microbial antigens in patients with chronic obstructive lung diseases. This is likely to 
be a result of T cell polarization or anergic from the burden of microbial infections. The 
measurement of T cell responses may therefore have minimal use as a biomarker in these 
lung diseases.  
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5.1 Background 
 
Patients with underlying pulmonary diseases such as BR and COPD are characterized by 
persistent intense bacterial infection which may accelerate their disease severity (Seemungal 
et al., 2001, Tan et al., 2003). The process of adaptive host defence and active cell-mediated 
immunity in health and disease conditions against many such pathogens occurs mainly 
through antigen-specific CD4+ T cells. These cells are important in the adaptive immune 
response by providing help for B cells to produce antibody and switch isotype and  to support 
virus-specific CD8+ cytotoxic T lymphocytes differentiation to combat intracellular 
infections, as well as having different effector functions; for example, via IFN secretion  (de 
Bree et al., 2007). Therefore, the generation of robust Th1-type CD4
+ T cell responses are 
an essential process to provide an effective immune response against bacterial infection 
(Kim et al., 2016). After acute infection, memory T cells are generated that can rapidly 
proliferate and perform effector functions upon reinfection. However, in some circumstances 
during chronic infections, T cells become exhausted, which is defined by the ineffective 
function and expression of various inhibitory receptors (Crawford et al., 2014). A great 
number of T cell infiltrates, mainly CD4+ and CD8+, within the lung mucosa of COPD and 
BR as a result of microbial stimulations, have been observed (Boyton et al., 2013, Gaga et 
al., 1998).  Several studies focusing on the protective role of T cell responses against 
bacterial and viral infections have found that IFN is crucial but not sufficient for protection 
against infection (Caccamo et al., 2010). Furthermore, IFN- and IL-2 production, as well 
as the capacity for CD4+and CD8+ proliferation, is central to immune protection. Indeed, 
multifunctional CD4+ and CD8+ T cells promote an effective immune response for microbial 
clearance (Caccamo et al., 2010).   
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The aims of this chapter are to evaluate CD4+ T cell responses against lung microbial 
antigens, to investigate the magnitude of T cell responses in patients with BR, COPD and 
asthmatics compared to healthy volunteers, and to determine whether or not T cell responses 
correlate with microbial colonization, lung functions and exacerbation status.     
5.2 Results   
5.2.1 Characterization of T cell responses to antigens in the study  
 
In order to establish that the response of T cells in the form of IFN is specifically made by 
CD4+ T cells and not innate cells, experiments were carried out to determine the effects of 
depleting CD4+ cells on IFNELIspot responses against selected antigens, as described in 
section 2.8.4. The findings showed decreased responses against P. aeruginosa, H. 
influenzae, M. tuberculosis, A.fumigatus and M. pneumoniae antigens following the 
depletion of CD4+T cells, indicating that CD4+ T cells are the predominant cell type 
responding to these antigens. Responses against RSV were only minimally reduced.  
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Figure 5.1: IFN ELIspot response of T cells to a panel of antigens in healthy controls. 
Data is presented as spot-forming cells per 106 PBMC with the medium only background subtracted. 
Decreased response of T cells was found following CD4+ depletion. The experiment was repeated 
three times with similar results obtained.  
 
5.2.2 Comparison of IFN ELIspot between fresh and frozen cells  
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Since the ELIspot assays were carried out on frozen cells, we wished to see if the freezing 
itself affects cell viability and functions, therefore, fresh PBMCs were compared to frozen 
cells obtained from a healthy control as described in section 2.8.5. The findings 
demonstrated that fresh and frozen cells gave mainly comparable levels of IFN ELIspot 
response, indicating that the PBMCs were stable after freezing. Notable exceptions were for 
M. tuberculosis and H. influenza, but even these responses were not lost entirely due to 
freezing.  
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Figure 5.2: IFN ELIspot of fresh and frozen cells. Fresh PBMC from a healthy volunteer 
was compared to frozen cells. 
Data are presented as spot-forming cells in 106 with the medium only background subtracted. The 
experiment was repeated twice with similar results obtained.   
  
5.2.3 Inhibition with Anti-class II antibody 
 
To further show the CD4+ T cell dependence of ELIspot responses, anti-class II antibody 
was utilised to inhibit antigen presentation to CD4+ T cells as described in section 2.8.6. The 
results showed an obvious inhibition of T cell responses against most of the antigens, which 
means that anti-class II antibody blocked the presentation of antigen to CD4+ T cells by 
antigen-presenting cells. The exceptions were RSV, B. cenocepacia and M. pneumoniae. It 
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is likely that CD4+ was therefore the main T cell responding to these antigens in the form of 
IFN. 
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Figure 5.3: IFN ELIspot with class II inhibition of T cells. 
Class II antibody was used to inhibit antigen presentation to CD4+ T cells. Data are presented as spot-
forming cells in 106 with the medium only background subtracted. The experiment was repeated 
twice with similar results obtained. 
  
5.2.4 T cell responses in bronchiectasis (BR) patients compared to healthy volunteers 
(HV)   
 
T cell responses were tested against the panel of antigens comprising lysates, extracts and 
peptides of bacteria, viruses or fungi, as well as anti-CD3 and PHA utilised as positive 
controls (see Table 2.5). The responses were measured by IFN ELIspot in BR patients and 
HV as described in section 2.8.2. The results (Figure5.4) showed significantly lower levels 
of T cell responses indicated by IFN production in BR patients compared to HV against P. 
aeruginosa (p=0.002), S. pneumoniae (p=0.001), A. fumigatus (p=0.03), B. pertussis 
(p=0.01) and M. tuberculosis (p=0.002). Similarly, the responses of T cells were also lower 
for RSV, B. cepacia, and M. pneumoniae but no significant differences were found here. 
Conversely, patients with BR displayed higher levels of IFN responses compared to HV 
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against Cytomegalovirus, but the increase was not significant (p=0.055). Responses to the 2 
positive controls, anti-CD3 and PHA, were comparable between the BR patients and the HV. 
These findings suggest that chronic infections may reduce the specific response of T cells in 
patients with BR.  
In this analysis, 11 BR patients having immunodeficiency (ID) were excluded (resulting 
group termed BR-ID). Comparison of the IFN response of the BR-ID group with the overall 
BR group including those with immunodeficiency, (BR+ID) and with healthy volunteers, 
(Figure 5.5) showed a significant difference between BR+ID and healthy volunteers 
(p=0.001) and a significant difference when comparing BR-ID and healthy volunteers 
(p=0.002). No significance differences were found between BR+ID and BR-ID (p=0.399). 
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Figure 5.4(A-C): Measurement of IFN production followed stimulation with antigens in both 
BR patients and healthy volunteer (HV). 
(A) positive controls stimulus, (B) and (C) microbial antigens. Data are shown as mean ± SEM. 
Statistical significance of these differences was analysed using the Mann-Whitney test. * p<0.05. 
n=103 for BR and n=27 for HV. 
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Figure 5.5: IFNproduction in response to P. aeruginosa in different groups of BR and 
healthy volunteer (HV). 
All BR patients (BR+ID patients) and those with immunodeficiency excluded (BR-ID) were 
compared to healthy volunteers. Significant differences were observed between +/- 
immunodeficiency compared to healthy volunteers. Data are shown as mean ± SEM. 
 
5.2.5 T cell responses in patients with chronic obstructive pulmonary disease (COPD) 
compared to healthy volunteers (HV) 
 
The responses of T cells were also measured in COPD patients against the same antigens 
and positive controls as in the previous section (Figure5.6). Patients with COPD had 
significantly lower levels of IFN in response to P. aeruginosa (p=0.014) and S. pneumoniae 
(p=0.031) compared to healthy volunteers. Although the responses were lower against H. 
influenzae, M. catarrhalis, A. fumigatus, B. pertussis, RSV, B. cepacia and M. pneumoniae 
there were no significant differences. In contrast, higher levels of IFNversus M. 
tuberculosis and Cytomegalovirus were seen in COPD, but without statistical significance. 
Furthermore, positive controls anti-CD3 and PHA show no significant differences. 
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Figure 5.6(A-C): T cell responses in the form of IFN in COPD patients and healthy 
volunteers (HV). 
Measurement of IFN production after PBMCs stimulation with lung antigens in COPD patients and 
HV. (A) positive controls stimulus; (B) and (C) microbial antigens. Data are shown as mean ± SEM. 
Statistical significance of these differences was analysed using the Mann-Whitney test. * p<0.05. 
n=57 for COPD and n= 27 for HV. 
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5.2.6 T cell responses in asthmatics compared to healthy volunteers (HV) 
Investigation of T cell responses against the panel of lung antigens from bacteria, fungi and 
viruses as well as positive controls were also carried out in asthmatics and compared to 
healthy volunteers. The result showed that (Figure 5.7) asthmatics had significantly lower 
levels of IFN compared to HV against P. aeruginosa (p=0.040). No significant differences 
for other antigens were seen in this analysis.  
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Figure 5.7(A-C): T cell responses in the form of IFN in asthma patients and healthy 
volunteers (HV). 
Measurement of IFN production followed stimulation of PBMC with the panel of lung antigens in 
both asthmatics and HV :( A) positive controls stimulus, (B) and (C) microbial antigens.  Data are 
shown as mean ± SEM. * p<0.05. n=14 for asthma and n=27 for HV. 
 
5.2.7 T cell responses versus microbial colonization in BR and COPD  
 
To investigate whether or not the responses of T cells are associated with microbial 
infections, IFN responses against each antigen were compared to the results of the incidence 
of microbial colonization, as classified in Table 4.2, for patients with BR and COPD. Figures 
5.8 and 5.9 show that no significant differences were found in IFN T cell response for BR 
or COPD patients between groups who were non-colonized or colonized to differing degrees 
and by different pathogens: P. aeruginosa, S. pneumoniae, H. influenzae, M. catarrhalis and 
A. fumigatus (p>0.05 for each). The results suggest that occasional colonization resulted in 
larger T cell responses than non- or chronic colonization in patients with BR. 
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Figure 5.8: IFN T cell responses of BR patients compared to microbial colonization. 
IFN response against each antigen was compared to the result of microbial colonization. Data are 
shown as mean± SEM. No significant differences were found. 
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Figure 5.9: IFN T cell responses of COPD patients compared to microbial colonization. 
IFN response against each antigen was compared to the result of microbial colonization. Data are 
shown as mean ± SEM. No significant differences were found.  
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5.2.8 T cell responses in exacerbated patients with bronchiectasis   
 
IFN T cell responses against P. aeruginosa and M. catarrhalis were investigated in patients 
with various degrees of exacerbation (Figure 5.10). Only 75 out 86 patients were measured 
for T cell responses because seven ID patients were excluded and there were four missing 
samples. These patients were classified into three sub groups according to Bronchiectasis 
Severity Index (BSI): <3 exacerbations, or >3 exacerbations per year, or hospitalised. 
Significant differences were found when <3 and >3 were compared to hospitalised patients 
(p=0.021 and p= 0.049 respectively) in response to M. catarrhalis. However, no significant 
differences were observed between these groups against P. aeruginosa.  
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Figure 5.10(A-B): IFN ELIspot against (A) P. aeruginosa and (B) M. catarrhalis was 
compared for each exacerbation score. 
Significant differences were observed in T cell responses among these categories to M. catarrhalis. 
Data are presented as mean± SEM. The number in each group is indicated.  
 
 
5.2.9 Correlation between T cell responses and lung function in BR and COPD 
patients  
T cell responses to P. aeruginosa and M. catarrhalis were plotted against FEV1% predicted 
to find out if they are significantly correlated and to determine if the responses of T cells can 
be a prognostic marker for lung function deterioration in patients with BR and COPD. The 
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results in Figures 5.11 and 5.12 show no significant correlation between the T cell 
responsiveness and lung function decline. This indicates that T cell response is not a 
sufficient marker for lung function decline. 
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Figure 5.11(A-B): Relationship between lung function and T cell responses in patients with 
BR. 
(A)P. aeruginosa; (B) M. catarrhalis. No significant correlations were found (Spearman correlation 
and Mann-Whitney analysis was used).  
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Figure 5.12(A-B): Relationship between lung function and T cell responses in patients with 
COPD. 
(A) P. aeruginosa; (B) M. catarrhalis. No significant correlations were found (Spearman correlation 
and Mann-Whitney analysis was used).   
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5.2.10 Relationship between antibody and T cell responses  
 
To determine whether the responses of antibody and T cells is correlated, Spearman 
corelation analysis was also  carried out on data for patients and healthy volunteers included 
in the study. The results shown in Table 5.1 demonstrate a significant negative correlation 
between antibody and T cell responsiveness in COPD patients against M. catarrhalis 
(p=0.005). Similarly, significant negative correlations were found among healthy volunteers 
in response to M. catarrhalis (p=0.030) and H. influenzae (p=0.017). Only negative 
correlations, but without significance, were seen in patients with COPD and BR against S. 
pneumoniae. Healthy volunteers also showed a negative but insignificant correlation against 
P. aeruginosa.  
Table 5.1. Spearman correlation analyses of antibody and T cell responses against selected 
antigens among patients and healthy volunteers included in the study. 
 BR COPD Asthma  HV 
Antigens  r  
 
P-value r P-value r P-value r P-value 
P.aeruginosa 0.0687 0.385 
 
0.039 0.772 0.00 1.000 -0.135 0.502 
S.pneumoniae -0.118 0.244 
 
-0.221 0.099 0.047 0.874 0.359 0.066 
A.fumigatus 0.015 0.895 
 
0.005 0.715 0.136 0.689 0.012 0.957 
M.catarrhalis 0.064 0.531 
 
-0.378 0.005 0.056 0.863 -0.419 0.030 
H.influenzae  0.139 0.165 -0.166 0.221 0.152 0.604 -0.456 0.017 
 
5.2.11 Measurement of cytokines by MSD of T cell-stimulation culture supernatants 
  
An analysis was conducted to assess the concentrations of various cytokines in the culture 
supernatant of antigen-stimulated T cells, in BR patients and healthy volunteers, including 
IFN, IL-2, IL-4, IL-5, IL-10, IL-13, IL-12 and-IL-17. PBMCs were stimulated with P. 
aeruginosa (PSA) or H. influenzae (Hi) antigens overnight and the supernatants were 
collected as described in section 2.10. The level of each cytokine produced (ng/ml) in 
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response to both stimuli are shown in Figure 5.13. No significant differences in IFN 
production were observed between patients and healthy volunteers in response to PSA 
(p=0.226) and Hi (p=0.419). The other cytokine levels were weak and no significant 
differences were detected between patients and healthy volunteers. Moreover, IFN levels 
were plotted against ELIspot IFN spot-forming cells/106 from the same individuals to see 
if they are significantly correlated (Figure 5.14). A significant negative correlation was 
observed for BR patients with respect to IFN spot-forming cells and MSD IFNin 
responseto H. influenzaeantigen (p=0.044). IFN spot-forming cells were also analysed 
against the other cytokines measured in this experiment and the result are shown in Table 
5.2. A significant negative correlation was also observed for IFN spot- forming cells and 
MSD IL-4 in response to P. aeruginosa in BR patients (p=0.049). Furthermore, a significant 
negative correlation was seen in BR patients against H. influenzae for IL-2 (p=0.003) and 
IL-12 (p=0.035).  
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Figure 5.13(A.G): Cytokines levels (ng/ml) in BR patients and HV following stimulation with 
P.aeruginosa and H.influenzae. 
(A) Production of IFNLC) IL-4 ; (D) IL-5 ; (E) IL-12 ; (F) IL-13 ; and (G) IL-17. Data are 
represented as mean± SEM. n=10 for BR and n=4 for HV.   
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Figure 5.14 (A-B): Spearman correlation analysis for BR patients of IFNspot-forming cells 
per 106 PBMC and IFNlevel measured by MSD. 
(A) P. aeruginosa; and (B) H. influenzae. A significant negative correlation was found between IFN 
ELIspot and the level of IFNmeasured by MSD in response to the H. influenzae antigen. (p=0.044). 
 
Table 5.2. Spearman correlation analysis for BR patients of IFNspot -forming cells per 106 
PBMC and MSD cytokines (ng/ml). 
The cells were stimulated with P. aeruginosa and H. influenzae * indicates that all values are = 0 
Stimulation with P. aeruginosa 
 
Stimulation with  H.influenzae   
 
Cytokines  
 
P-value 
 
 
Spearman r 
 
Cytokines 
 
 
P-value 
 
 
Spearman r 
IL-2 0.77 -0.103 IL-2 0.003 -0.837 
IL-4 0.049 -0. 669 IL-4 0.413 -0.292 
IL-10 0.213 -0.432 IL-10 0.137 -0.505 
IL-12p20 0.136 -0.506 IL-12p20 0.035 -0.669 
IL-13 0.705 -0.137 IL-13 0.397 -0.302 
IL-17 0.901 -0.045 IL-17 0.620 -0.180 
IL-5 * * IL-5 0.179 -0.464 
 
5.2.12 Determining the phenotypes of T cells responding to antigenic stimulation  
  
Experiments were performed to determine whether or not IFNcells were also CD69 
following antigen stimulation, because CD69+ was used in the flow cytometry to identify 
activated cells in response to antigen stimulation in the next section. PBMCs were obtained 
from a healthy donor and stimulated with medium only, anti-CD3, or P. aeruginosa 
overnight at 37°C in a 5% CO2 incubator.  The target cells were surface-stained for CD4 and 
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CD69 and intracellularly stained for IFN following fixation and permeabilization as 
described in section 2.9.2 and 2.9.3. The results show that within the responding CD4+ T 
cells most of the lymphocyte cells expressing IFN also expressed CD69.  
 
Figure 5.15: IFN T cells positive for CD69 on CD4+ and CD8+ following anti-CD3 
stimulation. 
The cells were gated within the lymphocyte population. The percentage of the lymphocytes positive 
and negative for IFN are shown. Eight colour flow cytometer were used. 
 
5.2.13 Expression of CD4+CD69+ in response to different stimulus in BR patients 
and healthy volunteers by Flow cytometric analysis 
  
PBMCs were stimulated with either anti-CD3, P. aeruginosa or H. influenzae, or with 
medium as a negative control, as described in section 2.9.2. Typical results are shown in 
Figures 5.16 – 5.19. The stimulated cells were stained for a range of activation and homing 
markers as described in section2.9.2. The results show that incubation with anti-CD3 
significantly increased the expression of CD69+ on CD4+ T cells in both patients (p<0.001) 
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and healthy volunteers (p<0.001) (Figure 5.20). The proportion of CD4+ cells co-expressing 
CD69+ also significantly increased when patients PBMCs were incubated with P. 
aeruginosa (p=0.003). However, there was no significant difference from healthy volunteers 
(p=0.1285). Significant differences were also observed when comparing resting cells and 
cells stimulated with H. influenzae for BR patients (p=0.0025) and for healthy volunteers 
(p=0.035) (Figure 5.21).  
 
Figure 5.16: Expression of phenotype markers on CD4+CD69+ cells following the stimulation 
of PBMCs with medium. 
The lymphocytes are gated on CD4+ and the percentages of each CD4+CD69+ are indicated for each 
candidate marker. Eight colour flow cytometry was used to analyse the data.    
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Figure 5.17: Expression of phenotype markers on CD4+CD69+ cells following stimulation of 
PBMCs with anti-CD3. 
The lymphocytes are gated on CD4+and the percentages of each CD4+CD69+ are indicated for each 
candidate marker. Eight colour flow cytometry was used to analyse the data. 
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Figure 5.18: Expression of phenotype markers on CD4+CD69+ cells following stimulation of 
PBMCs with P. aeruginosa antigen. 
The lymphocytes are gated on CD4+and the percentage of each CD4+CD69+ are indicated for each 
candidate marker. Eight colour flow cytometry was used to analyse the data. 
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Figure 5.19: Expression of phenotype marker on CD4+CD69+ cells following stimulate of 
PBMC with H.influenzae antigen. 
The lymphocytes are gated on CD4+ and the percentages of each CD4+CD69+ are indicated for each 
candidate marker. Eight colour flow cytometry was used to analyse the data. 
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Figure 5.20: Expression of CD69+ as a proportion of CD4+ in BR and HV on resting cells and 
after stimulation with anti-CD3. 
Data are presented as mean± SEM. ** indicates statistical significance with (p< 0.001) calculated by 
Mann-Whitney test. BR n= 10 and HV n=8. 
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Figure 5.21: Expression of CD69+ as a proportion of CD4+ following stimulation with P. 
aeruginosa and H. influenzae antigens in BR patients and HV. 
Data are presented as mean± SEM . ** indicated the significance p value are calculated by Mann-
Whitney test.  BRn= 10 and HV n=8. 
 
 
5.2.14 Expression of candidate markers on  CD4+CD69+ lymphocytes  
 
In order to ascertain the phenotype of the responding activated  CD4+CD69+ T cells, the 
levels of six other candidate markers were assessed. The results in  Figure 5.22 show that, 
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irrespective of the stimuli, activated cells (CD4+CD69+) expressed similar levels of the other 
candidate markers when compared to resting (CD4+CD69-) cells 
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Figure 5.22 (A-D): Expression of candidate markers on CD4+CD69+ cells in BR patients and 
HV in response to various stimuli. 
(A) PBMCs were stimulated with P. aeruginosa; (B) stimulation with H. influenzae;(C) stimulation 
with anti-CD3 and (D) incubation with medium. Data are analysed as mean± SEM. No significant 
differences were found. BR n= 10 and HV n=8.  
 
5.2.15 Expression of candidate markers on CD8+CD69+ lymphocytes 
 
By gating on the CD4- subset of lymphocytes, CD8+ cells could also be analysed. The 
phenotype of CD8+CD69+ cells was therefore also assessed in BR patients and healthy 
controls following stimulation as described in section 2.9.2. The findings in Figure 5.23 
show that both activated and resting cells expressed similar levels of the majority phenotype 
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markers studied.  However, OX40 and CCR6 were marginally expressed more highly on 
CD8+ cells following stimulation with anti-CD3. 
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Figure 5.23(A-D): Comparison of different phenotypes on CD8+CD69+ in BR patients and 
HV in response to different stimuli. 
(A) PBMCs were stimulated with P. aeruginosa; (B) stimulation with H. influenzae;(C) stimulation 
with anti-CD3 and (D) incubation with medium. Data are analysed as mean. ± SEM No significant 
differences were found. BR n= 10 and HV n=8.  
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5.3 Discussion   
   
In this study, it was first confirmed that CD4+ T cells were the predominant T cell responding 
to the lung antigens. IFN production was decreased after CD4+ depletion and it was blocked 
by anti-MHC class II antibodies, and activated CD4+ T cells producing IFN and expressing 
CD69 were identified by ICS. IFN is secreted by CD4+ Th1 cells, which distinguishes them 
from other subsets of T cells. Th1 cells are important in promoting an inflammatory response 
and eradicating intracellular pathogens (Pollard et al., 2012). Once these findings had been 
established, experiments were developed to investigate the responses of T cells against lung 
microbe antigens in patients with lung diseases compared to healthy volunteers.  
5.3.1 T cell responses in BR, COPD and asthma patients compared to healthy 
volunteers  
 
It was found that patients with BR had significantly lower levels of IFN compared to healthy 
volunteers against P. aeruginosa (p=0.002), S. pneumoniae (p=0.001), A. fumigatus 
(p=0.03), B. pertussis (p=0.01) and M. tuberculosis (p=0.002). Furthermore, lower levels of 
IFN but not significant lower, against the other antigens including H. influenzae, M. 
catarrhalis, Influenza virus, B. cepacia and M. pneumoniae were also observed in BR 
patients. Similarly, COPD patients had significantly reduced T cell responses against P. 
aeruginosa (p=0.014) and S. pneumoniae (p=0.031) compared to HV. These patients also 
had low responses against H. influenzae, M. catarrhalis, A. fumigatus, B. pertussis, RSV, B. 
cepacia and M. pneumoniae. Moreover, asthmatics had significantly lower levels of IFN 
against P. aeruginosa (p=0.040) compared to healthy volunteers. Reduced responses of T 
cells among asthmatics were also observed against S. pneumoniae, M. catarrhalis, A. 
fumigatus, B. pertussis, and RSV. These findings were in accordance with the previous work 
that showed decreased responses of T cells to outer membrane protein F (OprF) during P. 
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aeruginosa infections in non-cystic fibrosis bronchiectasis patients despite the high antibody 
production. The reason for this may be a skewed T cell response to P. aeruginosa protein 
antigen towards Th2 (Quigley et al., 2015). Furthermore, the reduced response of T cells in 
BR and COPD patients may be because of high pathogen loads resulting in anergic of T cells 
specific for the bacteria antigens. It has been shown that, in some chronic infections, high 
antigen loads generated dysfunction and impaired antigen-specific T cell populations (Han 
et al., 2010). Furthermore, in patients with COPD, the effector T cells defined as 
CD4+CD127+ expressed a high percentage of PD-1, with these cells lacking the energy to 
proliferate after exposure to bacteria (Singh, 2014). However, reduced IFN responses 
observed among asthmatics patients in our study may be because of the skew of T cell 
differentiation toward Th2 cells following antigen presentation, since increased Th2 
cytokines are associated with asthma (Robinson, 2010, Shalaby and Martin, 2010). The lung 
previously has been shown to became polarized for Th2 response. It was found that increased 
Th2 cytokines (IL-13) occurred in BAL fluid in a murine asthma model following rhinovirus 
infection (Kim et al., 2013). 
In these experiments, bacterial lysate extracts and peptides were utilized to stimulate CD4+ 
Th1 cells to produce IFN. A previous study has shown robust IFN responses by CD4+ T 
cells and high levels of IL-2 after Streptococcus agalactiae infection, suggesting that a type 
I pro-inflammatory response was generated. The bacterium has a thick capsule 
polysaccharide (CPS) which is thought to modulate CD4+ T cell activation and to help to 
induce strong cytokine production. Therefore, the polysaccharide may contribute to the 
CD4+ Th1 response to generate a high IFN production (Clarke et al., 2016). Interestingly, 
BR patients produced higher, but not significantly higher, IFN in response to 
Cytomegalovirus (p=0.055), whilst COPD patients showed higher IFN response to 
Cytomegalovirus, M. tuberculosis and influenza virus, though not significantly so. This 
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might be attributable to the responses of both CD8+ cytotoxic T cells and CD4+ T cells during 
viral persistence (Simpson et al., 2016). This shows that neither disease had reduced global 
T cell responses. Similarly, a slightly increased response of T cells was observed in 
asthmatics against H. influenzae, M. tuberculosis and M. pneumoniae. This may be 
attributable to these patients having more exposure to these pathogens compared to HV.  
In contrast, the high magnitude of T cell response observed in healthy volunteers compared 
to patients with BR, COPD and asthma suggests that these antigens may trigger T cell 
responses after encountering antigen during natural exposure or infection and that these 
persist for a few weeks and are then elevated later during secondary immune response (Hus 
et al., 2015).  Previous studies have shown that healthy volunteers have high levels of IFN 
responses against NTH. influenzae compared to patients with bronchiectasis. It was shown 
that the responses of healthy volunteers were made up of  Th1 cells, also expressing CD40L, 
which promotes antibody production, whereas patients with bronchiectasis exhibited a 
different immune response comprising Th2 cells and characterised by the production of IL-
4 and IL-10 (King et al., 2003).  
In this study, measurements of other cytokines such as IL-2, IL-4, IL-5, IL-13 and IL-17 
were also performed, but no significant differences were observed (this Data not shown). 
5.3.2 T cell responses versus microbial colonization  
 
In this study, patients who are classified as currently chronically infected have reduced T 
cell responses. This result contrasts somewhat with the antibody responses shown in sections 
4.2.3 and 4.2.4. Chronic microbial infection resulted in reduced T cell responses possibly 
due to T cell responses being overwhelmed by sustained antigen and becoming anergic 
progressively  , as shown in CD8+ unresponsiveness with chronic viral infection (Mueller 
and Ahmed, 2009). Continuous bacterial persistence also contributes to dysfunctional T cells 
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through the down-regulation of newly-primed antigen-specific effector CD4+T cells, and 
this results in the development of poor memory responses (Han et al., 2010).  
5.3.3 T cell responses in exacerbated BR patients and FEV1% predicted 
   
The study also demonstrated that a significant difference was seen in IFN production at > 
3 and <3 exacerbation compared to hospitalized status in patients with BR against M. 
catarrhalis but not P. aeruginosa. This suggests that IFN responses may be elevated and 
contribute to disease pathology during exacerbations and reduced when the patients were 
hospitalised. In contrast, no significant correlations were observed between IFN production 
and FEV1% predicted in BR and COPD patients, and thus T cell responses were not 
associated with decline lung function in patients with chronic obstructive lung disease.   
5.3.4 Relationship between antibody and T cell responses  
 
The relationship between antibody and T cell responses in patients and healthy volunteers 
was also investigated. The analysis showed a significant negative correlation in COPD 
patients in response to M. catarrhalis (p=0.005). Similarly, a significant negative correlation 
was seen for healthy volunteers against M. catarrhalis (p=0.030) and H. influenzae 
(p=0.017). In this study the response of T cells was assessed by the production of IFN in 
which Th1 are the main cell sources. Th1 cytokines predominantly mediate cellular immunity 
and activate inflammatory responses, while Th2 cytokines mediate humoral immunity and 
up-regulate antibody production. Each type of cytokine can cross inhibit the other type of 
cytokine resulting in mutual exclusion and negative correlation (Kidd, 2003, Maki et al., 
2016).  
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5.3.5 Measurement of cytokines by MSD of T cell-stimulation culture supernatants 
 
Measurements of cytokines by MSD of T cell-stimulation culture supernatants were also 
performed in this study. Our data showed that apart from IFN, the other cytokines were at 
low levels. Nevertheless, a significant negative correlation was found when comparing 
IFNspot-forming cells and secreted IFN against H. influenzae (p=0.04). A significant 
negative correlation was also observed between IFNspot-forming cells compared to 
secreted IL-2 and IL-12 against H. influenzae (p=0.003 and p=0.035 respectively). A 
significant negative correlation was also detected when comparing IFN and IL-4 against P. 
aeruginosa (p=0.045). As described in the literature review, Th1 cells mainly produce IFN, 
IL-2, IL-12 and IL-15, whereas, Th2 secrete more IL-4, IL-5, IL-10, and IL-13, and these 
cytokines antagonise each other and block each other’s effector functions. (Wilczynski, 
2005). Thus, it may be possible here that the high IFNlevel inhibited the production of IL-
4 resulting in lower IL-4 response. In contrast, it was surprising that IFN negatively 
correlated with IL-2 since both cytokines are secreted by Th1 cells. It may be possible that 
other factors affect the responses of these cytokines, including antigen dose, the nature of 
the antigens, and the cytokine receptors available on the naive cell (Kidd, 2003). Some 
limitations of this experiment should be acknowledged, namely the sample sizes were small 
with only 10 BR patients and 4 healthy controls included.   
5.3.6 Expression of CD4+CD69+ in response to different stimulus in BR patients and 
healthy volunteers 
 
This study examined the phenotypes of activated lymphocytes in both patients with 
bronchiectasis and healthy volunteers, as these cells have the potential to play an important 
role in the pathogenesis of bronchiectasis. The stimulation of PBMC with anti-CD3 was used 
as a positive control to demonstrate that the cells are healthy and able to respond to a 
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stimulus. Expression of CD69 was, as expected, significantly increased in both groups 
following anti-CD3 activation (Figure 5.20). The percentage of CD4+ cells co-expressing 
CD69+ was significantly higher in patients with BR following activation by P. aeruginosa 
compared to unstimulated (p=0.0036). A significant increase in CD69+ was also observed in 
both patients and healthy volunteers after H. influenzae stimulation (p=0.0025 and p=0.035, 
respectively) (Figure 5.21). This demonstrates that exposing PBMCs to lung antigens leads 
to the up-regulation of CD69. CD69+ cells have been suggested to play a major role in the 
pathogenesis of interstitial lung diseases (Heron et al., 2010), possibly because the rapid 
expression of CD69+ on T cells promotes activation and differentiation (Sancho et al., 2005).  
It is therefore likely that such activated cells may also contribute to the pathology of 
bronchiectasis. 
The results also demonstrate that activated T cells (CD4+ and CD8+) in patients and healthy 
volunteers express similar high levels of CD49d on their surfaces. This possibly indicates 
the continued stimulation and activation of lymphocytes in response to these stimuli. It has 
been found that the increased expression of CD49d on CD4+ and CD8+ in patients with 
asthma indicates the activation of T cells and the priming of these cells to migrate into the 
site of inflammation in the airway (Bazan-Socha et al., 2012). 
5.3.7 Expression of candidate markers on CD4+CD69+ lymphocytes 
 
By gating on CD4+CD69+ lymphocytes, the co-expression of several other candidate 
markers could also be determined. The results show minor expression of OX40, CXCR3, 
CCR6, CCR5 and PD-1 on CD4+CD69+ cells from BR patients and healthy controls for both 
antigens stimulated and resting cells. Stimulation with anti-CD3, however, enhanced the 
expression of OX40, CXCR3, and PD-1, demonstrating that anti-CD3 provides a powerful 
stimulus to CD4+ cells and results in them being highly activated.  In contrast, the small 
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percentage of expression of OX40, CXCR3, CCR6, CCR5 and PD-1 on CD8+CD69+ was 
observed in both BR patients and healthy controls even after stimulation with anti-CD3. This 
result agrees with those of a previous study, which found OX40 only slightly up-regulated 
in CD8+ cells following antigen stimulation (Zhong et al., 2010). This may be because CD8+ 
T cells were not highly activated here. It has been reported that CD8+ T cells may be rapidly 
expanded and activated after viral infection and provide long term protection against further 
viral infection through memory CD8+ T cells (Shaw et al., 2014). Further work using 
different stimuli such as viral antigens and more participants may be necessary to determine 
the expression of these molecules on CD8+cells.  
6 Conclusion   
In conclusion, microbial infections accelerate morbidity and mortality in patients with 
chronic obstructive pulmonary diseases. Understanding the interaction between the host and 
the pathogens may provide novel insights into the pathology pathways. In this study, it has 
been found that bacterial infection results in reduced IFN production through impaired Th1 
response or altered the response toward Th2. The findings showed that IFN significantly 
increased during the course of exacerbations to M. catarrhalis but it was not implicated in 
the worsening of lung functions. Thus, these finding suggest that the role of IFNproducing 
cells may be substantial in protection but are not, or are minimally, implicated in the 
pathogenesis of the disease.  
In this study, 10 BR patients and 8 healthy volunteers were included in the analysis. The 
study showed that the proportion of CD4+T cells which co-expressed CD69+ was 
significantly higher following stimulation with anti-CD3, H. influenzae and P. aeruginosa 
suggesting that CD4+ Th cells are the main cells activated in response to these stimuli. No 
significant differences were found for other candidate markers suggesting that further work 
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may be necessary to achieve a better understanding with more participants and different 
stimuli (e.g. viral antigens), and candidate markers, being investigated. 
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6 Chapter Six: Immune responses in patients with cystic fibrosis 
 
Abstract  
Aim: Cystic fibrosis (CF) is a chronic progressive lung disease associated with recurrent 
pulmonary infections and exaggerated inflammatory responses that promote irreversible 
damage, potentially ending in respiratory failure and death. Antibody responses play an 
active role in protection against lung infections in CF, whereas the role of T cells in its 
pathogenesis or protection is still unclear. Therefore, the purpose of this study was to 
examine specific immune responses against lung-infecting microbes in clinically 
characterised patients with CF, since immune responses may be contributing to disease 
pathology as well as protection from infection.  
Methods: Peripheral blood samples from CF patients (P.aeruginosa-colonised at RVI, or 
Burkholderia-colonised at Manchester) were used to obtain PBMCs and serum. T cell and 
antibody responses were measured against a series of lung-infecting microbial antigens 
(bacteria, fungi and viruses) using characterised ELIspot and ELISA assays. Furthermore, 
the sputum of patients was investigated for culturable microbial colonization. Patients were 
characterised for lung function (FEV1 %) and exacerbation frequency. 
Result:  The microbiology results confirmed that the predominant pathogens in the sputum 
of the RVI CF patient cohort were P. aeruginosa, as well as Candida sp, S. aureus and A. 
fumigatus. Patients with CF had significantly higher antibody responses compared to healthy 
controls for P. aeruginosa, S. maltophilia, M. catarrhalis, A. fumigatus and H. influenzae. T 
cell responses (in the form of IFN) were significantly higher in CF patients compared to 
healthy controls against B. cenocepacia (p=0.04). Furthermore, higher T cell responses were 
observed against H. influenzae, M. catarrhalis, M. pneumoniae and Cytomegalovirus, but 
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differences were not statistically significant. However, healthy volunteers had significantly 
higher T cell responses against S. pneumoniae compared to CF patients. Antibody and T cell 
responses did not correlate in CF except for a negative correlation for A. fumigatus. 
Deterioration of lung functions and impaired cellular immune response, but not antibody 
response, were significantly associated with exacerbations. The Manchester cohort showed 
associations of antibody responses with colonisation, and T cells secreting Th17 cytokines as 
well as IFN. 
Conclusion: The findings show that whilst colonization causes increased antibody levels, 
these levels are not associated with disease stability and lung function. On the other hand 
levels of IFN-secreting T cells against P. aeruginosa do associate positively and may be  
prognostic for disease, acting directly or through other cytokines and mechanisms.  
6.1 Background 
 
Cystic fibrosis (CF) is one of the most common and lethal autosomal recessive disorders of 
white European populations (Aureli et al., 2016, McGuire, 2015). Most of the morbidity and 
mortality of CF is caused by a progressive decline in lung function resulting from repeated 
microbial infection and inflammatory immune response (Milagres et al., 2009, Palaniyar et 
al., 2015). Typically, P. aeruginosa, S. aureus, B. cepacia complex, S. maltophilia and Non-
tuberculous mycobacteria are the most common pathogens detected by conventional 
microbiology (de Vrankrijker et al., 2010, Emerson et al., 2010). However, molecular 
techniques have found many microorganisms that were previously unidentified in the CF 
lung, such as, Lautropia mirabilis, Fusobacterium gonidiaformans, and Bacteroides fragilis, 
and thus these species may be novel potential CF-associated microorganisms (Rogers et al., 
2003). P. aeruginosa is the predominant pathogen associated with chronic infection in CF 
and is considered to exaggerate the inflammatory response caused by macrophage and 
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neutrophilic infiltration. These cells migrate to the site of infection and release inflammatory 
mediators and pro-inflammatory cytokines, causing lung injury and fuelling the vicious 
cycle of infection (Courtney et al., 2004, Moreau-Marquis et al., 2008). The diagnosis of 
microbial infections, in particular P. aeruginosa, may help in assessing early treatment and 
preventing disease progression. Therefore, testing for antibodies may provide surrogate 
markers to define the infection and colonization of CF patients by P. aeruginosa and other 
organisms, especially in young children who are unable to produce sputum (Ratjen et al., 
2007). It has been argued that the measurement of antibody against bacteria is an alternative 
approach to tracking bacterial colonization in cystic fibrosis. Previous studies have shown 
that a higher antibody titre is correlated with the acquisition of P. aeruginosa (Kappler et 
al., 2006). Increased inflammatory responses associated with bacterial infection have been 
described in patients with CF (Aldallal et al., 2002). Distinct patterns of pro-inflammatory 
cytokines have been reported in patents with CF, including of IL-1β, IL-6, IL-8, and TNF- 
in the serum and in BAL fluid (Casaulta et al., 2003, Conese et al., 2003). One study has 
shown that IL-10 plays an effective role in the inhibition of IFN and IL-2 synthesis by 
blocking the co-stimulatory signals for T cell activation, and it may regulate inflammatory 
responses in CF (Casaulta et al., 2003).   
The purpose of the present study is to investigate immune responses in relation to colonizing 
microorganisms in CF patients. Moreover, the relationship between specific T cell and 
antibody responses, and whether or not immune responses may contribute to clinical 
parameters such as pulmonary function and exacerbation in CF patients were investigated.   
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6.2 Methods 
  
6.2.1 Patient recruitment and protocols  
 
Adult cystic fibrosis patients (n=30) attending the outpatient CF clinic at the Royal Victoria 
Infirmary, Newcastle upon Tyne were recruited in this study. They were known to harbour 
P.aeruginosa. Twenty-eight healthy volunteers were recruited from the staff of the 
outpatient clinic at the Freeman Hospital Newcastle upon Tyne. Blood and sputum samples 
were collected and processed as described  in section 2.2.2. Assays were performed as per 
the patient samples in chapters 3 and 5. Demographic data for the RVI CF patients are shown 
in Table 6.1. Furthermore, 14 CF patients attending the Manchester Adult Cystic Fibrosis 
Centre, the University Hospital of South Manchester, were included in this study. Both 
groups of CF patients were negative for nontuberculous mycobacteria (NTM) The clinical 
data were collected from each patient (limited data) Table 6.1. Blood specimens were 
collected from each individual and processed as described in section 2.2.2. Sera and PBMCs 
were tested for antibody and T cell response against B. cenocepacia, B. multivorans and P. 
aeruginosa by indirect ELISA as described in section 2.7 whereas ELI-spot was carried out 
as described in 2.8.2.  
6.3 Results  
 
6.3.1 Demographics data of RVI cystic fibrosis patients 
 
The clinical characteristics and demographic data are shown in Table 6.1. Patients with CF 
had a high mean value of symptoms. Patients and healthy volunteers underwent a routine 
respiratory test, as shown; a mean FEV1 % predicted of less than 50% indicated impaired 
lung function, while healthy volunteers showed mean FEV1 values higher than 100% of the 
predicted value.  
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Table 6.1. Clinical characteristics of RVI and MAN cystic fibrosis patients  
 
   CF(RVI) 
N=30 
CF(MAN) HV 
N=27 
Sex (no.) 
Male/female 
 
19/11 4 / 10  Not av. 
Age (y) 
 
29    ±1.72 Not av 54±3.0 
 
Symptoms 
 
75     ±8.17 Not av Not app. 
Exacerbations (per year) 
 
3       ± 0.43 Not av Not app. 
FEV1 (% predicted) 
 
47     ±4.52 48±5.2 113±2.83 
 
FVC (% predicted) 
 
70     ± 4.29 72±4.7 118±2.7 
FEV1/VC ratio 59     ±2.65 Not av 83±1.75 
 
 
Abbreviations: FEV1=forced expiratory volume in one second. FVC=forced vital capacity.  The 
data is presented as mean ± SEM. Not av indicates that data were not available whereas Not app 
means that category not applicable. 
 
6.3.2 Microbial infections in cystic fibrosis patients 
 
Sputum or swab microbial cultures were carried out at the Freeman Hospital at Microbiology 
Department. Microbial pathogens were isolated from all patients enrolled in the study, with 
polymicrobial communities comprising of both bacterial and fungal species being present. 
The main pathogens isolated from sputum are presented in Table 6.2. The most abundant 
colonization was seen for P. aeruginosa followed by Candida sp., and the least was recorded 
for E. coli. These CF patients were selected specifically to possess clinical P. aeruginosa 
infections.   
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Table 6.2. The abundance of microorganisms from the sputum of RVI CF patients 
Organism  Cystic Fibrosis % 
P. aeruginosa 100 
Candida sp. 86 
S. aureus 70 
A. fumigatus 60 
H. influenzae 56 
S. maltophilia 26 
S. pneumoniae 10 
E.coli  6 
 
The Manchester patients were selected specifically to possess chronic infection by 
Burkholderia species. The following Table 6.3 demonstrates the microbiological isolation 
of Burkholderia. sp and P. aeruginosa in the 14 Manchester patients with CF. These patients 
were classified into no colonization, chronic colonization or intermittent colonization. The 
microbiology results in Table 6. 3 show that 5 out of 14 patients were chronically colonized 
by B. cenocepacia and 9 patients by B. multivorans. Furthermore, 4 patients had chronic 
colonization with P. aeruginosa, and 3 had intermittent infection.  
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Table 6.3. Microbial culture analyses for B. cenocepacia, B. multivorans and P. aeruginosa in 
Manchester CF patients 
CF subject number  B. cenocepacia B. multivorans P. aeruginosa 
MAN2 Chronic  No  No  
MAN9 No  Chronic  Chronic  
MAN21 No  Chronic  No  
MAN31 No  Chronic  Intermittent 
MAN41 No  Chronic  No  
MAN52 No  Chronic  Intermittent 
MAN65 No  Chronic  Intermittent 
MAN74 Chronic No  Chronic  
MAN75 Chronic No  Chronic 
MAN88 No  Chronic  No  
MAN111 No  Chronic  No  
MAN120  No  Chronic  No  
MAN121  Chronic No  Chronic 
MAN122 Chronic No  No  
 
6.3.3 Comparison of antibody titres in RVI CF patients and healthy volunteers  
 
IgG titre for CF patients and healthy controls against the lung-infecting organisms are shown 
in Figure 6.1. The results show that significantly higher IgG titres were observed in CF 
patients against P. aeruginosa (p<0.001), S. maltophilia (p<0.01), M. catarrhalis (p= 0.02) 
and A.fumigatus (p<0.001). CF patients also showed higher anti-NTH. influenzae titres but 
without statistical significance. However, the magnitude of IgG against H. influenzae 
polysaccharide was significantly higher in healthy controls (p<0.001) when compared to CF 
patients. IgG titre against S. pneumoniae lysate was slightly higher in healthy controls but 
no significant difference was found.  
 
 
 
183 
 
P.
ae
ru
gi
no
sa
S.
pn
eu
m
on
ia
e
N
TH
.in
flu
en
za
e
M
.c
at
ar
rh
al
is
S.
m
al
to
ph
ili
a
A
.fu
m
ig
at
us
 
H
.in
flu
en
za
e p
ol
ys
ac
ch
ar
id
e 
0
2000
4000
6000
CF
HV**
*
**
**
**
Antigens
Ig
G
 t
it
re
 
Figure 6.1: IgG titre against the key antigens examined in the study in CF patients and HV. 
Higher antibody titres were detected in most CF patients compared to the healthy volunteers. ** 
indicates p-value highly significant p≤0.001. * indicates p-value ≤ 0.05.  The data are shown as the 
mean± SEM. CF n=30 and HV n= 27. 
 
6.3.4 T cell responses in RVI CF patients  
 
Antigen-specific responses of T cells against lung antigens and positive controls were also 
measured in CF patients compared to healthy volunteers. In CF patients the level of IFN 
was significantly higher against B. cenocepacia (p=0.046) compared to healthy volunteers. 
In contrast, healthy volunteers showed significantly higher response of IFNagainst S. 
pneumoniae (p= 0.011). There was no significant difference between CF patients and healthy 
subjects in IFN specific for P. aeruginosa, A. fumigatus, M. tuberculosis, Cytomegalovirus, 
B. pertussis and RSV. A higher production of IFN was observed in CF patients for H. 
influenzae and M. catarrhalis, but this did not yield statistical significance (p= 0.065 and 
p=0.098, respectively). No differences were observed between responses to positive 
controls. 
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Figure 6.2(A-C): Antigen-specific response of T cells to different lung-infecting organisms. 
ELIspot was used to measure IFNagainst the lung antigens in CF patients and HV. * indicates p-
value ≤ 0.05: (A) positive controls; (B) and (C) lung microbe antigens. The data are shown as 
mean± SEM. CF n=30 and HV n=27. 
 
6.3.5 Relationship between T cell and antibody responses in CF patients 
 
The relationship between antibody and T cell responses against the main key organisms was 
assessed for CF patients. A negative correlation was found between T cell and antibody 
response for A. fumigatus (p=0.086; Fig.6.3E), but statistical significance was not reached. 
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No correlation was observed for the other antigens including P. aeruginosa, S. pneumoniae, 
H. influenzae and M. catarrhalis in CF patients. The analysis of antibody and T cell 
responses for healthy volunteers are shown in chapter 5. 
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Figure 6.3(A-E): Relationship between antibody titre and T cell responses against lung 
antigens in CF patients. 
(A) P. aeruginosa; (B) S. pneumoniae; (C) H. influenzae; (D) M. catarrhalis and (E) A. fumigatus; 
and. Data are shown as antibody titre and spot-forming cells/106 in each patient. Spearman analysis 
was used for the correlation and Mann-Whitney test for p-value.   
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6.3.6 Comparison of lung function with the clinical status (exacerbation and Stable 
patients)  
 
To determine if exacerbations contribute to decline in lung function, the clinical status of 
patients with exacerbating status and those who were stable were compared for FEV1 % 
predicted, as shown in Figure 6.4. A significant reduction in FEV1 % predicted was found 
in the exacerbating group compared to stable patients (p=0.037). 
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Figure 6.4: FEV1 % predicted of stable and exacerbated patients. 
FEV1% was significantly reduced in the exacerbating group. Data are presented as mean± SEM. The 
numbers were in each group are indicated.   
 
6.3.7 Antibody response compared with clinical status (exacerbating and stable) in 
CF patients   
 
IgG titre against P. aeruginosa and H. influenzae was investigated in exacerbated compared 
to stable patients to determine any association of IgG antibody titre in both clinical status 
and its association with pulmonary exacerbation. Figure 6.5 shows that the stable group had 
significantly higher antibody titre compared to those presenting with exacerbations against H. 
influenzae (p=0.003), whereas there was no significant difference for P. aeruginosa titre.   
 
 
 
187 
 
Exacerbating group Stable group
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
A
n=12 n=18
Status
A
n
ti
- 
P
se
u
d
o
m
o
n
a
s 
Ig
G
 t
it
r
e
 
p=0.003
Exacerbating group Stable group
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
B
n=12 n=18
Status
A
n
ti
-H
.i
n
fl
u
e
n
za
e
 t
it
r
e
 
Figure 6.5(A-B): IgG titres compared in exacerbating and stable patients. 
(A) antibody titres against P. aeruginosa;(B) IgG titre against H. influenzae. Data are shown as mean 
± SEM. Significant differences between both groups were seen in response to H. influenzae.   
 
6.3.8 Correlation between antibody, T cell responses and lung function in CF patients  
 
The relationship between antibody and T cell responses against P. aeruginosa and H. 
influenza, in relation to lung function were assessed in CF patients to evaluate if the immune 
responses may predict subsequent lung function. No correlation was observed between IgG 
titre and FEV1 predicted (Figure 6.6). However, a significant positive correlation was seen 
between T cell responses and FEV1 % predicted in response to P. aeruginosa (p=0.005) 
(Figure 6.7). 
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Figure 6.6 (A-B): Relationship between antibody titre and lung function in patients with CF. 
(A)P. aeruginosa;(B) H. influenzae.  No significant correlation was found (Spearman correlation was 
used).   
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Figure 6.7(A-B): Relationship between T cell responses and lung function in patients with CF. 
 (A) P. aeruginosa; (B) H. influenzae.  A significant positive correlation was found in response to P. 
aeruginosa (Spearman correlation was used).   
 
6.3.9 T cell responses compared with clinical status (exacerbating and stable) in CF 
patients.   
 
Figure 6.8 shows T cell responses in the form of IFN against P. aeruginosa and H. 
influenzae in both status groups to see whether or not T cell responses may contribute to 
exacerbation in CF. The results show significantly reduced T cell responses against P. 
aeruginosa in patients with exacerbation (p=0. 026).   
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Figure 6.8 (A-B):IFN produced by T cells in exacerbating and stable groups. 
(A) P. aeruginosa; (B) H. influenzae measured in patients with exacerbation and those who were 
stable. Data are shown as mean ±SEM. A significance differences in IFN were seen between both 
groups against P. aeruginosa.   
 
 
6.3.10 Immune responses in Manchester CF (MAN) patients colonized by 
Burkholderia sp and P. aeruginosa  
 
The serum IgG to B. multivorans, B. cenocepacia and P. aeruginosa was measured in 14 
adult CF (MAN) patients colonized with these pathogenic bacteria as described in Table 6.3. 
The results in Figure 6.9 show that all patients who were chronically colonized by B. 
multivorans had higher specific antibody titre to this antigen, except for patient MAN111 
who had slightly higher anti-B. cenocepacia. Similarly, increased antibody titre was also 
found in CF patients colonized by B. cenocepacia except for MAN74. Furthermore, patients 
who had Pseudomonas colonization also tended to have higher anti-Pseudomonas IgG titre, 
apart from MAN9. Although patients MAN52 and MAN9 were colonized with B. 
multivorans, and P. aeruginosa, the responses were only marginally higher versus both 
antigens. T cell responses were measured by ELIspot in three MAN patients for which 
PBMCs were available for IFN, IL-2, IL-5, IL-17 and IL-22 against lung antigens as 
described in Table 2.5.  
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The results in Figure 6.10 show that patient MAN122 had higher IFN against most of the 
antigens as well as IL-17 and IL-22 versus Candida. sp. In contrast, patient MAN 88 had 
higher IL-2, IL-17 and IL-22 against Candida. sp. As well as IL-5 against Candida.sp and 
B.cepacia. MAN 9 had higher IL-17 and IL-22 against Candida. sp. 
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Figure 6.9: Antibody response against B. multivorans, B. cenocepacia and P. aeruginosa in CF 
Manchester patients. 
Higher IgG titres were measured against these antigens in all patients colonized with these bacteria. 
Data are shown as end point titre for each patient. + indicates bacterial colonization. The straight 
horizontal line indicates mean anti-Pseudomonas IgG for healthy volunteers as a reference point. 
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Figure 6.10 (A-F): T cell responses in three MAN samples against a panel of antigens in the 
form of IFN, IL-2, IL-5, IL-17 and IL-22. 
 Data are represented as spot-forming cell/106 for each patient.  
 
 
 
192 
 
6.4 Discussion  
 
The culture-dependent approach revealed the typical microbial species colonizing the lungs 
of our CF patients, including bacteria and fungi. Table 6.2 confirms that all RVI patients 
were culture-positive for P. aeruginosa; indeed, it is the dominant pathogen isolated from 
CF airways. Previous studies found that 80-90% of CF patients were colonized with 
P.aeruginosa when associated with hospitalisation (Leid et al., 2005, Moreau-Marquis et 
al., 2008). The culture results in Tables 6.2 and 6.3 show that patients colonized by P. 
aeruginosa were also colonized by other bacterial species, suggesting that this bacterium can 
change the environment from aerobic to anaerobic and thus allowing more species to reside 
in the CF lung (Yoon et al., 2002). Besides, infection with the mucoid phenotype of 
Pseudomonas has been shown to impair the innate host defence and facilitate colonization 
by other bacteria  such as  B. cenocepacia in CF patients  (Chattoraj et al., 2010). 
6.4.1 Immune responses in CF patients  
 
Antibody levels may provide an early indicator of microbial infection of the lung in cystic 
fibrosis, and they may also have a role in protection. Highly significant IgG titres against P. 
aeruginosa, A. fumigatus, S. maltophilia and M. catarrhalis were found in CF patients 
compared to healthy controls. This reflects the greater degree of exposure to, and 
colonization with, these organisms, as observed in the microbiology results showing the high 
number of patients colonized with these organisms (i.e. 100% and 60% of patients colonized 
with Pseudomonas and Aspergillus, respectively). Indeed, increased antibody levels are 
strongly associated with the recurrent microbial infection of P.aeruginosa and S. maltophilia 
as shown in previous studies (Milagres et al., 2009, Teunis et al., 2012, Wettlaufer et al., 
2016). The results showed that IgG titre also associated with  A. fumigatus and M. catarrhalis 
in patients with CF.  The role of IgG titre in the protection against microbial infection in 
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patients with BR and COPD has been discussed in chapters 3 and 4. However, the response 
against H. influenzae polysaccharide was significantly higher in healthy volunteers 
compared to CF patients and it may be that the patients failed to give normal IgG responses 
against polysaccharide antigens. It has been shown by Browning et al. (2014) that children 
with CF have impaired antibody response against unconjugated polysaccharide vaccine. 
Thus, it is possible that patients produce less IgG compared to healthy volunteers against 
this antigen. Similarly, the response against S. pneumoniae lysate was lower in patients with 
CF compared to healthy volunteers, indicating infrequent S. pneumoniae colonization found 
in patients with CF and the failure of these patients to produce antibody responses.  Healthy 
volunteers may have higher degrees of antigen exposure as discussed in chapter 3, or may 
respond better and have higher memory responses than CF patients.  
T cell responses against lung-infecting microbes in the form of IFN were also investigated 
in patients with CF compared to healthy volunteers. These findings demonstrate that CF 
patients had significantly higher IFN production compared to healthy volunteers only 
against B. cenocepacia (p=0.046). Furthermore, the responses were higher in CF patients 
compared to healthy controls for H. influenzae and M. catarrhalis, but neither difference 
was statistically significant, yielding p-values of 0.065 for H. influenzae and 0.098 for M. 
catarrhalis. The increased IFN production in patients with CF indicates that the response 
against these pathogens is a Th1 response. A significantly lower T cell response against S. 
pneumoniae in CF patients was also observed (p= 0.011). Lower T cell responses were also 
shown by patients with BR, COPD and asthma in the previous chapter . 
It has been suggested that Th1 is characterised by the secretion of IFN and decreased 
antibody response, while Th2 is characterised by production of IL-4, IL-5, IL-10 and 
pronounced antibody response through the activation of B cells. Therefore, reduced 
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production of IFN by CD4+ T cells in response to these antigens is  an impaired Th1 function 
(Behar et al., 2014). Indeed, a previous study conducted by Moss et al. (2000)  showed that 
patients with CF produce lower levels of IFN and other Th1 cytokines, whereas higher IL-
10, a signature of Th2 and immune regulation (Lehar and Bevan, 2004). This may be 
explained by the fact that the up-regulation of IL-10 leads to the inhibition of IFN 
production and decreased co-stimulatory molecules on macrophages, resulting in impedance 
of antigen presentation and impairing effective immune response against P. aeruginosa, A. 
fumigatus and other pathogens (Moss et al., 2000). Further investigation of the role of 
antibodies, and specific Th2 and IL-10 responses in CF is required.  
Concerning the relationship between antibody and T cell responses in CF patients, no 
correlation was found between the magnitude of antibody and T cell responses, except for 
the negative correlation for A. fumigatus. Our findings were similar to those of a previous 
study conducted to examine antibody and T cell responses associated with experimental 
malaria infections (Walker et al., 2015). As the authors described, the generation of antibody 
response requires either T cell help through cytokine production to undergo class switching 
from IgM to IgG, or the activation of B cells through CD40 ligand–expressing T cells, with 
cytokines being less effective.   
It is important to note that in our study the healthy controls (with a mean age of 54 years) 
were older than the CF patients (mean age 29 years). Therefore, reduced responses in healthy 
volunteers against certain antigens may be associated with ageing. As has been reported 
previously, decline in the micro RNA (miRNA) network that is essential for T cell 
differentiations and consequently CD4+ T cell function, are observed with ageing (Kushwah 
et al., 2013).  
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6.4.2 Exacerbation and lung function test  
 
Exacerbation is the main risk factor for progressive obstructive lung disease in CF, which 
over time is associated with a deterioration in lung function. FEV1% predicted has been 
proven to be a marker of disease severity (Amadori et al., 2009, Schluchter et al., 2002). 
Therefore, FEV1 in stable patients was compared to those having exacerbation in order to 
ensure that FEV1 decline is the main indicator of CF deterioration. A significant reduction 
in FEV1 was found in patients having exacerbation compared to those who were stable 
(p=0.037). This is in agreement with a previous study showing impaired lung functions in 
association with exacerbations in CF patients (Nelson, 2011), and validates the 
categorization by exacerbation status.  
6.4.3 Immune response and exacerbations 
  
In evaluating the role of antibody levels and the risk of pulmonary exacerbation, an analysis 
was carried out on the patient cohort. The results show that exacerbated patients showed 
significantly lower levels of IgG titre against H. influenzae, whereas no significant 
differences were found for P. aeruginosa. As stated above, higher antibody titres are 
associated with greater exposure to P. aeruginosa, which may be protective. In our study, 
stable and exacerbated patients were exposed to similar level of P. aeruginosa as ascertained 
by antibody level and microbial colonization. Previous researches has demonstrated no 
significant differences between bacterial load and exacerbations (Dickson et al., 2014, 
Nelson, 2011, Tunney et al., 2013). Therefore, as the colonization or exposure levels are 
similar, we would not expect to see a higher level of antibody in patients with exacerbations.  
However, a significantly increased level of T cell responses against Pseudomonas was found 
in patients who were stable. Supporting this, lung function FEV1 % correlated with these T 
cell levels. The reason for this may be that, during acute exacerbation, Treg cells suppress 
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pro-inflammatory cytokines such as IFN through production of IL-10 and TGF-β which are 
essential in preventing lung damage (Jin et al., 2014, Tang and Bluestone, 2008). 
6.4.4 Antibodies and T cells against B. cenocepacia, B. multivorans and P. aeruginosa 
in MAN patients 
 
Increased antibody levels were broadly observed in MAN patients chronically colonized 
with B. cenocepacia, B. multivorans and P.aeruginosa, indicating that high microorganism 
exposure resulted in higher antibody response. Exceptions were that patient MAN74 was 
chronically colonized by B. cencepacia yet had low   antibody titre. MAN122 was 
chronically colonized by B. cenocepacia and yet had lower antibody titre against 
B.cenocepacia than B.multivorans. It may be that antibodies exhibit cross-reactive activity 
against B. cenocepacia, and B. multivorans species (Makidon et al., 2010). The lipid A 
endotoxic of lipopolysaccharide endotoxins is the main component of  B. multivorans which 
is responsible for triggering immune responses, and it is implicated in the pathogenesis of 
CF (Ierano et al., 2010).  In this study, the cell lysate was used as an antigen to stimulate 
antibody responses , and it is not clear in our result whether the elevated antibody reacted 
against the outer membrane or the LPS portion.   
As demonstrated in chapter four that increased antibody is associated with P. aeruginosa 
colonization, as has also been demonstrated in previous studies (Milagres et al., 2009, Teunis 
et al., 2012).  
The analysis of T cell responses was limited to 3 patients. Despite being heterogeneous in 
nature, as a group the responses against colonizing bacteria showed secretion of IFN, IL-5, 
IL-17 and IL-22. Although not as high as the anti-candida responses, these results suggest a 
role of these cytokines in protection against infection and conversely in disease 
immunopathology.  
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6.5 Conclusion   
            
Overall, these results show that patients with CF are colonized by various microbial species, 
with P. aeruginosa being the predominant pathogen. These pathogens stimulate immune 
responses, eliciting high IgG production. By contrast, the chronic microbial infection does 
not lead to a similarly-boosted T cell response. Moreover, in this study it was demonstrated 
that patients with exacerbation had significantly reduced lung function, which is a prognostic 
indicator for disease severity.  The IFN response of T cells against Pseudomonas was also 
higher in stable patients and correlated positively with lung function, suggesting that these 
cells (or ones they are associated with) may be implicated to prevent pulmonary destruction 
and thus can be prognostic for pulmonary exacerbation. 
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7 Chapter Seven: General Discussion 
 
Diseases of the airway, including bronchiectasis (BR), chronic obstructive pulmonary 
disease (COPD) and asthma, are characterised by persistent airway inflammation and 
involve both innate and adaptive arms of the immune response  as a result of microbial 
infection(Dickson et al., 2014). These factors facilitate disease progression and contribute to 
reduced life expectancy. The adaptive response is involved in the activation of leukocytes 
and production of  inflammatory mediators and the stimulation of other cell types (Panettieri, 
2002). These lymphocytes have two potential functions in respect to pulmonary lung 
diseases: to improve immunity against infection in association with inflammatory 
mechanisms, and to contribute to disease pathophysiology (Singh, 2014). A balance needs 
to be struck between the two processes. The challenge of understanding the 
immunopathogenesis of disease requires knowledge of the role of these cells, specific 
antibodies and cytokine profiles that may contribute to immunity. This research project was 
designed to investigate specific immune responses involving both T cells and antibodies in 
response to microorganisms that are associated with the status and progression of pulmonary 
conditions including BR, COPD, asthma and CF.  A panel of lung antigens including H. 
influenzae, P. aeruginosa, S. pneumoniae, M. catarrhalis and A. fumigatus (see Table 2.1) 
was selected to test the antibody responses in different clinical groups compared to healthy 
volunteers. These microorganisms were found to be the most abundant microbes isolated 
from the sputum of patients with BR, COPD and CF. These disease groups display 
polymicrobial infection created by combinations of different microorganisms including, 
viruses, bacteria, fungi, which can facilitate other micro-organisms as co-infecting pathogens 
(Brogden et al., 2005). In the respiratory tract, infection with viruses can promote secondary 
infection by bacteria by inducing immunosuppressive effects that lead to severe 
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complications (Peltola and McCullers, 2004). In contrast, P. aeruginosa can lyse other 
bacteria such as S. aureus and use it in certain environments where iron levels are low, 
contributing to persistent chronic P. aeruginosa infection in the CF lung (Mashburn et al., 
2005). The clinical groups studied here demonstrate high IgG titre against most of the 
antigens, being significant antigens. This suggests that microbial infections trigger the 
adaptive immune system and subsequently the production of high levels of immune 
responses. The high exposure to pathogenic microbes results in the boosting of the immune 
response, sustaining high levels of immunoglobulins in circulation (Wettlaufer et al., 2016).  
It has been found that increased IgG titres are associated with microbial infections in the 
lung. Antibodies can neutralize microbes by direct binding to their surface protein, which is 
important for attachment onto the host cells. Furthermore, antibodies stimulate the 
complement cascade and antibody-dependent cell-mediated cytotoxicity via the ligation of 
Fc receptors. The antibody most highly correlated with protection to be identified in the 
serum was the IgG type (Chiu and Openshaw, 2015). Therefore, it is clear that elevated IgG 
antibody following microbial infection is critical for protection. In contrast, asthmatic 
subjects showed lower level of IgG titre compared to other patients groups. This is possibly 
due to less frequent bacterial infection in patients with asthma. Furthermore, the switching 
of antibody isotype from IgM to IgE may be implicated in allergic diseases such as asthma 
(Holgate, 2012).  Most previous research has tested the development of antibody responses 
to P. aeruginosa infection in CF patients (Doring and Hoiby, 1983, Winnie and Cowan, 
1991). However, in our study, groups of patients with pulmonary conditions, including BR, 
COPD, asthma and CF, were tested for the relationships between immune responses, 
infection incidence and clinical status.   
The deterioration of lung function was associated with chronic current microbial 
colonization in both BR and COPD patients for a proportion of the microorganisms. 
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Colonization of bacteria and the augmentation of inflammatory responses contribute to the 
progression of damage in the lung architecture, and over years results in the impairment of 
lung function. It has been found that lung tissue damage increases with age of the disease in 
patients with CF (Helbich et al., 1999).   
While a great deal of research in CF patients has found that exacerbation contributes to lung 
function decline, the definitive conclusion to determine the cause of exacerbation in BR and 
COPD is still uncertain  (Amadori et al., 2009, Sanders et al., 2011). Several studies using 
culture approaches have found that there is no correlation between bacterial load and the 
induction of exacerbation (Dickson et al., 2014, Tunney et al., 2011, Wedzicha and 
Seemungal, 2007). Furthermore, in this study, reduced FEV1% predicted was associated with 
exacerbations in patients with different scores as defined by BSI and compared to the FEV1% 
of healthy volunteers. Similarly, impaired lung functions was also shown in exacerbated CF 
patients. Therefore, the decline in lung function may be a determinant of exacerbations in 
patients with BR and CF. Further analysis was performed to investigate the role of antibodies 
against P. aeruginosa, M. catarrhalis and S. maltophilia in patients with different degrees 
of exacerbation and FEV1% predicted. These bacteria were found to be pathogens associated 
with reduced lung functions in BR and COPD. Significant differences in antibody titre were 
observed between these categories of exacerbations, suggesting that bacterial colonisation 
may trigger antibody and inflammatory responses leading to the induction of exacerbation 
(Perera et al., 2007). However, no significant correlations between lung function and IgG 
titres for patients with BR, COPD, and CF were found. In contrast, exacerbated patients with 
CF have significant reductions in IgG against H. influenzae, which suggests different role 
for this bacterium in CF. 
T lymphocytes are also involved in protection against infections through the secretion of 
specific cytokine molecules. Intracellular bacteria and viruses broadly stimulate Th1, 
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whereas multicellular pathogens promote Th2 cytokines (Lehar and Bevan, 2004). During 
infections, dendritic cells recognise the microbial pathogens via TLR and then migrate to the 
lymphoid organ where they interact with T cells and induce T cell responses. This may 
contribute to the inability to clear the infections (Lehar and Bevan, 2004). In this study, the 
clinical groups were tested for T cells responses, and in particular Th1 through the production 
of IFN. The cells were initially stimulated with a selection of lysates and peptides to ensure 
that they were specifically activated. The findings show that patients with pulmonary 
diseases (BR, COPD and asthma) exhibit lower IFN production compared to healthy 
volunteers against most of the antigens.  In these circumstances, higher frequencies of 
microbial infection show a trend for reduced T cell responses due to dysfunctional T cells 
(Tiringer et al., 2013). Moreover, as the antibody levels were significantly higher against 
most of the antigens and were correlated with microbial colonisation, the responses of T 
cells were contradictory. This may indicate that the response of Th2 response was skewed 
toward Th2 rather than Th1. The high degree of continuing antigenic stimulation correlates 
with more rapid T cell exhaustion, whereas the lower antigen exposures resulted in 
intermediate impairment (Behar et al., 2014). It was concluded that the lack correlation 
between antibody and T cell responses in patients with lung disease is likely to be due to the 
different patterns of cells involved.   
The findings showed that the response of T cells was significantly reduced in BR against M. 
catarrhalis and P. aeruginosa in hospitalised and exacerbated patients, respectively. 
Meanwhile, a significant reduction against P. aeruginosa was also found in exacerbated CF 
patients. Although there is no correlation between antibody levels, T cell response and 
FEV1% predicted, a positive correlation was seen in relation to anti-Pseudomonas T cell 
response and FEV1% in CF patients. The results also showed that patients with CF have the 
highest antibody whereas; comparable T cell responses in CF and HV against P. aeruginosa 
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(Figure 7.1). All of these findings suggest the important role of antibodies and T cells as 
prognostic markers for microbial infection and the progression of clinical outcomes such as 
reduced pulmonary functions and progression exacerbation. 
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Figure 7.1(A-B): Antibody and T cell responses against P.aeruginosa in all clinical groups and 
healthy volunteers. 
A, antibody; B, T cells responses against P.aeruginosa. Patients with CF showed the highest antibody 
response in all groups but T cell responses also were higher compared to patients but comparable to 
HV.   
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Conclusion and Future Work 
 
In conclusion, the lungs of the BR, COPD and CF cohorts are colonized by polymicrobial 
communities comprising bacterial and fungal species. These microorganisms promote the 
perpetuation of immunological responses and drive a vicious cycle of re-infection and 
further inflammation. The study shows that patients with current microbial colonization are 
also associated with impaired FEV1%, and the lung function of most BR and COPD patients 
is in the GOLD stages II or III.   
Measurement of antibody levels in patients with pulmonary diseases can help to identify 
those with microbial colonization, especially in individuals unable to produce sputum 
specimens and those at risk of pulmonary exacerbation who could benefit from earlier 
antibiotic treatment. Nevertheless, high microbial stimulation results in T cell exhaustion 
and is likely to lead to the impaired ability of cells to control the infection. T cells responses 
were not associated with pulmonary exacerbation in BR and COPD patients but they were 
in CF. Among the pathological mechanisms of established BR, COPD and CF, there are 
likely to be a large number of factors that interact to cause a specific level of disease. These 
clearly include the initial aetiology (genetics, triggers), microbial exposure and colonization, 
innate immunity and adaptive immunity. Any one parameter relating strongly with disease 
would seem to be difficult to identify.  These findings offer merely a snapshot in time of the 
diseases, but indicate a role for immunological investigations as earlier diagnostic tools to 
predict microbial colonization using antibodies, and to determine the pulmonary 
exacerbations and function in certain groups. Further investigations are hence warranted. 
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Future Work 
 
In this study, anti-microbial immune responses were tested on a single occasion in relation 
to microbial colonization and clinical status in different groups of pulmonary lung disease. 
Large datasets were generated from which hypothesis-driven analysis was carried out. 
Furthermore, the genomic analysis of sputum samples was also carried out, the results of 
which were not available for inclusion in the analysis in this thesis. Once available, complex 
multi-factor statistical analysis with multiple corrections would be warranted.  Furthermore, 
the measurement of Th17- and Th2-cell responses were conducted only in three patients with 
CF due to the limitations of PBMCs, and therefore further investigation of these cytokines 
are necessary in a larger cohort to assess their role of the response to microbial infections in 
different clinical categories.  
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Appendix 1: Ethical approval 
  
NRES Committee North East - County Durham & Tees Valley   
Room 002  
TEDCO Business Centre  
Viking Industrial Park  
Rolling Mill Road  
Jarrow  
Tyne & Wear  
NE32 3DT  
  
 Telephone: 0191 
4283545  Facsimile: 0191 4283432 26 July 2012  
  
Dr Anthony DeSoyza  
Senior Lecturer, Honorary Consultant in Respiratory medicine  
Newcastle Upon Tyne Hospitals NHS Foundation Trust 
Sir William Leech Centre for Lung Research  
Freeman Hospital  
Newcastle Upon Tyne  
NE7 7DN  
 Dear Dr DeSoyza  
  
Study title:  Inflammation, aging and lung disease study  
REC reference:  12/NE/0248  
 Thank you for your e-mail correspondence of 23rd July 2012 responding to the Committee’s 
request for further information on the above research and submitting revised documentation.  
 The further information has been considered on behalf of the Committee by the Chair.  
  
Confirmation of ethical opinion  
 On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below.  
Ethical review of research sites  
 NHS sites  
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 The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below).  
 Non-NHS sites  
 Conditions of the favourable opinion  
  
The favourable opinion is subject to the following conditions being met prior to the start of 
the study.  
 Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned.  
  
Management permission ("R&D approval") should be sought from all NHS 
organisations involved in the study in accordance with NHS research governance 
arrangements.  
 Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.    
  
Where a NHS organisation’s role in the study is limited to identifying and referring 
potential participants to research sites ("participant identification centre"), guidance 
should be sought from the R&D office on the information it requires to give 
permission for this activity.  
  
For non-NHS sites, site management permission should be obtained in accordance 
with the procedures of the relevant host organisation.   
 Sponsors are not required to notify the Committee of approvals from host organisations  
  
It is the responsibility of the sponsor to ensure that all the conditions are 
complied with before the start of the study or its initiation at a particular site (as 
applicable).  
 Approved documents  
  
The final list of documents reviewed and approved by the Committee is as follows:  
   
Document     Version     Date     
Covering Letter      12 June 2012   
GP/Consultant Information Sheets   GP Letter Version 1.0  24 January 2012   
Investigator CV   Dr DeSoyza   04 April 2012   
Investigator CV   Jodie Birch   11 June 2012   
Other: Normal Volunteers Consent Form   1.0   28 January 2012   
Participant Consent Form   1.0   28 January 2012   
Participant Information Sheet: Patient Information 
Leaflet   
Version 1.1   23 July 2012   
Participant Information Sheet: Volunteer 
information Leaflet   
Version 1.1   23 July 2012   
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Protocol   1.0   14 February 2012   
REC application          
Response to Request for Further Information          
 Statement of compliance  
 The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK.  
 After ethical review  
 Reporting requirements  
  
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
 Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
  
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures.  
 Feedback  
  
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website.  
 Further information is available at National Research Ethics Service website > After Review   
  
12/NE/0248  Please quote this number on all 
correspondence  
  
With the Committee’s best wishes for the success of this project  
 Yours sincerely  
  
pp  
  
Dr A MacSween Chair  
 Email: hayley.jeffries@nhs.net  
 Enclosures:  “After ethical review – guidance for researchers” [SL-AR2]  
  
Copy to:  Jill Peacock, Newcastle upon Tyne Hospitals NHS Foundation Trust  
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Appendix 2:  Microbiological Reagents 
 
Media for culturing bacteria lysate  
Brain heart infusion broth     1.85 g 
Deionised water                    50 ml 
Bradford Reagent 
Bradford Dye Reagent (blue)  
BSA (Bovine serum albumin) 
96 well ELISA Plate 
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Appendix 3: SDS-PAGE for protein analysis 
 
SDS-PAGE running buffer X10 
Running buffer was made up to 10X concentration and (diluted to 1X before use).  
Tris-HCl            30.3 g  
Glaycine            144.0g  
SDS                   10.0 g 
12% (W/V) SDS Acrylamide resolving gel components  
40% (w/v) solution (37.5:1 acrylamide:biscrylamide)  3.0 ml 
Solution B*                                                                  2.5ml 
Deionised water                                                           4.50 ml 
10% (w/v) ammonium persulphate (ASP)                  50 µl 
TEMED                                                                       10 µl 
*Solution B   
2M Tri-HCL, PH 8.8        75ml   per 100 ml                                                            
10%(w/v) SDS                 4ml      per 100 ml  
4% (W/V) Acrylamide stacking gel components  
40% Acrylamide                             250 ml 
10% ammonium persulphate (APS) 30µl 
Deionised water                              1.2 ml 
Solution C*                                    500 µl 
TEMED                                           10 µl 
* Solution C                                        
1M Tris-HCL, PH 6.8                      50 ml per 100 ml                                                            
10 %( w/v) SDS                              4 ml per 100 ml                                                            
SDS-PAGE sample buffer  
60mM Tris-HCL pH 6.8                0.6ml per 10 ml  
10 %( w/v) SDS                           2.0 ml per 10 ml 
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50% (v/v) glycerol                       5.0ml per 10 ml 
14.4 mM - Mercaptoethanol       0.5 ml per10 ml 
0.1% (w/v) Bromophenol Blue   1.0 ml per 10 ml 
Deionised water                          0.9ml per 10ml  
Coomassie blue gel stain solution  
Coomassie Brilliant Blue R250    1.0g per L 
Glacial acetic acid                         100.0 ml per L 
Methanol                                     450.0 ml per L 
Coomassie gel destain solution    
Glacial acetic acid                       100.0 ml per L 
Methanol                                   100.0ml per L 
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Appendix 4: Pierce® LAL Chromogenic Endotoxin Quantitation Kit 
 
Endotoxin-free-water                1 vial, 30mL  
Limulus Amebocyte Lysate (LAL), lyophilized, 2vial, 1.4mL 
E. coli Endotoxin standard (011: B4), lyophilized, 1 vial,15-40 endotoxin unit (EU)/mL       
upon reconstitution                28EU/ml  
Chromogenic substrate, lyophilized, 1 vial, 6.5mL/vial upon reconstitution (7mg of 
lyophilized substrate was reconstituted in 9 ml of in endotoxin-free water) 
Acetic acid  
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Appendix 5: Reagents for ELISA 
 
Phosphate Buffer Saline PH =7.0 (PBS) 
Phosphate Buffer was made up to 10X concentration (and diluted to 1X before use) 
NaCl                                        81.7 g 
Na2PO4                                                      11.2 g 
NaH2PO4.H2O                          2.2g  
Deionised water                       up to 1L 
PBS/0.05 Tween 20 (washing buffer in-between steps) 
Phosphate Buffer Saline (1XPBS) 1L  
Tween 20                                        0.5 ml  
PBS Tween (PBST) + skimmed milk (blocking buffer) 
Skimmed milk powder           50 g  
PBS- Tween 20                   up to 50ml 
PBS Tween (PBST) + skimmed milk for diluent solution  
Blocking buffer     5ml  
PBST                   45 ml  
Diluent solution for keeping sera long time 
Diluent solution       50 ml  
Azide                      50 µl 
Citrate phosphate Buffer (for substrate solution) 
Citric acid          5.1g 
Na2HPO4            7.31g 
Deionised water   up to 1L 
Substrate solution  
Citrate buffer                                          25ml 
Orthophenylenediamine (OPD)            20 mg tablet 
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H2O2                                                     20 µl 
1.2.7. Stopping reaction 
Sulphuric acid                                          2M        
All chemicals were from Sigma-Aldrich, Gillingham, Kent 
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Appendix 6: Reagents for ELIspot 
 
Bicarbonate Buffer, 0.05 M pH 9.6 for coating  
Carbonate –bicarbonate buffer          1 capsule  
Deionised water                              100 ml  
Phosphate Buffer Saline (PBSx1) for washing (see 3.1.2.1) 
Substrate solution  
The solution made for 1 plate  
AP Conjugate substrate kit    50 µl of each (A&B)  
AP development buffer                  200 µl  
Deionised water                             4700 µl        
Medium for washing the cells (R0) 
RPMI-1640                                     500ml                                                  
Medium for culturing the cells (R10) 
RPMI-1640                                     500ml   
Supplemented with penicillin (100U/ml), streptomycin (100mg/ml), L-glutamine (2mM) 
(Invitrogen, UK) and 10% heat-inactivated FBS (Biosera, UK)          5ml 
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Appendix 7:  Flow cytometry reagents 
 
Anti-Mouse Ig, κ/Negative Control Compensation Particles Set    6.0 ml (1 ea) 
Brilliant Stain Buffer (BD Horizon™)      50 μl 
Permeabilization Buffer                      10X (100ml)  
Fixation Buffer                                  (IC Fixation Buffer 125ml)               
Brefeldin A                                        (Golgi plug, BD Bioscience  
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Appendix8: Meso Scale Discovery for cytokines ELISA 
 
Cytokines panel1 (human) multi-spot 96 well (10 spot plates) 
Pro-inflammatory panel 1(human) multi-spot 96well (10 spot plates 
MSD Blocker B                                             1g  
MSD Diluent1                                                50ml  
Diluent 3                                                         5ml  
MSD Read Buffer (4X) with surfactant          50ml  
Detector antibody pro-inflammatory panel 1(human) kit (calibrator blend):  
Anti-human IL-2 antibody 
Anti-human IL-4 antibody  
Anti-human IL-10 antibody  
Anti-human IL-13 antibody 
Anti-human IFN antibody 
Anti-human IL-12P70 antibody 
Cytokines panel 1 human kit (calibrator blend) 
Anti-human IL-5 antibody 
Anti-human IL-17A antibody  
Capture antibody  
IFN-γ: Mouse Monoclonal 
IL-1β: Mouse Monoclonal 
IL-2: Mouse Monoclonal 
IL-4: Mouse Monoclonal 
IL-5: Mouse Monoclonal 
IL-8: Mouse Monoclonal 
IL-10: Rat Monoclonal 
IL-12p70: Mouse Monoclonal 
IL-13: Rat Monoclonal 
TNF-α: Mouse Monoclonal 
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Appendix 9: Antibody screening for BR, COPD, asthma and healthy volunteers 
 
 
Screening profile of BR sera against S. pneumoniae at 1in 25 to establish the first dilution for antibody titration.  
Absorbance values for each BR patient are given.
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Screening of COPD sera against S.pneumoniae at 1:25 to establish the first dilution for 
antibody titration. 
 
Screening of asthmatics sera against S.pneumoniae at 1:25 to establish the first dilution for 
antibody titration. 
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Screening of healthy volunteers sera against S.pneumoniae at 1:25 to establish the first dilution for antibody 
titration.  
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Screening of BR sera against A. fumigatus  at 1in25 to establish the first dilution for antibody titration.  
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Screening of COPD sera against A.fumigatus  at 1in 25 to establish the first dilution for antibody titration.
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Screening of asthmatics sera against A.fumigatus at 1in25 to establish the first dilution for antibody 
titration. 
 
Screening of healthy sera against A.fumigatus at 1:25 to establish the first dilution for antibody 
titration. 
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Screening of BR sera against A.alternata at 1in25 to establish the first dilution for antibody titration 
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Screening of COPD sera against A.alternata at 1in25 to establish the first dilution for antibody titration. 
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Screening of asthmatics sera against A.alternata at 1:25 to establish the first dilution for antibody 
titration. 
 
Screening of healthy volunteer’s sera against A. alternata at 1in 25 to establish the first dilution for 
antibody titration. 
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Screening of BR sera against M. catarrhalis at 1in 25 to establish the first dilution for antibody titration 
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Screening of COPD sera against M. catarrhalis at 1in 25 to establish the first dilution for antibody titration 
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Screening of asthmatics sera against M. catarrhalis at 1in 25 to establish the first dilution for antibody 
titration. 
 
Screening of healthy volunteers sera against M. catarrhalis at 1in 25 to establish the first dilution for 
antibody titration.  
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Screening of BR sera against NTH.influenzae  at 1in25 to establish the first dilution for antibody titration 
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Screening of COPD sera against NT.H.influenzae at 1:25 to establish the first dilution for antibody titration 
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Screening of asthmatics sera against NTH.Influenzae at 1in25 to establish the first dilution for 
antibody titration. 
 
Screening of healthy volunteers sera against NTH.Influenzae at 1in 25 to establish the first dilution 
for antibody titration.  
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Screening of BR sera against S.maltophilia at 1:25 to establish the first dilution for antibody titration. 
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Screening of COPD sera against S.maltophilia at 1in 25 to establish the first dilution for antibody titration. 
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Screening of Asthmatic sera against S.maltophilia at 1:25 to establish the first dilution for antibody 
titration. 
 
Screening of healthy volunteers sera against S.maltophilia at 1in 25 to establish the first dilution for 
antibody titration.  
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Screening of BR sera against S.pneomoniae polysaccharide at 1in 25 to establish the first dilution for antibody titration 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
L
A
0
0
0
1
L
A
0
0
0
3
L
A
0
0
0
7
L
A
0
0
1
0
L
A
0
0
1
3
L
A
0
0
1
5
L
A
0
0
1
7
L
A
0
0
1
9
L
A
0
0
2
1
L
A
0
0
2
5
L
A
0
0
3
4
L
A
0
0
3
6
L
A
0
0
3
9
L
A
0
0
4
6
L
A
0
0
4
9
L
A
0
0
5
2
L
A
0
0
5
5
L
A
0
0
6
5
L
A
0
0
7
1
L
A
0
0
7
5
L
A
0
0
7
7
L
A
0
0
8
1
L
A
0
0
8
4
L
A
0
0
8
6
L
A
0
0
9
4
L
A
0
1
0
2
L
A
O
1
0
9
L
A
O
1
1
5
L
A
O
1
2
1
L
A
O
1
2
3
L
A
0
1
2
7
L
A
O
1
3
6
L
A
O
1
3
9
L
A
O
1
4
4
L
A
O
1
4
6
L
A
O
1
4
8
L
A
O
1
5
3
L
A
O
1
5
5
L
A
O
 1
6
1
L
A
O
 1
6
7
L
A
O
 1
7
2
L
A
O
1
7
6
L
A
O
1
7
8
L
A
O
1
8
4
L
A
O
1
8
6
L
A
O
1
8
8
L
A
O
1
9
6
L
A
O
1
9
8
L
A
O
2
0
5
L
A
O
2
1
4
L
A
O
2
1
6
L
A
O
2
2
1
A
b
so
rb
a
n
ce
 
BR patients 
 
 
 
267 
 
 
Screening of COPD sera against S.pneomoniae polysaccharide at 1in 25 to establish the first dilution for antibody titration 
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Screening of Asthmatic sera against S.pneomoniae polysaccharide at 1in 25 to establish the first 
dilution for antibody titration. 
 
Screening of healthy sera against S.pneomoniae polysaccharide at 1:25 to establish the first dilution 
for antibody titration 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
A
b
so
rb
a
n
ce
Asthma patients 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
A
b
so
rb
a
n
ce
Healthy volunteers 
 
 
 
269 
 
 
Screening of BR sera against P.aeruginosa (LPS) at 1in 25 to establish the first dilution for antibody titration. 
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Screening of COPD sera against P.aeruginosa (LPS) at 1in 25 to establish the first dilution for 
antibody titration. 
 
Screening of asthmatics sera against P.aeruginosa (LPS) at 1in 25 to establish the first dilution for 
antibody titration. 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
L
A
0
0
2
2
L
A
0
0
2
7
L
A
0
0
2
9
L
A
0
0
3
2
L
A
0
0
4
0
L
A
0
0
4
3
L
A
0
0
4
5
L
A
0
0
5
3
L
A
0
0
6
4
L
A
0
0
6
9
L
A
0
0
8
7
L
A
0
0
9
5
L
A
0
0
9
9
L
A
O
1
0
8
L
A
O
1
1
2
L
A
O
1
1
8
L
A
0
1
2
8
L
A
0
1
3
0
L
A
O
1
3
5
L
A
O
1
4
2
L
A
O
1
5
2
L
A
O
1
5
9
L
A
O
1
6
6
L
A
O
1
6
9
L
A
O
1
8
1
L
A
O
1
8
9
L
A
O
2
0
6
L
A
O
2
1
3
L
A
O
2
2
0A
b
so
rb
a
n
ce
COPD patients
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
A
b
so
rb
a
n
ce
Asthmatics 
 
 
 
271 
 
 
 
Screening of healthy sera against P.aeruginosa (LPS) at 1in 25 to establish the first dilution for 
antibody titration. 
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Appendix 10: Isotypes for asthma and healthy controls 
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Appendix 11: BSI exacerbation scores 
 
Exacerbation score 5=hospitalised, 2=3 or more outpatient exacerbations, 0=<3 
exacerbations per year 
Numbers  BSI Aetiology Exacerbation 
score  
LA0001 14 COPD 5 
LA0002 13 ASTHMA 5 
LA0003 14 IMMUNE DIFICIENCY 2 
LA0004 15 
 
5 
LA0005 8 POST INFECTIOUS 2 
LA0006 11 IDIOPATHIC 2 
LA0007 10 POST INFECTIOUS 5 
LA0008 8 POST INFECTIOUS 2 
LA0010 9 IDIOPATHIC 0 
LA0012 7 IDIOPATHIC 2 
LA0013 15 IDIOPATHIC 5 
LA0014 13 IDIOPATHIC 5 
LA0015 4 INFLAMATORY BOWEL DISEASE 2 
LA0016 6 IDIOPATHIC 2 
LA0017 2 IDIOPATHIC 0 
LA0018 15 ASTHMA 5 
LA0019 12 RA/POST INFECTIOUS 5 
LA0020 6 IDIOPATHIC 0 
LA0021 13 COPD 2 
LA0023 3 IDIOPATHIC 0 
LA0025 5 POST INFECTIOUS 2 
LA0031 11 IDIOPATHIC 2 
LA0034 6 IDIOPATHIC 2 
LA0035 12 IDIOPATHIC 2 
LA0036 3 IDIOPATHIC 0 
LAO 037 3 POST INFECTIOUS 0 
LAO038 6 IDIOPATHIC 0 
LA0039 8 POST INFECTIOUS 2 
LA0041 6 IDIOPATHIC 0 
LA0046 3 POST INFECTIOUS 0 
LA0047 15 IMMUNE DIFICIENCY 5 
LA0048 9 PINKS DISEASE 
LA0049 7 
 
2 
LA0051 5 IDIOPATHIC 2 
LA0052 7 
 
2 
LA0054 14 PINKS DISEASE 5 
LA0055 4 IDIOPATHIC 2 
LA0056 2 IDIOPATHIC 0 
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LA0067 3 Immune Deficiency CVID 0 
LA0065 9 IDIOPATHIC 
LA0068 2 IDIOPATHIC 0 
LA0071 8 IDIOPATHIC 
LA0072 9 RA 
 
LA0074 3 IMMUNE DIFICIENCY 2 
LA0075 9 IDIOPATHIC 
LA0076 8 RA 0 
LA0077 9 IDIOPATHIC 2 
LA0079 3 INFLAMATORY BOWEL DISEASE 
LA0081 4 IDIOPATHIC 2 
LA0083 6 
 
2 
LA0084 5 IDIOPATHIC 0 
LA0085 11 IDIOPATHIC 0 
LA0086 11 IDIOPATHIC 0 
LA0093 11 IDIOPATHIC 2 
LA0094 7 IDIOPATHIC 
LA0100 5 IMMUNE DIFICIENCY 2 
LA0101 16 RA 5 
LA0102 7 IDIOPATHIC 
LA0105 7 IDIOPATHIC 
LAO107 1 IMMUNE DIFICIENY  CVID 
LA0109 9 POST INFECTIOUS 2 
LAO114 6 ASTHMA 
 
LAO115 9 POST INFECTIOUS 
LAO117 11 IDIOPATHIC 2 
LAO121 8 IMMUNE DIFICIENY 5 
LAO122 4 IDIOPATHIC 
LAO123 5 ASTHMA 2 
LAO124 7 IMMUNE DIFICIENCY 
LAO125 2 POST INFECTIOUS 
LAO127 5 IDIOPATHIC 
LAO134 9 
 
0 
LAO136 4 POST INFECTIOUS 0 
LAO137 12 IDIOPATHIC 
LAO138 4 POST INFECTIOUS 0 
LAO139 8 
 
2 
LAO141 9 ASTHMA 
 
LAO144 8 IMMUNE DEFICIENCY 2 
LAO145 4 IDIOPATHIC 0 
LAO146 6 POST INFECTIOUS 
LAO147 5 IDIOPATHIC 
LAO148 9 
 
2 
LAO149 3 
 
0 
LAO153 
  
5 
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LAO154 10 IDIOPATHIC 2 
LAO155 4 
 
0 
LAO161 1 
 
0 
LAO164 2 INFLAMATORY BOWEL DISEASE 0 
LAO171 6 
 
0 
LAO172 9 IDIOPATHIC 2 
LAO176 17 IDIOPATHIC 2 
LAO177 15 asthma (Deceased) 5 
LAO178 2 IDIOPATHIC 
LAO179 5 Immunodef 0 
LAO183 2 
 
0 
LAO184 3 
 
0 
LAO185 6 
 
0 
LAO186 4 
 
0 
LAO187 12 IDIOPATHIC 5 
LAO188 13 
 
2 
LAO190 11 ASTHMA 5 
LAO193 2 IMMUNE DEFICIENCY 0 
LAO194 4 IMMUNE DEFICIENCY 
LAO196 10 
  
LAO197 14 ASTHMA 5 
LAO198 18 ASTHMA 5 
LAO203 7 IDIOPATHIC 0 
LAO204 11 PINKS DISEASE 5 
LAO205 5 COPD 0 
LAO211 7 IDIOPATHIC 
LAO214 18 RA 5 
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